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Abstract  
(word count 500) 
Background:  
Timely diagnosis enables access to antiretrovirals, which reduces mortality, morbidity, and 
further transmission in people living with HIV. In the UK late diagnosis among black African 
people persists. Novel methods to enhance HIV testing in this population are needed.  
Objectives:  
To develop a self-sampling kit (SSK) intervention to increase HIV testing among black 
Africans using existing community and healthcare settings (Stage I) and to assess feasibility 
for a Phase III evaluation (Stage II).  
Design: A two stage, mixed-method design. Stage I  involved a systematic literature review, 
focus groups and interviews with key stakeholders and black Africans. Data obtained 
provided the theoretical base for intervention development and operationalisation. Stage II 
was  a prospective, non-randomised study of a provider-initiated, HIV SSK distribution 
intervention targeted at black Africans. The intervention was assessed for cost effectiveness. 
Process evaluation explored feasibility, acceptability and fidelity.  
Setting:  
12 GP practices and 3 community settings in London.  
Main outcome measure:  
HIV SSK return rate 
Results:  
Stage I: The systematic review revealed support for HIV SSKs, but with scant evidence on 
their use and effectiveness among black Africans. Although the qualitative findings supported 
SSK distribution in settings already used by black Africans concerns were raised about the 
complexity of the SSK and the acceptability of targeting. These findings were used to 
develop a theoretically informed intervention. 
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Stage II: Of 349 eligible people approached, 125 (35.8%) agreed to participate. Data from 
119 were included in the analysis. 54.5% (65/119) of those who took a kit returned a sample; 
83.1% of tests returned were HIV negative. 16.9% were not processed due to insufficient 
samples. Process evaluation showed the time pressures of the research process to be a 
significant barrier to feasibility. Other major barriers were difficulties with the SSK itself and 
ethnic targeting in GP settings. Convenience and privacy of SSK were described as beneficial 
aspects. And those who used the kit mostly found the intervention to be acceptable. Research 
governance delays prevented implementation in Glasgow. 
Limitations:  
Due to the study failing to recruit adequate numbers (intended sample 1200) we are unable to 
evaluate the effectiveness of SSKs in increasing HIV testing in black African people. No 
samples were reactive so we were unable to assess pathways to confirmatory testing and 
linkage to care. 
Conclusions:  
Our findings indicate that although aspects of the intervention were acceptable, ethnic 
targeting and the SSK itself were problematic, and  scale up of the intervention to a Phase III 
trial isnot feasible. The preliminary economic model suggests that for the acceptance rate and 
test return seen in the trial, SSK is potentially a cost-effective way to identify new cases of 
HIV.  
Future work:  
Sexual and public health services are increasingly utilizing self-sampling technologies 
however alternative user-friendly SSKs that meet user and provider preferences and UK 
regulatory requirements are needed, and additional research is required to understand 
effectiveness and cost-effectiveness for black African communities.  
Study registration:  
PROSPERO registration number: CRD42014010698. IRAS project ID 184223  
Funding details:  
NIHR HTA Programme; BHA for Equality in Health & Social Care.  
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Scientific summary 
(word count 2384) 
Background 
Black African people compose over half of heterosexuals living with HIV in the UK, and are 
more likely than other ethnic groups to present to HIV services with advanced infection. 
Reducing late presentation to HIV services is the most effective way to reduce morbidity and 
mortality attributed to HIV.  
Innovative HIV testing methods are required to overcome challenges associated with 
traditional HIV testing options. Though community-based point-of-care testing, blood- and 
saliva-based self-sampling kits (SSK), and self-testing kits are increasingly available, the 
evidence base on the acceptability of such options to potential users and distributors is still 
weak - especially in regard to black African users. To address this evidence gap, the aims of 
the HAUS Study were: (1) To develop an SSK-based intervention to increase the provision 
and uptake of HIV testing among black Africans using existing community and healthcare 
provision (Stage 1), and 2. To conduct an evaluation of selected SSK distribution models to 
assess the feasibility of a future Phase III evaluation (Stage 2). 
Objectives  
The HAUS Study involved two sets of objectives.  
Objectives for Stage 1  
• Examine/evaluate barriers and facilitators to provision, access and use of HIV SSK by 
 black Africans, in primary care, pharmacies and community outreach settings. 
• Determine appropriate SSK-based intervention models for different settings. 
• Determine robust HIV result management pathways. 
• Develop an intervention  manual to enable intervention delivery. 
Objective of Stage 2 
• Determine the feasibility and acceptability of a provider-initiated, HIV self-sampling 
 kit distribution intervention targeted at black African people in two settings: 
o General Practice (GP) surgeries and  
o Community based organisations (CBOs). 
xiv 
 
Secondary objectives included:  
• Establish acceptability of interventions for providers and users. 
• Evaluate the effectiveness of self-sampling for HIV in increasing HIV testing by 
black African people. 
• Determine the cost effectiveness of distributing the SSKs among black African people 
 over other screening methods. 
• Monitor ability to trace participants with reactive results, confirmatory testing and 
 linkage into specialist care. 
• Determine the cost per person kit distributed and cost per HIV diagnosis per setting. 
• Assess the feasibility of collecting data for a lifetime cost-effectiveness model. 
• Assess feasibility, and if appropriate, the optimal trial design (including sample size 
 parameters) for future Phase III evaluation. 
Methods 
Stage 1 
The objectives of Stage 1 were met through three activities:  
1. A systematic literature and policy review, 
2. Focus group discussions with non-specialists and service providers and one-to-one 
interviews with the latter, and  
3. Developing a theoretically informed intervention.  
The systematic review focused on the feasibility, acceptability and effectiveness of HIV self-
sampling in increasing HIV testing. Only studies published since 1st January 2000 in English 
and conducted in the European Union/European Free Trade Agreement countries, North 
America, New Zealand or Australia were included. Ten electronic databases were searched 
and NICE quality appraisal tools were used (last search 3rd May 2016). All papers were 
appraised independently by two reviewers. PROSPERO registration number: 
CRD42014010698.  
Qualitative methods were used to collect data using focus group discussions (FGDs) and one-
to-one interviews. Ethical approval was obtained from the UCL Research Ethics Committee, 
project ID 3321/001.  
Twelve FGDs were conducted: Six of which were with non-specialist members of the public 
who identified as black African and, and six with professionally, culturally and ethnically 
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diverse people who provide HIV and other social services to black Africans. From the latter 
group, nine participants also participated in one-to-one interviews. Analysis was undertaken 
using a ‘blended’ thematic approach drawing heavily on framework analysis. NVivo (version 
10) software was used to synthesise and code data within a thematic matrix. 
The development of the intervention manual for a feasibility trial in Stage 2 followed a 
systematic four-step approach drawing on the theoretical domains framework.  
Stage 2 
The objectives for Stage 2 were met through three activities: 
1. A feasibility study, 
2. A process evaluation, and  
3. An economic analysis.  
Feasibility study 
GP surgeries and CBOs who serve black African communities were trained to offer the 
intervention during routine appointments or outreach activities. An enrolment log captured 
demographic information on all potential participants. An intervention script was provided to 
distributors to introduce the study. Only participants who self-identified as black African, 
were at least18 years of age, and able to provide informed consent were eligible. The 
recruitment target was 1,200 across sites in London and Glasgow. Ethical approval was 
obtained from the East of England- Cambridge South Research Ethics Committee (REC 
reference 15/EE/0412; IRAS project ID 184223). 
Reasons for declining to participate were captured on the enrolment log. Participants also 
completed a baseline questionnaire, which collected demographic data and a brief risk 
assessment. The distributors then gave the participant a SSK, briefly explained how to use it 
and how results would be communicated. Unique ID numbers linked consent and baseline 
forms, to the kit itself.  Paper forms were used in GP settings but either paper or electronic 
forms were available in CBO settings. 
Kit users needed to return a form with three unique identifiers (initials, date of birth and 
unique ID number) to enable processing of the sample, and were invited to complete an 
acceptability questionnaire. Participants with negative results were informed by automated 
SMS delivered from the processing laboratory. If only a landline was provided, or the result 
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was reactive or unable to be processed (due to under filling of TINY vial or gross 
haemolysis) the results was passed to a senior Health Advisor (HA) who contacted the 
participants by telephone to notify them of the result and arrange follow up as appropriate. 
Postal code information was provided to the HA to enable referral to services appropriate to 
the participant.  
Consent for participation in optional follow-up telephone interviews was obtained at study 
recruitment. Interviewees were purposively selected to provide diversity in gender, age, 
recruitment site, and study outcome (those who used and did not return a kit, and those with 
both negative and insufficient samples). Interviews lasted approximately 30 minutes, were 
recorded and transcribed verbatim, and interviewees were sent a £10 voucher for their time. 
Transcripts were coded and analysed using a thematic approach on NVivo software. 
Process evaluation 
The process evaluation investigated the acceptability, fidelity and reach of the 
implementation through analysis of ten data points: research diaries, training evaluations, 
enrolment and weekly logs submitted by distributors, site visit notes, observed data flow, 
communications between the study team and distributors, site summaries and close-down 
interviews, and qualitative interviews with study participants. 
Economic analysis 
A patient level simulation was developed to assess the cost-effectiveness of SSKs amongst 
black Africans in the UK compared to current practice. The model was developed using 
published data and results from the HAUS study to predict individual’s transitions, costs and 
health outcomes. The model was created in Microsoft Excel 2010 according to 
methodological recommendations for evaluations of new health care technologies and 
interventions. A hypothetical cohort of 8,000 patients was tested under two different HIV 
screening arms: (i) intervention (SSK); or (ii) comparator (current practice). 
Results 
Stage 1 
Thirteen studies were included in the systematic review, which originally located 4052 
articles. The majority of papers focused on non-black African populations outside of the UK. 
Overall quality of the studies was mixed and relatively poor. Evidence to support the 
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acceptability, feasibility and effectiveness of SSKs to increase HIV testing was limited, and 
absent for black Africans people of all sexualities in the UK. A further 11 documents that 
contained guidance on HIV self-sampling or testing in the UK published between January 
2008 and July 2016 were included in the policy review. Most of the policy guidance 
documents were not specific to SSKs. The reviews confirmed a need for well-conducted trials 
to assess if self-sampling interventions can increase HIV testing among all high-risk 
populations and black African people in particular. 
The FGDs and one-on-one interviews revealed concern over the amount of time that 
providers had (particularly general practitioners) to initiate discussion and encourage use of 
SSKs, and about the amount of blood required to provide a sample. Targeted distribution of 
SSKs was seen as a broadly positive means of expanding the range of opportunities for black 
African people to test for HIV. There was specific support for the fact that SSKs could 
provide an opportunity for the initiation and follow through of an HIV testing discussion in a 
setting that black African people were already accessing.  
The findings of the policy and systematic review, and the FGDs and interviews fed into the 
four-step process guiding intervention development. The theoretically informed intervention 
focussed upon the targeted offer of an HIV SSK distributed by in GP clinics and by 
Community Workers. A scripted discussion that provided a rationale for HIV testing and 
explained how the kit was used was central to the intervention. Use of the script along with 
the intervention manual would ensure consistency across Stage 2 of the study. 
Stage 2 
Results of feasibility study 
Staff at 12 GP surgeries and three CBOs in London were trained to offer the intervention, no 
sites were opened in Glasgow. A total of 349 eligible persons were approached and 125 
(35.8%) agreed to participate. Data from 119 were included in the analysis. The mean age 
was 42.6 years, slightly less than half were male, and the majority (76%) were recruited at 
GP surgeries. The SSK return rate was 54.5% (65/119); 83.1% of tests returned were HIV 
negative. However, 11 samples (16.9%) were unable to be processed due to the vial being 
under filled or sample grossly haemolysed. There were no reactive results.  
The two most common reasons for declining to participate were having recently tested for 
HIV, and low HIV risk perception. Eligible people visiting their GP were significantly more 
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likely to be recruited than those approached via a CBO (odds ratio 1.96 95% CI 1.2 -3.19). 
There was no relationship between gender or age and enrolment status. 
The majority of participants who returned a SSK also returned the acceptability 
questionnaire. None felt the location in which they were offered the kit was unacceptable. 
The majority found the SSK instructions easy to understand and over two thirds were 
comfortable with taking the sample themselves Just under a third reported watching the 
online video; of these most found the video helpful and increased confidence. The majority of 
kit returners reported that they would be willing to use one of these kits again. The least 
acceptable aspect of the intervention was the targeting of black Africans with over a third 
reporting it was unacceptable. 
Twenty-one participants were interviewed; the median age of interviewees was 40 years; 12 
were women; and 17 recruited at GP surgeries. Of the 21, nine had received negative results, 
four sent samples that were unable to be processed (due to the samples being under-filled), 
and eight had not returned their sample. The acceptability of the HAUS intervention was 
compromised by the specific SSK used, as well as issues with follow-up for insufficient 
samples, and stigma around HIV and HIV testing. Conversely, acceptability was supported 
by the convenience and privacy afforded by the use of SSKs, clear instructions and trust in 
the distributor. The interviewees widely reported that targeting black Africans specifically 
was acceptable. 
Many distributors at GP surgeries felt unease at targeting black African patients only, despite 
the training and provision of a script to initiate this discussion. Despite these misgivings, 
many primary care staff felt that the intervention was worthwhile and expressed 
disappointment when the distribution period finished. Some distributors noted that targeting 
was complicated as information on ethnicity on patient databases is sparse, and there was 
limited time to check this data prior to appointments. These issues manifested in a large 
variety of methods employed at GP surgeries to select patients to offer the intervention.  
The acceptability of the intervention to staff at CBOs remained high throughout the study, 
with the SSKs generally viewed as a valuable add-on to service menus. However, significant 
barriers to recruitment were noted, including stigma around HIV and limited time and 
capacity to conduct the intervention.  
Results of process evaluation 
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Most distributors found it difficult to recruit to and almost all found it too time consuming to 
deliver in the context of a busy GP surgery or during community outreach. The research 
process attached to the intervention was the principal driver of this barrier. Fidelity to the 
intervention was not the norm. While local adaptations were not always agreed in advance, 
they maintained the fidelity of form for the intervention, in that they followed the 
standardised structures and processes and represent reasonable tailoring of the intervention to 
the specific local context in which it was being delivered. Almost all deviations were 
intentional, motivated by a desire to speed up the recruitment process. 
Results of economic analysis 
The model of a SSK test dispensed to black Africans in GP or in community settings suggests 
that SSKs are potentially a cost-effective way to identify new cases of HIV, with SSK 
compared to current practice as shown in increased quality adjusted life years for less cost.  
More work is required to test this result. 
Conclusions 
Our findings indicate that although many aspects of the intervention were acceptable, scale 
up of the intervention to a Phase III trial is not feasible. Alternative user-friendly SSKs that 
meet user and provider preferences and UK regulatory requirements are needed. The 
preliminary economic model suggests that for the rates of acceptance and return of the test 
seen in the trial, SSK is a cost-effective way to identify new cases of HIV but further work is 
needed to validate this result. Importantly the study also found busy services do not have time 
to ‘bolt-on’ a SSK intervention  or research generally, unless there is a strong incentive to do 
so. 
Research studies comparing acceptability and return rates of different types of self-sampling 
methods can help better understand their impact on recruitment. Blood-based kits not 
requiring users ‘to milk’ blood and  diagnostic assays that meet CE criteria for testing saliva 
are required.  
Changes in commissioning of sexual health services, as well as funding for HIV prevention 
initiatives in the UK, are affecting research capacity. Although efforts are being made to 
reduce time for obtaining REC and R&D approvals, continually changing systems breed 
confusion and affect study timelines and feasibility of assessing research questions 
substantially.  
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Sexual and public health services are increasingly utilizing self-sampling technologies 
however additional research is required to understand effectiveness and cost-effectiveness for 
black African communities and the population as a whole. 
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Plain English summary 
(word count 313) 
HIV diagnosis among black African people in the UK often happens long after infection – 
increasing the likelihood of ill health and further infections. Innovative ways to increase HIV 
testing are needed.  
We wanted to find out if distributing HIV self-sampling kits (SSKs) through community and 
healthcare services would increase HIV testing among black African people. Self-sampling 
involves taking your own sample and sending it to a laboratory that lets you know the result.  
The first stage of the HAUS study was designing a way to distribute SSK within existing 
services that was acceptable, workable and affordable. A review of published studies, focus 
group discussions and interviews helped to develop this. General Practice (GP) and 
Community Based Organisations (CBO) were chosen to distribute SSK. A script was 
developed that reassured distributors and potential users about targeting black Africans, and 
ensured that SSK were introduced consistently.  
We had hoped to run Stage 2 in Glasgow and London  but due to various reasons could only 
test the intervention in London, at 12 GPs and 3 CBOs. A third of those approached took part 
(36%, 125/349). Around half of those who took a kit (55%, 65/119) sent back their sample. 
No one had a reactive test but 17% sent back samples with not enough blood to be processed. 
Participants and distributors felt that people liked the idea of SSKs, the location of the 
intervention, and that the offer encouraged them to test. However, some found it difficult 
taking blood and many felt uncomfortable about ethnic targeting. The main barrier was time, 
particularly for those working in GP surgeries. Our economic model suggests that this 
approach may be cost-effective. 
Although our study did not prove feasible, it highlighted the need to develop more user-
friendly SSKs. It also found busy services do not have time to ‘bolt-on’ a SSK intervention 
unless there is a strong incentive to do so. 
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Chapter 1:  Background 
HIV infection in the UK 
Since 2003, more people have been living with heterosexually-acquired HIV in the United 
Kingdom (UK) than HIV acquired via sex between men. Black Africans account for 55% of 
people with heterosexually acquired HIV and 2% of new HIV diagnoses in men who have 
sex with men (MSM); thus people of black African ethnicity account for almost one third of 
the 103,000 (95% credible interval 97,500-112,700) adults estimated to have HIV in the 
UK.(1) This equates to nearly four out of every 100 black Africans being HIV positive. (2)  
Effective antiviral therapy means HIV incidence is likely to be driven by the undiagnosed 
fraction of people living with HIV and most HIV-related morbidity and mortality is 
increasingly associated with diagnosis at a late stage of infection (as defined by a CD4 count 
of <350 cell/mm3).(2-4) Black Africans in the UK are more likely to present to HIV services 
with advanced infection than other ethnic groups.(5, 6)  
Late diagnosis is associated with a tenfold increased risk of death in the first year post 
diagnosis when compared to people who are diagnosed with less advanced infection.(2) Late 
diagnosis also implies that a person has been living with undiagnosed HIV for a substantial 
period of time, which increases the risk of HIV transmission to other people. Reducing late 
presentation to HIV services is the single most useful way of decreasing the ill health and 
death associated with HIV, and reducing late diagnosis is the only HIV-specific indicator 
within the Public Health Outcomes Framework.(7) HIV prevention efforts have increasingly 
focused on increasing opportunities for people to have an HIV test, which reduces both late 
presentation and undiagnosed HIV infection. UNAIDS have set a global target of 90% of 
people living with HIV to be aware of their diagnosisby 2020, increasing HIV testing is the 
only means by which this can be achieved.(8) 
HIV testing among black African communities in the UK 
HIV testing in the UK is predominantly offered at sexual health clinics. Black Africans are 
less likely to use these services compared to other higher risk communities.(1) General 
practice is accessed by this population, but opportunities for earlier HIV diagnosis are often 
missed.(9) Black African men in particular have high rates of undiagnosed infection and late 
presentation,(10) partly because they have less contact with health services than women. In 
addition, concerns regarding confidentiality,(11, 12) stigma and discrimination(11-13) and 
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fear of HIV positive status(14) present barriers to effective testing initiatives. These obstacles 
are compounded by structural issues which discourage access to HIV prevention, diagnostic, 
and treatment services such as poverty, unemployment and lack of childcare,(11) the 
reticence of non-specialist health staff to offer HIV testing,(15) a lack of political will to 
recognise the pervasive health inequalities faced by many migrants,(16) and a lack of African 
representatives in decision-making processes.(14) Despite these obstacles, there is evidence 
to suggest that many black Africans will test for HIV if provided the opportunity.(10, 17)  
At a population level, no single intervention is likely to control HIV. However, HIV testing is 
the starting point from which to build effective strategies. A negative test results can support 
individual vigilance to remain uninfected. For those testing positive, it opens treatment and 
prevention options. Timely diagnosis and treatment means that those affected can expect 
near-normal life expectancy.(18) 
Due to the challenges associated with traditional HIV testing options for black Africans, 
innovative methods to increase the uptake and opportunities for testing amongst this 
population are required. Interventions should extend testing opportunities and directly 
address the barriers that foster late and undiagnosed infection. Such interventions could 
incorporate developments in testing technology that reduce the need to attend specialist 
services (for example use of self-sampling or self-testing kits) or through targeting testing 
interventions to specific populations (e.g. considering the psychosocial and socio-cultural 
contexts of target populations such as black African communities rather than general 
population). These interventions must also address the barriers that exist at a service provider 
level. Interventions need to be time and cost efficient, easy to use and deliver, and supported 
by robust clinical pathways. 
Self-sampling kits 
The range of HIV testing options continues to expand, with community-based point-of-care 
testing (POCT) and blood and oral self-sampling kits (SSKs) increasingly available.(19) HIV 
self-testing kits are also now licensed for use in the UK. Self-sampling negates the need for 
dedicated staff or special infrastructure for specimen collection, and can be used at a time and 
in a setting of the users’ choice. SSKs accessed via clinical settings and online have been 
shown to be an acceptable and feasible alternative to clinic attendance for HIV testing, and 
may increase testing among hard-to-reach men who have sex with men (MSM).(20-22) 
Testers have shown an overall preference for oral-based sample rather than blood-based, 
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especially amongst first-time testers.(23) Research among young men in the UK also 
demonstrated acceptability of SSKs for HIV testing, with healthcare settings being the 
preferred venue for accessing kits.(24)  
Despite the burgeoning research base focused on SSKs, there is little evidence to support the 
acceptability or feasibility of using SSKs to increase the uptake of HIV testing among black 
Africans in the UK. A pilot study initiated by Terrence Higgins Trust/HIV Prevention 
England and Dean Street At-Home has documented success in reaching black African people 
through internet-based SSK distribution.(25) Though the study had greater success in uptake 
among MSM than black African people of all sexualities, it found that 9.8% of the 7,761 kits 
requested were by black Africans and 7.3% of those were returned, with a positivity rate of 
2.6%.  
Embedding SSKs within existing health services (including health promotion initiatives and 
National Health Service [NHS] screening) may facilitate the uptake of HIV testing. A cross-
sectional study undertaken among black Africans in England revealed that nearly one third of 
participants without diagnosed HIV said they would prefer to have a future HIV test at their 
GP surgery.(26) This may indicate the acceptability of offering SSKs via existing primary 
care venues. However, a lack of evidence persists regarding testing preferences by ethnicity, 
gender, and age.  
In 2012 the National Institute of Health Research Health Technology Assessment (NIHR 
HTA) released a commissioned call (12/138) driven by the following research question: What 
is the feasibility and acceptability of interventions to overcome individual and healthcare 
professional barriers to the provision and uptake of HIV testing in black African adults in the 
UK?  
The hypothesis behind the following research was that embedding SSKs for HIV testing in 
existing services is an acceptable and feasible means to increase the provision and uptake of 
HIV testing among black Africans residing in the UK. 
1.1 Aims  
The overall aims of our research were: 
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1. To develop an SSK-based intervention to increase the provision and uptake of HIV 
testing among black Africans using existing community and healthcare provision 
(Stage 1 of project). 
2. To conduct an evaluation of selected SSK distribution models to assess feasibility, 
and optimal trial design for future Phase III evaluation (Stage 2 of project).  
In order to answer the research question, the following objectives and outcomes were 
established. 
1.2 Objectives 
Stage 1 
1. Examine/evaluate barriers and facilitators to provision, access and use of HIV SSK by 
black Africans, in primary care, pharmacies and community outreach settings 
2. Determine appropriate SSK-based intervention models for different settings 
3. Determine robust HIV result management pathways 
4. Develop an intervention manual to enable intervention delivery. 
Stage 2 
1. Determine the feasibility and acceptability of a provider-initiated, HIV self-sampling 
kit distribution intervention targeted at black African people in two settings 
a. General Practice (GP) surgeries 
b. Via community based organisations (CBOs). 
Secondary objectives 
1. Establish acceptability of interventions for service providers and service users. 
2. Evaluate the effectiveness of self-sampling for HIV in increasing the uptake of HIV 
testing by black African people. 
3. Determine the cost effectiveness of distributing the SSKs among black African people 
over other screening methods. 
4. Monitor ability to trace participants with reactive results, confirmatory testing and 
linkage into specialist care. 
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5. Determine the cost per person kit distributed and cost per HIV diagnosis per setting. 
6. Assess the feasibility of collecting data for a lifetime cost-effectiveness model. 
7. Assess feasibility, and if appropriate, the optimal trial design (including sample size 
parameters) for future Phase III evaluation. 
1.3 Outcomes 
Primary outcome: HIV SSK return rate.  
Secondary outcomes:  
1. Point of delivery outcomes:  
a. Acceptability of targeted HIV SSK distribution,  
b. Acceptability and feasibility of targeted SSK distribution among specified 
service providers.  
2. Data collection outcomes:  
a. Ability to record the numbers of people offered SSK, accepting SSK, and 
returning SSK. 
b. Feasibility of collecting correct contact details enabling follow-up, reminders 
and communication of results. 
3. Pathway to care outcomes:  
a. Proportion of those whose samples are reactive who:  
i. Are informed of results in person and 
ii. Who attend for confirmatory testing at an NHS setting of their choice. 
4. Overarching outcomes:  
a. Cost per person kit distributed and cost per HIV diagnosis per setting. 
b. Attrition rates. 
27 
 
5. Confirmatory testing, proportion of those receiving an HIV positive diagnoses, and 
clinical stage at diagnosis. 
Feasibility and sensitivity of outcome measures (testing, behavioural and economic) for a 
definitive trial. 
1.4 Structure of the report 
The report is structured according to the aims and objectives of Stages 1 and 2 of the study. 
Chapters 2 through 5 address the objectives of Stage 1, and Chapters 6–10 through address 
the objectives for Stage 2, with discussion and conclusions in Chapter 11. 
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Chapter 2:  Study design and methodology of Stage 1  
In order to develop an SSK-based intervention to increase the provision and uptake of HIV 
testing among black Africans using existing community and healthcare provisions we first 
needed to address the following objectives:  
 Examine/evaluate barriers and facilitators to provision, access and use of HIV SSK by 
black Africans, in primary care, pharmacies and community outreach, 
 Determine appropriate SSK-based intervention models for different settings, 
 Determine robust HIV result management pathways, and 
 Develop an intervention manual to enable intervention delivery. 
The objectives were met via three main research activities: 
1. Conducting a systematic literature and policy review exploring the feasibility and 
acceptability of self-sampling for HIV testing, and the effectiveness of self-sampling 
for HIV in increasing the uptake of HIV testing (see Chapter 3), 
2. Conducting focus group discussions with non-specialists and service providers and 
one-to-one interviews with the latter to gain stakeholder input into the development of 
an acceptable SSK distribution pathway and protocol via community-based health and 
HIV prevention services already accessed by black African people (see Chapter 4) 
3. Developing an intervention manual for the feasibility trial in Stage 2, drawing on 
theoretical frameworks and findings from the first two research activities  
(see Chapter 5).  
The remainder of this chapter focuses on the methodological and analytical approaches to the 
literature review; qualitative data collected through focus group discussions and one-to-one 
interviews; and the intervention manual development.  
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2.1 Methodology of the systematic literature review  
2.1.1  Search strategy and identification of studies 
Ten electronic databases were searched using detailed search strategies. The search strategy 
used for OvidSP MEDLINE is provided in Appendix F.  
 OvidSP MEDLINE  
 OvidSP Embase Classic+Embase 
 OvidSP Global Health 
 OvidSP Social Policy and Practice 
 OvidSP PsycINFO 
 Ovid SP HMIC Health Management Information Consortium 
 EBSCO CINAHL Plus with Full Text 
 Cochrane Library 
 Web of Science™ Core Collection 
 SCOPUS  
Only studies written in English were included. The results were downloaded into a de-
duplicated database in EndNote 7. The initial search was undertaken on 26 September 2014. 
Two further searches to update the database were undertaken 17 April 2015 on and 3 May 
2016. Additional grey literature was retrieved from websites operated by the following 
organisations: 
 Avert (www.avert.org) 
 Terrence Higgins Trust (www.tht.org.uk) 
 National AIDS Trust (www.nat.org.uk) 
 Lambeth Council (http://www.lambeth.gov.uk/consultations/lambeth-southwark-
lewisham-sexual-health-strategy-consultation) 
 Naz Project London (http://naz.org.uk) 
 Sexual Health Sheffield (http://www.sexualhealthsheffield.nhs.uk) 
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2.1.2 Inclusion and exclusion criteria 
Only studies published since 1st January 2000 were included since studies published earlier 
would be unlikely to reflect current technology or attitudes to HIV testing. Only studies 
conducted in the European Union/European Free Trade Agreement countries, North America, 
New Zealand or Australia were included, as studies conducted in other locations (particularly 
resource-poor settings) would likely have markedly different contexts and thus their results 
would not be applicable to the UK. Study populations that included lay groups as well as 
health professionals were included. Only studies that examined home/self-sampling for HIV 
were included as intervention studies. Studies without comparators were also included as well 
as studies that compared home/self-sampling for HIV with routine service provision or other 
HIV testing interventions. Studies were included if they reported on any of the following 
outcomes: 
 Increase / decrease in number of HIV tests 
 Proportion /number of confirmatory tests 
 Proportion /number of participants linked into care 
 Adverse events associated with HIV self-sampling 
 Proportion/number of false positives or failed tests 
 Increase / decrease in the reported history and frequency of taking HIV tests  
 Increase / decrease in the number and types of venue where HIV testing is offered 
Qualitative studies were included only if they reported either or both of the following: 
 Barriers or facilitator to self-sampling reported by general population 
 Barriers or facilitators to self-sampling reported by service providers 
The following study designs considered for inclusion: 
 Randomised or non-randomised controlled trials 
 Prospective or retrospective cohorts 
 Cross sectional studies / prevalence studies  
 Pilots or feasibility studies 
 Qualitative studies (using in-depth interviews, focus group discussions, and document 
analysis) 
Studies that examined the use of, or views about, self-sampling for HIV in healthcare workers 
were excluded because the review focus was on uptake among testers not service providers as 
were all conference communications because of insufficient detail and lack of peer review. 
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Studies that focussed solely on, or whose outcomes were predominantly about self testing for 
HIV also were excluded at the study selection stage.  
2.1.3  Study selection 
Studies were selected using a two-stage screening approach. Reviewers Ibi Fakoya (IF) and 
Esther Mugweni (EM) devised a checklist to independently screen titles and abstracts (See 
Appendix F). Where a consensus could not be reached about study inclusion, a third reviewer 
(Fiona Burns [FB]) was consulted. Full paper copies of the selected studies were screened 
and assessed independently by IF and EM using a screening tool (see Appendix F). Updated 
searches were screened using the same approach by Caroline Park (CP), Thomas Hartney 
(TH) and Lisa McDaid (LMcD). Inter-reviewer reliability scores of the different stages of the 
review were calculated using Kappa in Microsoft Excel. The full paper screening achieved a 
Kappa score of 1.0, which indicates a high level of agreement between reviewers.  
2.1.4 Data extraction, analysis, and synthesis  
Structured data extraction tools were developed to capture the required information from the 
included papers on study types, populations, SSK interventions, and acceptability, feasibility 
and efficacy outcomes. Data were extracted by CP and checked by TH. 
A meta-analysis was not conducted due to the heterogeneity of the study designs and 
methods, samples and outcomes of the included studies. There are a number of narrative 
approaches to data synthesis, including integrative synthesis to primarily combine and 
summarise data and interpretative synthesis that aims to generate new concepts and theory 
(27). An integrative approach to summarise and present the data was appropriate to this 
review. The narrative synthesis is supported by tables in the findings section that outline the 
key characteristics and findings of each included study, as relevant to the research questions. 
To reduce bias, the extracted data were first summarised by LMcD and then reviewed by TH. 
Disagreements in interpretation were resolved through discussion between the two authors. 
2.1.5 Quality appraisal 
Quality of the eligible papers were appraised by TH using the NICE quality appraisal 
checklist for quantitative papers (28) and the NICE quality appraisal checklist for qualitative 
papers (28). Each quantitative paper was assigned a score for internal and external validity, 
from ++ (high quality) to – (poor quality). Each qualitative paper was assigned a single 
overall score. The appraisal process was validated by a second researcher (LMcD) assessing a 
sample of papers with high agreement reached. Any papers that did not present self-sampling 
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data separately to other forms of testing were excluded, but papers were not excluded on the 
basis of quality. 
2.2 Methodology of focus group discussions and one-to-one interviews 
Qualitative research methods were used to collect data using focus group discussions (FGDs) 
and one-to-one interviews in late 2014. Ethical approval was obtained from the UCL 
Research Ethics Committee (REC), project ID 3321/001.  
The study team conducted 12 FGDs, a method which was selected in order to maximise the 
extent of interaction between research participants in order to establish group similarities as 
well as differences by encouraging discussion, exchange and justification of divergent 
viewpoints.(29) Six of these groups were conducted with non-specialist members of the 
public who identified as black African and, and six with professionally, culturally and 
ethnically diverse people who provide HIV and other social services to black Africans. From 
the latter group, nine participants also participated in one-to-one interviews, a choice that was 
made to primarily enable interviewers to tailor the topic guide in ways that would help to best 
capture the specific world-view of these expert interviewees.(30)  
Topic guides for the non-specialist and service provider FGDs (see Appendices A and B 
respectively) were developed in consultation with members of the steering group and study 
team. The topic guide for the one-to-one interviews was adapted from that for service 
provider FGDs. These guides structured flexible discussions about participant views toward 
SSKs, community trust of SSKs, practicalities and rationales for selecting potential 
community settings outside of sexual health clinics, mechanisms for returning the sample and 
communicating and confirming results to users, and the content of SSK packs. Group 
facilitators and interviewers sought to create a balance between the a priori issues outlined 
above while also harnessing participant-led articulation of perspectives, social norms and 
discourses. 
During the FGDs participants were shown a video produced by the producers of the TINY 
Vial SSK (http://www.tdlpathology.com/test-information/test-service-updates/tdl-tinies). In a 
number of groups participants were also shown an instructional video developed by a 
community organisation (https://www.youtube.com/watch?v=FSm0zP1TGUo) on self-use of 
dried blood spot sampling kits. TINY Vial SSKs were displayed, distributed and discussed in 
all groups. As it was known that the use of an oral fluid kit was not possible within the 
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context of the HAUS study, no oral-based kit was demonstrated during the groups. However, 
these kits were discussed by participants.  
Participatory methods such as ranking activities were used to enhance data collection and 
participant engagement during FGDs.(29) The study team members who collected qualitative 
data in this stage were: CD, EM, SW, CP, GP and IW. CD, SW and IW already posessed 
extensive training and experience in this format of data collection in the HIV field among 
specialist service providers and non-specialists alike, and CD and IW in particular were 
responsible for the training and oversight of research development of EM, GP and CP 
respectively. Intially, all focus group discussions were led by those with the greatest 
experience, and ‘seconded’ by EM, GP and CP, and over time these roles started to switch as 
the latter group gained familiarity and experience with the method and the research tools 
being used. Two researchers attended every group to better enable data capture (including 
observation). All those involved in data collection had considerable opportunity to discuss 
challenges, successes and possible improvements to data collection during fortnightly core 
team meetings, designed to assist such exchange. EM and GP undertook all one-to-one 
interviews, and each had considerable experience with and training in this method. 
 
2.3 Non-Specialist black African focus group discussions 
Participants in the non-specialist FGD included members of the public who self-identified as 
black African (n=48). Three of the FGDs occurred in Greater Glasgow, and three in Greater 
London. The participants were recruited via social media (n=1) and African embassies in 
London (n=6), as well as university student groups (n=16), and community based 
organisations (n=24) in both Glasgow and London (missing=1). Participants were eligible if 
they self-identified as being black African and were aged 18 years and over. The sample was 
purposively selected sequentially during recruitment (with some interested individuals being 
set aside into a ‘pool’ of recruited participants in case they were needed at a latter stage) to 
ensure diversity of age, region of birth, and HIV testing experience. Men were slightly 
overrepresented in the sample, numbering 28 out of 48 participants (58%), compared to 20 
women (42%). The age ranged from 18 to 60 years old. Participants were born in various 
regions of Africa, including East Africa (n=17), Southern Africa (n=10), West Africa (n=10), 
Central and North Africa (n=3), and some born in the UK, Europe or United States of 
America (USA) (n=7) (missing data n=1). In order to ensure a balance of voices, one of the 
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FGDs was comprised only of people under the age of 30 (in London), another of men only (in 
London) and a further group of people living with diagnosed HIV (in Glasgow). The other 
three FGDs were mixed in terms of gender, age, and HIV testing experience (London and 
Glasgow). Nineteen participants had never tested for HIV. The black African non-specialist 
FGD participants were compensated £25 for participating in the discussion. Each FGD lasted 
between one and a half to two hours, with an average of nine participants in each group 
(range between 7 and 11). The FGDs were audio recorded and transcribed verbatim. 
2.4  Service provider focus group discussions and interviews 
Six FGDs were conducted with service providers: three in Glasgow and three in London. 
Sequential purposive sampling (undertaken with the support of simple screening questions 
asked during the recruitment process) ensured a diversity of service providers from a range of 
professional backgrounds, all provided HIV-related or other social services to black Africans. 
Black African ethnicity was not a criterion for involvement in these FGDs. General Practices 
were recruited via the Clinical Research Networks (CRNs) in London, and through 
established working relationships with members of the research team in both cities. 
Community workers in both cities were recruited from organisations with extensive 
experience of delivering HIV prevention and care as well as a range of other non-HIV-
specific services to black Africans. The research team approached pharmacies within areas 
with high concentrations of African residents in both cities, with support from local pharmacy 
associations. Almost all specialist FGDs comprised those from diverse working backgrounds 
in order to elicit contrasts within working and experiential contexts.  
In total, 53 service providers participated in either an FGD or a supplementary interview. 
Those taking part in FGDs included HIV CBO staff (n=15), pharmacists and pharmacy 
assistants (n=9), GPs (n=7), black African service providers (non-HIV focused) (n=5), GP 
practice and specialist nurses (n=3), African faith leaders (n=3), and a Health care assistant 
(HCA) (n=1). The service provider FGD participants were offered reimbursement for their 
travel and their time given to the study. The level of reimbursement varied according to 
profession. The service provider FGDs lasted between one and a half to two hours, with an 
average of seven participants  in each group (range between 4 and 10). These sizes fall within 
the ideal range to prompt discussion while ensuring the participation of everyone in the 
group.(30) 
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Following the FGDs, interviews with ten highly specialised HIV service providers (including 
HIV clinicians, HIV service managers and service commissioners) in London (n=3) and 
Glasgow (n=7) were conducted, to help check the acceptability of intervention and 
procedures. This approach was undertaken in order to include diversity of voice in FGDs, 
accompanied by highly specialised expertise gained through interviews. Each interview 
lasted between 30 and 45 minutes. The FGDs and interviews were audio recorded and 
transcribed verbatim.  
2.5  Analysis of focus group discussions and interviews 
Analysis of the qualitative data was undertaken using a ‘blended’ thematic approach drawing 
heavily on framework analysis.(31) NVivo (version 10) software was used to synthesise and 
code data within a thematic matrix to enable elucidation of conceptual associations. Both a 
priori concepts used in the development of the FGD topic guide as well as emergent concepts 
arising from the data informed the process of identifying the key thematic categories used in 
data coding. Two researchers devised an agreed coding frame, which was then used to index 
and chart the findings. The integrated model of behavioural prediction and change was used 
as the theoretical framework to assess attitudes, willingness, and perceived behavioural 
control to use HIV SSKs.(32)  
Broad descriptive themes included the feasibility and accessibility of HIV testing, existing 
knowledge and uptake of SSKs, and the practicalities of distribution emerged. Cross-cutting 
themes also surfaced which influenced our analysis, particularly those concerned with trust 
and HIV-related stigma. The themes were then refined to devise a more detailed participant-
led, inductive, thematic framework. Researcher-team discussions and iterative analysis 
focussed upon the internal coherence and face validity of the resulting analytic structure.  
2.6 Methodology and analytic approach of intervention development  
At the outset, it was recognised by the study team that successful interventions to increase 
HIV testing are particularly challenging due to the sexual transmission aspect and stigma 
associated with HIV, the latter being particularly prevalent among African communities in 
the UK. To mitigate the complexity inherent in developing and implementing an HIV SSK, a 
systematic four-step approach to intervention development was adopted drawing on the 
Behaviour Change Wheel(33) (see Figure 1). 
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Figure 1: The Behaviour Change Wheel 
(from Michie et al, Implement Sci 2011)) 
 
 
2.6.1 Step 1: Delineate key intervention components 
The intervention development process began with identifying and conceptualising the diverse 
intervention components arising from a combination of existing SSK distribution practice, 
and process-oriented data emerging from Stage 1. The research team considered their 
sequential flow across social contexts, health professionals, SSK recipients and clinical 
governance procedures. In this way, the study team systematically considered the 
segmentation and flow of the intervention chain. This conceptual work also assisted in 
informing the topic guides for follow-up interviews with participants who agreed to take an 
SSK (regardless of whether they ultimately used it) (see Appendix C) and the choice of 
analytic approach for the intervention development work that followed.  
2.6.2 Step 2: Intervention barriers and enablers and relation to theoretical domains 
Step 2 involved further consideration of the key intervention components identified in Step 1 
by utilising Stage 1 data on barriers and facilitators to the intervention. Appendix D provides 
an example of how the study team analysed the relevant data regarding the component ‘the 
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appearance and packaging of the HIV SSK.’ Key barriers and facilitators were then mapped 
onto the Theoretical Domains Framework (TDF).(34)  
The TDF is a meta-theoretical framework which integrates key theoretical domains known to 
be important in understanding behaviour change across a range of populations. It provides a 
coherent way of organising explanations of why things do or do not happen in relation to 
either behaviour change or the implementation of particular intervention components. It 
enables insights into potential mechanisms of action for developing or optimising 
interventions. Table 1 below illustrates the key domains of the TDF and provides a brief 
explanation of the content to which the particular domain refers.  
Table 1: Theoretical Domains Framework – Domains and Explanatory Statements 
Domains Explanatory Statement of the domain 
Knowledge An awareness of the existence of something 
Skills Ability or proficiency acquired through practice 
Professional 
roles/identity 
Coherent set of behaviours and personal qualities of an individual 
in a work setting 
Beliefs about 
capabilities 
Acceptance of the truth or validity of an ability that a person can 
put to constructive use 
Optimism Confidence that things will happen for the best or that desired 
goals will be obtained 
Beliefs about 
consequences 
Acceptance of the truth or validity about outcomes of a behaviour 
Reinforcement Increasing the probability of a response by arranging a dependent 
relationship between the response and a contingency 
Intentions Conscious decision to perform a behaviour or act in a certain way 
Motivation and goals Representation of outcome that individual wants to achieve 
Memory and decision 
processes 
Ability to retain information, focus selectively, and choose 
between two or more alternatives 
Environmental context 
and resources 
Any circumstances of a situation or environment that 
discourages/encourages development of skills, abilities and 
competencies 
Social influences 
(norms) 
Interpersonal processes that can cause individuals to change their 
thoughts, feelings or behaviours 
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Figure 2: The COM-B model 
Adapted from the original figure (see Michie et al, Implement Sci 2011) through inclusion 
of description of the three domains 
 
Domains Explanatory Statement of the domain 
Emotions Complex reaction pattern, involving experiential, behavioural and 
physiological elements 
Behavioural regulation Anything aimed at managing or changing objectively observed or 
measured actions 
Adapted from Cane, O'Connor & Michie. Implement Sci, 2012.(35) 
Analysis and the mapping of barriers and facilitators to the TDF domains were discussed 
within a single all-day event attended by the research team. Differences of opinion were 
resolved through consensus. 
2.6.3 Step 3: Identifying intervention components that could overcome barriers and 
enhance the enablers 
In step 3, an ideal hypothetical intervention that minimized key barriers and amplified key 
facilitators was constructed. The behaviour change wheel was then used to structure the 
intended intervention guided by the ideal intervention.  
The behaviour change wheel links the domains of the TDF to the COM-B (‘capability,’ 
‘opportunity,’ ‘motivation’ and ‘behaviour’) model of behaviour change (36) (see Figure 2). 
The COM-B model suggests that behaviour change is related to three key factors: capability, 
opportunity and motivation. These three factors can be broken down into finer-tuned 
categories and eventually to the TDF domains. Table 2 below shows how the TDF domains 
relate to each COM-B component.  
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Table 2: Connection between COM-B and Theoretical Domains Framework (TDF) 
components 
COM-B component  TDF Domain 
Capability  Psychological  Knowledge 
 Cognitive and interpersonal skills  
Memory, attention and decision 
processes 
Behavioural regulation 
Physical Skills 
Opportunity Social  Social influences (norms) 
Physical  Environmental context and 
resources 
Motivation 
 
Reflective  Professional roles/identity  
Beliefs about capabilities  
Optimism 
Beliefs about consequences 
Motivation and goals 
Intentions 
Automatic Reinforcement 
Emotions 
Adapted from Webster et al.Translational Behavioral Medicine, 2016.(36)  
2.6.4 Step 4: Viability of intervention  
The outcome of Step 3 provided a range of potential ways in which the intervention could be 
structured that would reflect key mechanisms of action and reduce barriers to effective 
implementation. However, it was important to ensure that the resulting intervention was 
viable within busy service delivery contexts. Thus, the study team evaluated the intervention 
content with the APEASE criteria (Affordability, Practicability, Effectiveness and cost-
effectiveness, Acceptability, Site-effects/safety, and Equity)(32) assessing the viability of 
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intervention function and behaviour change techniques for a real world intervention 
implementable within the UK.  
2.7 Summary of Stage 1 methods 
This chapter has described and provided a rationale for each of the activities undertaken to 
meet the key objectives for this stage of the project, namely: 
- Reviewing the available literature on SSKs with regard to feasibility, acceptability 
and effectiveness of this technology at increasing HIV testing uptake; 
- Gain insight from experts and non-experts into the best means of targeted distribution 
of SSKs for the benefit of black African people in the UK, as well as their perspective 
on kit use and functionality; and 
- Conversion of these insights using a a systematic four-step approach to intervention 
development drawing on the Behaviour Change Wheel. 
2.7.1 Strengths and limitations 
Although limited in scope and scale, the range of methods used in Stage 1 enabled the team 
to select a mix of data sources and analytical approaches in their systematic, theoretically 
driven approach to intervention development.  
Findings of the formative Stage 1 focus group discussions and interviews with specialist 
service providers and non-specialist members of the public, and the ensuing intervention 
development process are presented in Chapters 4 and 5 respectively. The next chapter 
presents the methodology and results from the policy and systematic literature review. 
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Chapter 3: Systematic policy and literature review 
A systematic literature and policy review exploring the feasibility and acceptability of self-
sampling for HIV testing, and the effectiveness of HIV self-sampling in increasing the uptake 
of HIV testing was conducted. The overall purpose of this exercise was to address the first 
three objectives of Stage 1: to clarify barriers and facilitators to provision, access and use of 
HIV SSK by black Africans, in primary care, pharmacies and community outreach, to 
determine appropriate SSK-based intervention models for different settings, and to determine 
robust HIV result management pathways. This review also informs the fourth objective, to 
develop an intervention manual to enable intervention delivery. This Chapter contains the 
methodology and results of the policy and systematic literature review.  
The systematic review was registered on PROPERO (study number CRD42014010698). 
3.1  Policy Review 
A policy review was conducted with the aim of summarising current approaches to and 
policies/protocols around use of SSK for HIV in the UK to add context and to inform the 
development of the HAUS SSK intervention manual. Eleven policy statements, clinical 
guidelines, reports and strategies that contained programmatic or clinical guidance on HIV 
self-sampling or on HIV testing in the UK or specific guidance on HIV testing for black 
Africans in the UK published between January 2008 and July 2016 were included (Appendix 
E). Below we provide an overview of the policy approaches and recommendations relevant to 
SSK.  
3.1.1 Policy approaches and recommendations relevant to self-sampling kits 
Most of the policy guidance documents yielded by this search were not specific to SSKs. The 
UK National HIV testing guidelines were produced by the British HIV Association 
(BHIVA), the British Association of Sexual Health and HIV (BASHH) and the British 
Infection Society in 2008 against the background of late HIV diagnosis and undiagnosed HIV 
status in the UK.(37) The guidelines advocated for expansion of HIV testing services 
including routine offering of HIV testing in general practice in areas where the prevalence is 
higher than 2 per 1000 among 16-59 year olds, to patients attending specified services such as 
sexual health clinics or pregnancy termination services, and to patients who report high risk 
behaviour and patients with indicator conditions.(37) Implementation of these guidelines was 
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assessed using eight pilot projects in acute medical settings, emergency departments, primary 
care and community settings.(38) Findings from the pilot projects showed that the 
implementation of guidelines to expand HIV testing in the medical and community settings 
was both feasible and acceptable; HIV SSKs were successfully used in one of the pilot 
projects. A later review by Public Health England (PHE) on the evidence of the effectiveness 
of HIV testing in medical and community settings noted that self-sampling could broaden the 
available testing options.(39) Other strategies have advocated for self-testing as an alternative 
option.(40) Indeed, the national response to HIV continues to evolve and in April 2014 HIV 
self-testing kits (STKs) became legal in the UK.(41, 42)  
With regard to policy specific to the black African community, the National Institute of 
Health and Clinical Evidence (NICE) published specific guidance on increasing HIV testing 
among black Africans in 2011.(43) In 2014, NICE provided detailed recommendations for 
commissioners including local authorities, Clinical Commission Groups and NHS England 
on delivering HIV testing services (44). NICE recommended that commissioners assess local 
need for HIV testing for black Africans and then develop a local HIV testing strategy with 
clear referral pathways, particularly for outreach point of care services. To address 
undiagnosed HIV and late diagnosis of HIV, NICE recommended that commissioners 
promote HIV testing including the use of modern HIV tests and reduce barriers to HIV 
testing among black Africans. In line with the 2008 guidelines mentioned above,(37) NICE 
recommended that HIV testing be offered by health professionals in primary and secondary 
care. Although SSKs were not specifically mentioned in these guidelines, SSKs have been 
commissioned by some local authorities as part of their HIV testing services. These NICE 
guidelines are currently beingwere updated and new guidance to address late diagnosis in 
groups at risk is expected be published in late December 2016, and . In the draft guidelines 
issued for consultation earlier this year, SSKs and self-testing kits were endorsed considered 
a potentiallyas innovative ways of increasing uptake of HIV testing among black Africans 
given that they may potentially address the known barriers to HIV testing in this risk 
group.(45) Despite support within the policy documents for HIV SSK as a means of 
increasing uptake of testing, evidence on the impact of SSK on uptake compared to clinic-
based testing was limited to one study. 
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3.2  Results of systematic literature review  
A total of 4,052 documents were retrieved, of which 1,994 were duplicates. Reviewers 
identified 85 eligible for full paper screening, with 1,973 excluded as they did not meet the 
inclusion criteria. Seventy-two papers were excluded after full paper screening due to: not 
including SSK for HIV testing or only presenting combined results with other types of testing 
(n=38), inappropriate publication type (n=26), inappropriate study type (n=6), and irrelevant 
country setting (n=2). Figure 3 contains a flow chart of the study search and selection 
process. Thirteen studies were selected for inclusion in the literature review.  
3.2.1  Description of included studies 
Table 3 presents the description of the 13 studies included in the review. Of the included 
studies, nine were conducted in the USA and four in the UK. Eight were cross-sectional 
surveys, three were prospective cohort studies, one was qualitative and one a randomised 
controlled trial (RCT). The total sample size across the papers was 15816, with an average 
response rate of 78% (range: 38%-100%; information not provided in two studies.(46, 47) 
The majority of the studies included communities at high risk of HIV infection. Ten included 
MSM, three included injection drug users (IDUs), and three included non-specified at-risk 
individuals or clinic populations. Only two focused on high-risk heterosexual populations 
(both in the USA); all of the UK studies included only MSM. The only RCT in the included 
studies was conducted with IDUs. Most studies reported a predominantly white sample, 
although the sample in the RCT was 48% African-American. Where provided, the average 
age of participants ranged from 18-47 years. 
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Figure 3:Flow chart of study search and selection 
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Table 3: Description of included studies 
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1 
Bartholow 
(2005)55 
RCT 
To compare the likelihood of HIV 
testing and obtaining test results 
between participants 
randomized to Traditional 
Counselling and Testing and 
Consumer Controlled Testing 
among methadone 
maintenance, detoxification, and 
out-of treatment drug users 
USA IDU 489 92% 
Mean age 
40, 71% 
male, 48% 
African 
American 
Dried 
blood 
spot 
Provided in 
drug clinic 
Post ++ / ++ 
2 
Colfax et al. 
(2002)46 
Multiple 
cross 
sectional 
surveys 
An examination of intent to use 
SSK, actual use and barriers to 
use among persons at high risk 
of HIV infection 
USA 
MSM, IDU, 
high risk 
hetero-
sexuals 
3471 
Not 
report
ed 
74% male, 
44% white 
Dried 
blood 
spot 
Purchased 
(presumably 
from 
pharmacy) 
Not 
specified 
+ / + 
3 
Fisher et al. 
(2015)50 
Prospective 
observational 
cohort 
To determine uptake of SSKs for 
HIV and STIs compared to 
conventional clinic-based 
testing, and to determine 
whether the availability of SSKs 
would increase STI testing 
amongst HIV infected MSM and 
those attending a community-
based HIV testing service 
compared to historical controls 
UK MSM 
433 
(80 for 
HIV 
testin
g) 
75% 
Median age 
33, 84% 
white British 
Oral 
fluid 
By post Post + / + 
4 
Formby, 
Hirst & 
Cripps 
Cross 
sectional 
survey 
To evaluate the Time 2 test pilot 
study which was based on the 
use of SSKs  
UK MSM 126 100% 
Median age 
24, 89% 
white British 
Oral 
fluid 
Postal and 
public sex 
environment
Post - / - 
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(2010)51 s 
5 
Greensides 
et al. 
(2003)49 
Cross 
sectional 
survey 
To determine the levels of 
awareness and use of 
alternative HIV tests (SSKs and 
rapid tests among people at high 
risk of HIV infection 
USA 
MSM, IDU, 
high risk 
hetero-
sexuals 
2836 66% 
Mode age 
25-34, 73% 
male, 39% 
white 
Dried 
blood 
spot 
Not specified 
Not 
specified 
+ / + 
6 
Osmond et 
al. (2000)54 
Cross 
sectional 
survey 
To test the feasibility of 
obtaining HIV test results by 
SSK from a probability 
telephone sample of MSM 
USA MSM 490 78% 
Urban 
areas, 67% 
white, 71% 
aged 18-29 
Oral 
fluid 
Mailed Post ++/ + 
7 
Sharma, 
Sullivan & 
Khosropour 
(2011)56 
Cross 
sectional 
survey with 
randomisatio
n 
To describe the factors 
associated with willingness of 
internet-using MSM to take a 
free anonymous home HIV test 
as part of online prevention 
activities 
USA MSM 6163 68% 
Median age 
18-24, 43% 
white, 31% 
Hispanic 
Not 
specifie
d 
Not specified Post + / + 
8 
Sharma et 
al. (2014)53 
Cross 
sectional 
survey 
To investigate attitudes towards 
six different HIV testing 
modalities presented collectively 
to internet -using MSM and 
identify which options rank 
higher than others in terms of 
intended usage preferences 
USA MSM 973 38% 
Median age 
26, 77% 
white 
Dried 
blood 
spot 
Not specified 
Not 
specified 
+ / + 
9 
Skolnik et 
al. (2001)52 
Cross 
sectional 
survey 
To examine preferences for 
specific types of HIV tests 
(public clinic test, doctor test, 
SSK, home self-test) as well as 
for test attributes such as cost, 
USA 
Public 
clinics 
354 96% 
Mean age 
34, 77% 
male, 63% 
white 
Dried 
blood 
spot 
Mailed or 
pharmacy 
Post + / + 
47 
 
S
tu
d
y
 N
u
m
b
e
r 
A
u
th
o
r 
(y
e
a
r)
 
S
tu
d
y
 d
e
s
ig
n
 
S
tu
d
y
 a
im
s
 
S
e
tt
in
g
 
P
o
p
u
la
ti
o
n
 (
ie
 
c
li
n
ic
, 
in
te
rn
e
t,
 
M
S
M
 e
tc
) 
S
a
m
p
le
 s
iz
e
 
R
e
s
p
o
n
s
e
 r
a
te
 
S
a
m
p
le
 
c
h
a
ra
c
te
ri
s
ti
c
s
 
(i
e
, 
a
g
e
, 
g
e
n
d
e
r,
 
e
th
n
ic
it
y
) 
T
y
p
e
 o
f 
H
IV
 
te
s
ti
n
g
 s
a
m
p
le
 
M
e
th
o
d
 o
f 
S
S
K
 
d
is
tr
ib
u
ti
o
n
 
M
e
th
o
d
 o
f 
re
tu
rn
 
Q
u
a
li
ty
 
a
p
p
ra
is
a
l 
s
c
o
re
 (
in
te
rn
a
l 
/ 
e
x
te
rn
a
l)
 
counselling and privacy 
1
0 
Spielberg 
et al. 
(2000)21 
Prospective 
cohort 
To assess the feasibility and 
acceptability of bimonthly home 
oral fluid and dried blood spot 
collection for HIV testing among 
high risk individuals 
USA 
At-risk 
individuals 
enrolled in 
vaccine 
study 
241 84% 
Mainly white 
male, 58% 
MSM, mean 
age 36  
Dried 
blood 
spot or 
oral fluid 
Choice of 
mailed or 
collected 
from study 
site 
Post ++ / +  
1
1 
Spielberg 
et al. 
(2001)57 
Cross 
sectional 
survey 
To evaluate attitudes about SSK 
and telephone counselling 
among participants, HIV 
counsellors, community advisory 
board members and cohort 
participants 
USA 
Clinic staff 
and at-risk 
individuals 
126 ~80% 
Mean age 
35, 71% 
male, 54% 
white 
Dried 
blood 
spot or 
oral fluid 
Not specified Post -/ - 
1
2 
Wayal et al. 
(2011)48 
Qualitative 
interviews 
To explore preferred mechanism 
for offering home-sampling kits, 
perceptions about using SSKs to 
screen for STIs and HIV and 
views about STI clinic use and 
SSKs 
UK MSM 24 80% 
Median age 
39, mainly 
white 
Not 
specifie
d 
Range of 
options 
assessed 
Several 
options 
+ (overall) 
1
3 
Wood, Ellks 
& Grobicki 
(2015)47 
Prospective 
cohort 
To compare the results of a pilot 
outreach STI service using 
nurse-delivered screening and 
SSKs at a sex on premises 
venue against screening within a 
sexual health clinic 
UK MSM 90 NA 
Median age 
47  
Dried 
blood 
spot 
Collected in 
sauna 
Post - / + 
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The majority of the studies evaluated a dried blood spot SSK (n=8), while five assessed an 
oral fluid test (two assessed both types of sampling and another two did not specify type).  
The methods by which SSKs were distributed varied across the studies with five including 
the option of kits being mailed out to participants and six requiring participants to pick up a 
SSK from a study site (including pharmacies, drug clinic, public sex environment, sauna or 
unspecified study site). Three offered participants a choice of both options and four did not 
specify how kits were distributed. Nine studies required participants to return kits by post (the 
remainder did not specify the method of return or it was not applicable to the study type). The 
qualitative study assessed a range of options with participants.(48) 
3.2.2 Quality appraisal 
According to the criteria used for both qualitative and quantitative studies only a few high-
quality papers were identified that related to the study outcomes. The majority of studies took 
the form of cross sectional surveys (8 of 13 papers), with only one RCT identified.  
Only the RCT scored ++ for both internal and external validity. Two of the three prospective 
cohort studies scored ‘+’ or higher for both categories, as did six of the eight cross sectional 
studies. The qualitative study scored ‘+’ overall. Two of the cross sectional studies assessed 
the acceptability of a hypothetical offer of self-sampling, and overall few of the studies 
directly compared the efficacy of different forms of testing. Those studies that scored poorly 
on both categories commonly featured a small sample size and/or deficient level of analysis. 
3.2.3 Acceptability, feasibility and effectiveness of self-sampling 
All but one of the included studies(49) reported on some measure of the acceptability of self-
sampling (Table 4). In total, only five studies (three from the USA and two from the UK) 
reported on the distribution and return of SSKs. Within these, 1652 SSKs were distributed 
(range: 80-716) and 1373 participants returned a specimen (range: 60-665). This suggests a 
medianreturn rate of 77.5% (range: 47.6%-92.9%). The two UK studies (50, 51 respectively), 
distributed 80 and 126 HIV SSKs, with 62 (77.5%) and 60 (47.6%) returned, respectively. 
Both of these studies used oral fluid sampling, and no inadequate samples were reported. 
Twelve of the included studies did include (self-reported) data on acceptability of SSK to 
participants, but measures used were inconsistent. Self-reported acceptability was generally 
high, with self-sampling reported to be broadly acceptable to participants (see Table 4). For 
example, Spielberg et al. (2000) reported that 98% of participants agreed to take part in either 
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oral fluid or dried blood spot bimonthly sampling in the future.(21) Similarly, Fisher et al. 
(2015) reported that 81% of MSM found (oral fluid) SSK to be acceptable.(50) However, 
Colfax et al, Wood, Ellks & Grobicki (2015), Skolnik et al. (2001) and Sharma et al. (2014) 
reported that few took up the offer of testing and/or found it to be the least preferred option 
among participants – it is notable that all of these used blood sampling.(46, 47, 52, 53) In 
terms of comparing the different types of tests, Spielberg et al. (2000) found no difference in 
testing rates between dried blood spot and oral fluid testing, but this was the only study to 
compare the two method.(21) Acceptability did not vary significantly by distribution method.  
In terms of feasibility, only six studies included any documentation of how tests were 
completed, errors in testing, communication of results, or linkage to care. Three of these 
studies used oral samples, two blood, and one both. There were few reports of errors in 
testing. Spielberg et al. (2000) reported that 99% of both oral fluid and dried blood spot 
samples were adequate for testing, (21) while Osmond et al. (2000) reported two 
indeterminate results and 10 insufficient samples (out of 412 returned oral fluid samples)(54) 
and Formby, Hirst & Cripps (2010) reported that seven equivocal oral fluid samples had to be 
re-tested (out of 126) (all tested negative).(51) Wood, Ellks & Grobicki (2015) reported that 
3/30 tests of dried blood spot samples were not processed.(47) Spielberg et al. (2000) 
reported that staff was concerned about the efficacy of telephone counselling(21) and 
Osmond et al. (2000) found that only half of those tested telephoned for their results.(54) 
Similarly, Bartholow (2005) reported that 22% of those tested did not report receiving their 
test results(55) and Wood, Ellks & Grobicki (2015) reported that 4/30 test results were not 
communicated to participants.(47) Fisher et al. (2015) reported that 2/62 required a reminder 
to return their sample.(50) Formby, Hirst & Cripps (2010) also reported that oral fluid 
samples were delayed in getting to the laboratory, which required participants to be contacted 
and asked to re-send their samples to ensure accuracy of results.(51) Linkage to care was not 
assessed because most studies (n=9) had no reactive results. The studies that did have 
reactive results were unable to check on outcomes for linkage to care due to features of their 
methodology. 
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Table 4: Acceptability, feasibility and efficacy of self-sampling for HIV 
S
tu
d
y
 N
o
 
A
u
th
o
r 
(y
e
a
r)
 
N
o
. 
S
S
K
 r
e
tu
rn
e
d
 /
 
N
o
. 
S
S
K
 
d
is
tr
ib
u
te
d
 
C
o
m
p
le
ti
o
n
 r
a
te
 
(%
) 
H
IV
 p
o
s
it
iv
it
y
 r
a
te
 
S
e
lf
-r
e
p
o
rt
e
d
 
a
c
c
e
p
ta
b
il
it
y
 
 
F
e
a
s
ib
il
it
y
 
E
ff
ic
a
c
y
 (
ie
, 
in
c
re
a
s
e
s
 i
n
 H
IV
 
te
s
ti
n
g
 u
p
ta
k
e
) 
1 
Bartholow 
(2005)55 
174 / 240 
(self-reported; 
not clear if all 
self-sampled 
tests) 
72.5% 
3.4% 
(6/174) 
Those in SSK arm rated 
satisfaction higher than 
those in clinic testing arm. 
37 (22%) of those who reported being 
tested did not report receiving their test 
results. 
Those in SSK arm were twice as 
likely to have tested in past month. 
However, they were not more likely 
to obtain their results. 
2 
Colfax et al. 
(2002)46 
NA NA NA 
19% chose SSKs for their 
next test in first survey 
(pre-marketing), but in 
second survey only 1% 
had used them.  
NA 
Availability of SSKs had not 
increased testing rates among 
those not tested previously. 
3 
Fisher et al. 
(2015)50 
62 / 80 77.5% 
0% 
(0/62) 
Acceptable to 81% of MSM 
in sexual health clinic 
setting. 
2 out of 62 required reminder to return 
sample. 
Greater acceptance compared to 
clinic-based testing (62.5% vs 
37.5%) 
4 
Formby Hirst 
& Cripps 
60 / 126 47.6% 
0% 
(0/60) 
Pre-study survey showed 
52% of MSM chose SSKs 
Some samples were delayed in getting 
to laboratory, meaning participants had 
Pilot successfully reached those not 
regularly engaging with HIV testing, 
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(2010)51 as preferred method of 
testing. Anecdotal 
evidence suggested 
demand for pilot to 
continue. 
to be contacted to re-send. 7 samples 
had equivocal results and were re-
tested (all negative). Capacity issues 
within virology for processing oral 
samples. 
including higher than expected 
numbers of bisexual men, men not 
otherwise tested in last year and 
those not accessing GUM 
5 
Greensides et 
al. (2003)49 
NA NA NA - NA 
High levels of awareness, but low 
reported usage of SSK use in past 
year (4%). 
6 
Osmond et al. 
(2000)54 
412 / 490 84% 
1.5% 
(6/412) 
Many participants 
commented on how easy it 
was to provide oral fluid 
samples.  
Two indeterminate test results. 10 
insufficient samples. 6 new diagnoses 
made. Only half of those tested 
telephoned for their results. 
SSK found to be effective method 
at estimating population 
seroprevalence among MSM.  
7 
Sharma 
Sullivan & 
Khosropour 
(2011)56 
NA NA NA 
62% likely and 20% 
somewhat likely to take an 
offered SSK 
NA 
SSK is acceptable, and future 
research and interventions should 
focus on addressing self-identified 
barriers faced by MSM to testing 
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using SSKs. 
8 
Sharma et al. 
(2014)53 
NA NA NA 
SSK was least likely option 
among those available: 
appealed to less than half 
participants 
NA 
Novel approaches needed to 
increase HIV testing frequency, 
including combination packages. 
9 
Skolnik et al. 
(2001)52 
NA NA NA 
1% preferred SSK option 
of clinic or self-testing.  
NA 
Most preferred self-testing and 
clinic testing to SSK. 
10 
Spielberg et 
al. (2000)21 
665 / 716 92.9% 
0% 
(0/665) 
98% agreed to participate 
in bimonthly testing in 
future. 99% said easy to 
use. 
Staff concerns raised about efficacy of 
telephone counselling. Anxiety 
reported among 28% of male IDU. 
99% test adequacy: no positive 
diagnoses made. 
No detectable difference in testing 
rates between dried blood spot and 
oral fluid samples. 
11 
Spielberg et 
al. (2001)57 
NA NA NA 
92% of participants willing 
to enrol in monthly SSK 
study.  
NA 
Despite staff concerns, majority 
expressed willingness to submit 
regular SSKs.  
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12 
Wayal et al. 
(2011)48 
NA NA NA 
Acceptability of oral 
specimens examined with 
different parameters; 
broadly acceptable to 
MSM. 
NA 
SSKs could be a viable alternative 
to meet the increasing demand for 
sexual health services, but to 
improve uptake the method of 
service provision must be culturally 
sensitive and acceptable. 
13 
Wood, Ellks & 
Grobicki 
(2014)47 
NA NA NA 
Lower rates of acceptance 
for SSKs than nurse 
delivered testing (33 over 
the pilot vs 80 tests) 
3/30 tests not processed. 4/30 test 
results not communicated 
Combination outreach screening 
approach, including SSKs, is 
effective in targeting MSM using 
sex on premises venues.  
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Only six studies provided data on the effectiveness of SSKs for HIV in increasing the uptake 
of HIV testing. In the one RCT included in the review, Bartholow (2005) reported that those 
in the self-sampling arm were twice as likely to have tested for HIV in the past month, but 
they were not more likely to obtain their results compared to those in the clinic-based testing 
arm.(55) In the USA, Colfax et al. (2002) reported that the availability of SSK had not 
increased testing rates among those not tested previously, or significantly changed testing 
behaviour among those who do get tested.(46) In the UK studies, Formby, Hirst & Cripps 
(2010) reported that SSK offered an alternative means of testing, with 35% of participants 
having never tested for HIV before,(51) while Fisher et al. (2015) reported greater uptake of 
SSK (62.5%) compared to clinic-based testing (37.5%).(50) Formby, Hirst & Cripps (2010) 
concluded that the pilot successfully reached those not regularly engaging with HIV testing, 
including higher than expected numbers of bisexual men, men not otherwise tested in last 
year and those not accessing existing sexual health services.(51) Other studies provided data 
in support of this stance as well. For example, the only qualitative study included in the 
review noted SSK could be a viable alternative to meet increasing demand for sexual health 
services, but to improve uptake the method of service provision must be culturally sensitive 
and acceptable.(48) Wood, Ellks & Grobicki (2015) concluded that including self-sampling 
in outreach settings could be effective in targeting MSM using sex on premises venues.(47) 
Finally, four studies reported the HIV positivity rate, which was an average of 0.9% 
(12/1311). Two studies (both with MSM in the UK) reported a positivity rate of 0%. 
3.2.4 Barriers, facilitators and motivators to self-sampling for HIV 
The final section of the review assessed the barriers, facilitators and motivators to HIV self-
sampling (Table 5). Key barriers included anxiety, concerns over the accuracy of testing, 
concerns about confidentiality, privacy and the lack of face-to-face counselling, and fears 
about the difficulty or pain involved in collecting samples. On the other hand, one of the UK 
studies reported that there was no difference in uptake related to importance of accuracy of 
results or willingness to wait for results.(50) Test reliability was reported to be a barrier in the 
other UK study.(51) Wayal et al. (2011) additionally reported potential barriers to uptake 
among British MSM to include preference for medical venues (which were perceived as 
discrete and appropriate, especially if symptomatic), fear that distribution in gay social 
venues could trivialise testing or promote stigma, concerns about unreliability of postal 
service for delivering samples, and anxiety over waiting for results.(48) 
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Conversely, reported facilitators to SSKs were the availability of telephone (as opposed to 
face-to-face) counselling, and perceived anonymity, accuracy, convenience and ease of use. 
Finally, additional motivating factors that were reported to contribute to the acceptability of 
self-sampling were awareness of the seriousness of HIV(48) and the benefits of regular/early 
testing,(21, 55) and agreement or awareness of being at risk of HIV.(21, 48, 53, 55) Two 
studies also noted that a cash incentive could be a motivating factor to test.(54, 56)  
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Table 5:Barriers, facilitators and motivators to uptake of self-sampling for HIV 
Study 
No 
Author (year) Barriers Facilitators Motivators (ie factors contributing 
to the acceptability of SSK) 
1 
Bartholow 
(2005)55 
Difficulty of collecting blood sample. Negative 
reactions from others if diagnosed.  
Attendance at syringe exchange.  
Perceptions of personal risk of HIV. 
Perceived benefits of regular testing.  
2 
Colfax et al. 
(2002)46 
Most common concern was accuracy (56%)   
3 
Fisher et al. 
(2015)50 
No difference in uptake related to importance of 
accuracy of results or willingness to wait for 
results 
- - 
4 
Formby, Hirst & 
Cripps (2010)51 
Reliability of test result. Speed of obtaining test 
results.  
Ease of use of kit. Ease of following 
instructions. Lack of 
embarrassment.  
Number of partners in previous year.  
5 
Greensides et 
al. (2003)49 
Concerns raised about accuracy, privacy and 
cost by those who had not used self-sampling. 
Convenience and privacy cited as 
main advantages. Ease of use also 
mentioned.  
Awareness of alternative testing 
methods.  
6 
Osmond et al. 
(2000)54 
42% (241/568) of study subjects expressed 
concerns:  
 unsure about accuracy (130/568; 23%) 
 lack of in-person counselling (81; 14%) 
 worried about confidentiality (26; 5%) (22%; 
28/125 among those who declined) 
- 
Cash incentive used to recruit to study 
(resulting in high uptake among those 
with previous HIV diagnosis) 
7 
Sharma Sullivan 
& Khosropour 
(2011)56 
Barriers cited: 
 Accuracy of test results (519/1047; 47%) 
 Unwillingness to provide address (396; 
- 
Hypothetical cash incentive being 
offered to test. 
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Study 
No 
Author (year) Barriers Facilitators Motivators (ie factors contributing 
to the acceptability of SSK) 
36%) 
 Desire for counselling (391; 36%) 
 Living with others (311; 28%) 
 Recently tested (277; 25%) 
 No need for test (245; 22%) 
 Not wanting to prick finger (217; 20%) 
 Not wanting to know status (61; 6%) 
8 
Sharma et al. 
(2014)53 
- - 
Motivations for HIV test (across all 
methods) 
 Test routinely (55%) 
 new partner (25%) 
 opportunity (21%) 
 recent unprotected anal 
intercourse (15%) 
 partner with STI (10%) 
 symptoms of STI (10%) 
 partner with HIV (3%) 
 felt need to test (2%) 
9 
Skolnik et al. 
(2001)52 
99% selected other test methods, most important 
attributes: 
 accuracy/timeliness 
 privacy of results disclosure 
 linking of test results 
Reasons for selecting self-sampling 
as first choice (n=2): 
 Anonymity 
 Convenience 
 Accuracy 
- 
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Study 
No 
Author (year) Barriers Facilitators Motivators (ie factors contributing 
to the acceptability of SSK) 
10 
Spielberg et al. 
(2000)21 
Reasons for refusal to participate in the study: 
 lack of time (19/45; 42%) 
 collecting samples would be too difficult or 
painful (10; 22%) 
 not wanting to collect specimens at home 
(6; 13%) 
 anxiety (5; 11%) 
 Frequency of projected use 
inversely dependent on cost 
 Availability of telephone rather 
than face to face counselling 
Agreement that early treatment for 
HIV results in prolonged health 
11 
Spielberg et al. 
(2001)57 
Anxiety over receiving regular test results. Fear 
of pain of collecting sample. Concerns over 
inaccuracy of results. Waiting time for blood 
spots to dry.  
Key themes convenience (51%), 
ease of use (32%), time efficiency 
(29%) 
Help with reducing high-risk 
behaviour.  
12 
Wayal et al. 
(2011)48 
 Preference for medical venues, perceived 
as discrete and appropriate, especially if 
symptomatic 
 Distribution in gay social venue may 
trivialise testing or promote stigma 
 Concerns about unreliability of postal 
services 
 Anxiety over waiting for results: mixed 
feelings over ‘no news is good news’ policy 
 Desire for kits to be packaged 
as ‘health check’ to promote 
discretion 
 Availability in routine 
commercial venues 
 Being able to drop samples off 
in clinic 
 Having multiple options for 
receiving results 
 Testing for multiple STIs at 
once 
 Convenience of self-sampling 
 Desire for peace of mind 
 Having a negative sexual 
experience 
 Need to be aware of HIV 
status due to serious 
implications 
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Study 
No 
Author (year) Barriers Facilitators Motivators (ie factors contributing 
to the acceptability of SSK) 
 Availability of oral sample kits 
13 
Wood Ellks & 
Grobicki 
(2015)47 
- 
Clear supporting information and 
opportunity to access health 
promotion advice.  
- 
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3.3 Summary  
Few studies have examined the acceptability or feasibility of self-sampling for HIV testing 
and only 13 studies met the inclusion criteria to be included in this review. The majority of 
the evidence came from cross-sectional surveys or cohort studies, and there was only one 
qualitative study and one randomised controlled trial. Most studies were conducted in the 
USA, with just four in the UK. The majority of the studies, and all of those conducted in the 
UK, focused on MSM. Overall quality of the studies was mixed and relatively poor. 
Few studies assessed acceptability and feasibility in terms of actual uptake and return of tests, 
with only five studies assessing distribution and return of SSK. Acceptability varied by 
sample type. The majority of the studies evaluated a dried blood spot SSK and these appeared 
somewhat less acceptable to participants than oral fluid sampling.(46, 47, 52, 53) However, 
the one study that directly compared the two found no difference in testing rates between 
dried blood spot and oral fluid sampling.(21) Only one UK study (with MSM) included dried 
blood spot SSK and the method proved less acceptable than nurse-led testing.(47) The 
methods by which SSK were distributed varied across the studies, but acceptability did not 
differ substantially by distribution method. It was not possible to assess acceptability by 
method of return because all of the studies that specified a return method reported that SSK 
were returned by post. Overall, feasibility was mixed and problems were reported with the 
return of tests and communicating results to participants. Again, there did not appear to be 
any significant difference by sample type; three of the studies reporting on feasibility having 
used oral samples, two blood, and one both. Evidence on linkage to care was particularly 
lacking and not assessed because most studies had no reactive results.  
Evidence on the effectiveness of self-sampling for HIV in increasing the uptake of HIV 
testing was also limited. In the one RCT included in the review, Bartholow (2005) reported 
that those in the self-sampling arm were twice as likely to have tested for HIV in the past 
month, but they were not more likely to obtain their results.(55) Two of the UK studies 
reported increased testing among groups never tested before, including higher than expected 
numbers of bisexual men, men not otherwise tested in last year and those not accessing 
existing GUM services, but neither study included African communities.(50, 51) Although 
other studies reported that SSK could be a viable means of reducing pressure on existing 
sexual health services,(47, 48) the HIV positivity rate (where reported) was low for the high 
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risk populations included (two studies with MSM in the UK reported a positivity rate of 0%, 
(50, 51) suggesting that those most at risk of HIV were not using this method of testing. 
Despite the limitations in assessing acceptability, feasibility and efficacy, all 13 studies in the 
review included some data to inform understanding of how SSK could work in practice, with 
concerns about anxiety over testing process, the accuracy of testing, confidentiality, and 
privacy being key barriers. The qualitative study also noted that there was a preference 
among the MSM interviewed for testing to remain in clinical settings. Conversely, key 
facilitators were the availability of telephone (as opposed to face-to-face) counselling, 
perceived anonymity, accuracy (although the latter was also identified as a barrier), 
convenience and ease of use (again, somewhat in contrast to opposing fears about difficulties 
in collecting samples). A number of studies also noted that awareness and perceived personal 
risk of HIV were motivating factors for testing.(21, 48, 53, 55, 57)  
3.3.1 Strengths and limitations 
The studies included in this review were of relatively poor quality, with most data derived 
from cross-sectional studies and only one RCT included in the review. Most studies were 
conducted in USA, which raises questions about the transferability of the findings to the UK 
context. Most, and all of the UK studies, were conducted with MSM, which again raises 
questions about the transferability of the findings to black Africans not identifying as MSM 
in the UK. Furthermore, data on actual uptake and return of tests, effectiveness of self-
sampling in increasing HIV testing and effectiveness of processes for linkage to care were 
largely absent and represent key knowledge gaps. The lack of standardised reporting of 
outcomes also made it difficult to compare findings across studies. Only one qualitative study 
was yielded by the search, despite the potential for such studies to inform the design and 
implementation of self-sampling for HIV interventions. 
3.5 Conclusion 
Self-sampling for HIV testing has been suggested as an approach to broaden the available 
testing options,(39) and was successfully used in one pilot project set up to assess 
implementation of the UK National HIV testing guidelines.(37) NICE guidance on increasing 
HIV testing among black Africans did not specifically recommend self-sampling,(43) but 
SSKs were commissioned by some local authorities as part of their HIV testing services. 
These guidelines are currently being updated and new guidance to address late diagnosis in 
groups at risk is expected be published in December 2016. In the draft guidelines issued for 
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consultation, SSK and self-testing kits are endorsed as innovative ways of increasing uptake 
of HIV testing among black Africans. However, our review suggests that evidence to support 
the acceptability, feasibility and effectiveness of this as an approach to increase HIV testing 
is limited, and absent for black Africans people of all sexualities in the UK. There is a need 
for well-conducted trials of self-sampling interventions to assess acceptability, feasibility, and 
whether the approach can increase HIV testing among all high-risk populations and black 
African people in particular. It is important that these studies include detailed description of 
processes for, and the acceptability, feasibility and effectiveness of the processes for linkage 
to care including uptake of confirmatory testing and methods for linking those who test HIV-
positive to care and treatment services. This will be particularly important for self-sampling 
(and self-testing) interventions to be implemented in practice. 
The next Chapter presents the findings yielded via focus group discussions with non-
specialists and service providers and one-to-one interviews with the latter regarding the 
development of an acceptable SSK distribution pathway and protocol via community-based 
health and HIV prevention services already accessed by black African people.  
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Chapter 4: Findings from focus group discussions and one-to-one 
interviews 
As stated in Chapter 1, the aim of Stage 1 of the HAUS Study was to develop a SSK-based 
intervention that could increase the provision and uptake of HIV testing among black 
Africans using existing community and healthcare provisions. In doing so, it was important to 
understand the barriers and facilitators to HIV testing in general, to consider how participants 
responded to the SSK itself, and gain their insights into the most feasible distribution, 
collection and communication of results procedures. This Chapter presents qualitative 
findings drawing on FGDs and interviews, as described in section 2.2 above.  
4.1 Perceptions of HIV testing interventions 
Non-specialist black African participants demonstrated awareness of the range of settings in 
which most HIV testing currently takes place. It was clear amongst all participants, however, 
that specialist sexual health and HIV services were regarded as playing a crucial role in 
recommending and facilitating HIV testing, as well as providing ongoing social support for 
those who are diagnosed with or affected by HIV. Experience of, and opinions about, 
community and non-HIV/sexual health clinic offers of HIV testing were various, with most 
mentioning HIV testing during antenatal care, new GP registrations in high prevalence areas 
and POCT in community-based HIV charities. The vast majority regarded HIV testing as an 
acceptable and effective intervention due to the universal availability of anti-retroviral 
treatment in the UK. 
Some service providers highlighted that undocumented African migrants were often isolated 
from the UK medical system and unaware of free access to HIV treatment, presenting 
barriers to HIV testing. One commented:  
I think on a social level, from what I have experienced while working, is that a lot of 
people who are undocumented in this country don't understand the fact that the test is 
free, and the treatment is free [London non-specialist group 3]. 
Furthermore, there was some concern that a profusion of HIV testing interventions could lead 
to a disjointed and confusing service landscape. Some felt that unfamiliarity with the NHS 
could mean that a proportion of black African people may be unaware of the confidentiality 
provisions, particularly those pertaining to HIV and sexual health. 
There was considerable agreement that the stigmatising association of HIV with ‘sexual 
immorality’ and promiscuity (an association that many FGD participants and interviewees 
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described as being heightened within black African communities) provides an ongoing 
disincentive to test.  
Aligned with findings from previous research (9, 58), some service provider and non-
specialist participants alike pointed out that testing uptake may continue to be low because an 
HIV diagnosis was regarded as having profound health, social, financial, insurance and 
immigration implications. These views were often based on assumptions or considerably 
outdated information, even among service providers. One service provider queried with 
regard to HIV testing:  
I don’t know if I’m right about this, but does that not affect your credit rating? 
[Glasgow service provider group 1].  
Furthermore, a strong association between HIV and mortality among black Africans was 
repeated across service providers and non-specialists.  
Some participants also believed that HIV exceptionalism had structurally prevented HIV 
testing integration into mainstream health services such as primary care. They described the 
historic requirements for pre- and post-test counselling and the requirements of careful results 
management barriers for both offers and uptake of tests.  
4.1.1 Recognition of risk as a precursor to HIV testing 
In many cases, a crucial factor that determines whether or not an individual undertakes an 
HIV test is the recognition that they have faced an elevated risk of exposure to HIV (i.e. a 
motivation to test), along with having the capacity and opportunity (time and skills) to act on 
that concern. With the exception of interviews undertaken among HIV clinicians and some 
service providers in London, improved recognition of personal HIV risk and the need for 
awareness of the disproportionate impact of HIV among black African people in the UK were 
rarely linked with the need for improved HIV testing uptake in this population. The findings 
summarised in this Chapter draw attention to the ways that HIV-related stigma and fear are 
inevitably linked to inaccurate risk perception, which in turn influences the motivation and 
capacity to test for HIV. 
Perhaps unsurprisingly, the findings reveal a dissonance in perceptions of HIV risk between 
the epidemiological data on black African communities’ and the way that the risk is 
perceived by individuals within such communities. What we are referring to here specifically 
is the lack of awareness (and acceptance) of surveillance estimates that reveal people of black 
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African ethnicity account for almost one third of adults with HIV in the UK.(1) Some 
participants felt that where potential targets were unaware of the scientific rationale for 
segmenting the population in relation to epidemiological categories, such approaches would 
be met with resistance. 
I just see there being a bit of a disconnect, unless people are made to understand that 
this is, these are the clear [epidemiological] results that have been found, and this is 
why we’re, you know, suggesting to you. Until that gap is bridged, I just don't. I just 
believe you’re going to be almost, you know, you’re just going to be met with, you 
know…“Uh”? [London non-specialist group 3]. 
At least some service provider participants felt that the dissonance that emerged between 
individual risk perception and community risk profiling was a challenge that may often be 
beyond the capacity of the service provider to bridge in ‘one-off’ encounters. These findings 
demonstrate that the diverse range of participants had pervasive concerns about the 
interpersonal and wider social implications of targeting HIV testing interventions for black 
African people in the UK. 
4.1.2 Competing imperatives 
The relatively low priority of HIV screening among people who had many more pressing 
needs to be met was frequently raised, as was lack the time or funds to reach a testing site. In 
addition, some participants highlighted that there are those who lack the freedom or control in 
their lives to undertake a test while maintaining adequate levels of privacy to avoid HIV 
related stigma. Qualms were also expressed about the extent to which confidentiality within 
health services could be trusted, which meant the prospect of disclosure presented too much 
risk for vulnerable individuals.  
4.1.3 Targeting HIV testing on the basis of actual or perceived ethnicity 
A range of issues emerged among participants about the underlying inequalities that can 
impede the success of HIV testing interventions designed to target black Africans. There 
were intense concerns about such offers being perceived to be driven by racism and 
discrimination across both service providers and non-specialist participants, awareness of the 
particular sensitivities that targeting could fuel anti-migrant discourse, and the threat that 
targeting would be perceived as divisive. Similalry concern was expressed that targeting all 
people considered, by a service provider, to be black African implied complicity with the 
homogenisation of highly diverse cultures and communities. Finally there was discomfort 
with the assumption that targeting would probably rely on appearance and colour of skin 
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(being ‘black enough’, as one specialised HIV health care provider mentioned). Therefore, 
imbalances of power pervade accounts of black African people’s engagement with HIV 
testing to a considerable extent. Participants reflected on the way that such imbalances 
affected offers and uptake of HIV screening, and this is amplified rather than minimised 
when it comes to interventions that are designed to disproportionately benefit black African 
people. 
This concern was further evidenced by a few non-specialist participants who raised concerns 
about HIV testing interventions in acute services that they perceived to be based on skin-
colour rather than an individual’s actual HIV risk. It was argued that black African people 
had valid reasons to distrust the health service, due to previous experiences of racism, being 
patronised, not given fully informed consent, or being exposed to racial micro-aggressions in 
these settings (59).  
Participant 1: By the way, if you find yourself in an A&E, and if you’re black African, 
you will get a test anyway. So…[Others laugh]  
Participant 2: He is right. 
Participant 1: They will just… They will just, you know, shove it into you, and when 
you ask a question, why didn’t you tell me, they go, oh, oh we are very sorry. But it’s 
always like that. It’s just not new, particularly if you’re in South London [London 
non-specialist group 2]. 
Concerns were also expressed about the difficulty of ensuring fully informed consent in the 
busy and emotionally heightened environment of acute care services. Others mused that they 
assumed that most bloods drawn for routine purposes were already being screened for HIV, 
and that HIV screening was happening ‘behind closed doors’. In both types of discussions, 
non-specialists demonstrated little confidence in mainstream NHS providers’ judgment and 
communication strategies when it came to HIV.  
Not all discussion about targeted approaches focussed on their negative impact or 
repercussions. Some service providers noted that rationalising limited resources made sense 
within a current climate of reduced public spending. As such, although targeting HIV testing 
to black Africans was seen as problematic for a number of reasons as outlined above, it was 
often counterbalanced by the epidemiological and practical need for such targeting:  
Participant 1: I have trouble just targeting just Black communities with that kit, for 
me it has to be universal for everyone I wouldn’t like to just target a specific 
population group.  
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Participant 2: This is screening! If the epidemiological studies that there’re high 
prevalence and new incidence rate in that race, in that particular community, that is 
really...really where resources should be [London service provider group 2].  
Epidemiological evidence was presented as a neutral counterpoint to the barriers to targeting: 
I think you can target in a way that’s honest…. Because, for example, I think it’s very 
clear and honest to say, if you are from a high prevalence area – if you’ve had 
unprotected sex in a high prevalence area of HIV and then name where the high 
prevalence areas are – you are at more risk of acquiring it [London service provider 
interview 1]. 
Furthermore, some service providers argued that the offer of an HIV test may be catalytic for 
individual testing decisions. From a provider perspective, acknowledging the consequences 
of not offering an HIV test to a black African service user or patient was considered as one 
way to support providers in deciding to offer the test, even where they acknowledge that a 
challenging discussion could follow.  
Finally, participants focused on reducing barriers to targeting through participant-led and 
culturally sensitive ‘approaches to enhancing targeting’. These included embedding the offer 
of an HIV test within a wider ‘bundle’ of targeted interventions to diffuse the specific stigma 
of HIV, for example, within offers of targeted approaches to address sickle cell or bone 
marrow transplant donations or hypertension. A culturally sensitive approach to targeting that 
ensured the co-production of targeting approaches with representatives of black African 
communities was also suggested, as was the introduction of such interventions by black 
African providers. These approaches were seen to reduce barriers to targeting by being 
particularly sensitive to the ethnic mix of those involved within the targeting interaction. 
Participants further noted that attention needs to be paid to the potential of health promotion 
or research materials which can which link HIV to black Africans in the minds of the general 
public, and the harmful social outcomes that could result if such interventions were 
misconstrued by a wider audience. 
4.2 Perspectives on the use of HIV Self Sampling kits  
There was considerable (although not universal) enthusiasm around the abstract notion of 
distributing SSKs to black Africans.  
4.2.1 Device practicability 
Prior to taking part in this research, awareness of SSKs was not widespread amongst the non-
specialist participants, and only a handful disclosed having used one in the past. A 
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considerable proportion initially assumed that results would be instant (ie. self-testing) as 
there were national media reports about that technology being licenced just before the period 
of research. Additionally, participants were invariably surprised by the volume of blood (400 
microlitres) required for a sufficient TINY Vial sample, and service providers in particular 
stressed routinely that they did not think that most members of the public would be able to 
produce a sufficient sample.  
I mean, we do health checks and we take blood from the finger and our machines just 
been changed to take a much smaller sample, we have to take 40 microns of the 
blood, not a big amount which is why I kind of, I was a bit shocked at this. And just 
getting that amount of blood is actually sometimes quite traumatic for a person 
[London service provider group 1]. 
While fear of needles and blood was also discussed, a few pharmacists, nurses and GPs held 
the view that physiologically, their black patients often struggled to produce fingerprick 
samples because of thickened skin on the fingertips.  
Many of the service providers and non-specialist participants felt that the TINY Vial kits 
would prove to be too complex for most people to use correctly. As one participant in a 
service provider group in Glasgow expressed:  
I think that will be quite tricky. Certainly, I don't think it’s one that you can tell them 
it’s that easy to do […] maybe if the test was simpler [Glasgow service provider 
group 3]. 
Furthermore, a number of participants expressed concern that SSKs could be easily 
contaminated by users. Participants questioned the robustness of the technology and 
procedures on offer to the public, and also whether samples would be mismatched between 
two users. There was also an underlying worry that unskilled members of the public who 
used SSKs might introduce risk to others (through contamination or spills) or increase the 
chance of invalid/inconclusive results in some way. 
Can I be very honest? I don’t like this, and the reasons why I don’t like it is because it 
isn’t simple… It isn’t easy and, of course, this will not be popular. […] By the time 
people put a jab and then put their hands and blood starts dripping, one, two, three, 
four, five, six, seven, eight, up to 20, I find it a bit… very, very cumbersome. It makes 
it very, very… It’s liable to a lot of mistakes. And so what do you then do? [London 
non-specialist group 2]. 
In many of the discussions with service providers, they raised comparisons between these 
HIV SSKs and a range of kits for other conditions that are now designed for self-sampling. 
These comparisons highlighted that many such kits had not been a great success (chlamydia 
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and bowel screening kits in particular were perceived as under-used and not cost-effective). 
In contrast, HIV service providers with experience using dried blood spot kits for HIV self-
sampling among MSM were encouraged by the benefits that self-sampling could bring to 
black African users. 
4.2.2 HIV Stigma and the need for privacy and discretion  
HIV-related stigma was among the most pervasive concern emerging within this data data 
which supports extensive theoretical and empirical work in the field more broadly.(13, 60, 
61) All participants were clear about the profound challenges that HIV stigma presents for 
prevention and testing interventions. The role of stigma was particularly evident in the 
concerns about potential isolation and resulting harm that could be experienced by SSK users. 
Indeed, it is this pervasive stigma that continues to make the promotion of HIV testing within 
this population so challenging. Stigma predicates against self-perception of risk and promotes 
profound fear about being seen to be accessing an HIV testing service due to of the social 
implications that may follow. It also makes providers uncomfortable in offering the test 
because they too are aware of these social implications. While SSKs were considered by 
many participants as having some scope in reducing these social risks of discovery, they were 
simultaneously understood to be a means of ‘keeping HIV underground’, providing cover to 
those who desired increasingly secretive means of confirming whether or not they are 
infected. 
Closely connected to the matter of HIV stigma, and directly related to the feasibility and 
acceptability of SSK community distribution, were the many facets of privacy that 
participants discussed. Although service providers may consider health providers and 
pharmacists to be trusted professionals who understand and adhere to data protection 
requirements, non-specialists were far less likely to share this view. Not only did they worry 
that presenting in such environments and requesting an HIV test might result in judgment and 
bias, it was also clear that a considerable proportion of these participants held deep-seated 
fears about who else may acquire access to their most personal health information as a result 
of such an interaction. In conjunction with this concern, other non-specialist participants 
pointed out that some potential users may lack power vis-à-vis their partner in order to 
independently use an SSK. One participant offered a scenario of a husband and wife, where 
the former possessed control over the latter and prevented her from using the SSK, or where 
intention to use the SSK led to conflict in the household.  
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Among the many beneficial elements identified, privacy, discretion and the capacity to 
determine one’s own status in an environment of relative anonymity were regarded as 
considerable strengths, particularly among potential lay users of the kit. Participants felt that 
the ability to use a kit privately was an essential benefit for those who were frightened about 
attending a sexual health clinic, raising the issue in a clinical setting, or seeking out a 
community organisation that provides HIV testing. To this extent, taking a sample in private 
was regarded as a means of avoiding the stigma that is heavily associated with those who 
seek out an HIV test.  
[It’s] quite hard for some people to go and approach GPs or doctors to explain their 
situation. Like myself, I've been thinking about it. It's been in my mind for a long time 
to do a test, because I've been hearing people, I've been watching this, I've been… you 
know what I mean, media’s talking about it, so I don’t even know my status, but when 
something like this came up, if it's, like you said, I think it's an opportunity for people 
like me to take the chance to do it [Glasgow non-specialist group 3]. 
But you’ve got to understand, most people, especially with location, where people 
live, they don’t have that time to go to the hospital and go through the whole process 
of getting a HIV test. And it’s not even a matter of going to the hospital. It’s a matter 
of I could just come home, I could do this and I could keep going with what I do in a 
normal day and then get my results, like they did [with] chlamydia tests [London non-
specialist group 1].  
Thus for some, SSK distribution was regarded as a way to access to HIV testing that is non-
stigmatised, highly accessible, and convenient, potentially increasing appeal to those who had 
not considered testing in the past.  
4.2.3 Choice and autonomy as both opportunity and risk 
The findings described above should not be interpreted to mean that SSKs were perceived by 
research participants as a means of replacing traditional and POCT HIV testing. Instead, 
SSKs were described as a means to bolster the array of options on offer.  
I like the idea of home sampling because it gives more choice, flexibility and 
opportunity for people to have an HIV test. So for example, if people are worried 
about confidentiality, they can do the test in the privacy of their own home. And even 
though they still have to send the result in to a lab, at least it’s not done through a 
third person, having to disclose their history and why they’re worried about HIV 
[London service provider interview 1]. 
Service providers and non-specialists alike were interested in the extent to which the SSK 
increased individual’s autonomy over their health, their HIV testing options, and their 
decision-making around how, when and where to have a test. There was also an extent to 
which this autonomy introduced a sense of liberation around HIV, and a few participants 
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(mainly service providers) mentioned that making SSKs available in public spaces for private 
use might help to tackle HIV stigma at a structural level. Not everyone agreed with this last 
point, however, as it was also mentioned that increasing the extent of privacy through the use 
of SSKs may serve to hide HIV even further away. 
Chief among the concerns expressed about SSK distribution was that the kits appeared to 
circumvent the provision of sustained interpersonal engagement and support. In almost all 
groups and several interviews, participants voiced their concern that users would be alone 
while waiting to hear their results and most crucially when discovering the results. In a 
considerable proportion of groups and interviews, participants felt that the risk of suicide and 
self-harm was elevated among SSK users learning of a reactive result, because they would 
not be in the physical presence of a professional for this discussion. Where self-testing for 
HIV was discussed, this concern was even greater, and the SSK was at least regarded as a 
means of better ensuring linkage to care than self-testing technologies. There was an 
assumption embedded within these exchanges that linkage to support and care services was 
far more assured with face to face testing services, and there was considerable doubt that this 
could always be achieved with SSKs.  
To some extent, such comments reveal a fundamental concern about the loss of systems 
control that SSKs represent. This is ultimately a direct consequence of increased user 
autonomy. It is not surprising that this was a key tension that emerged among participants 
with regard to this technology, and of note that potential isolation as a key drawback of SSKs 
was raised by service providers and non-specialist participants in equal share.  
4.2.4 SSKs and Point of Care Testing 
There was also considerable discussion about ensuring that HIV testing is accompanied by a 
talking intervention given by a skilled professional, enabling risk assessment, pre-test 
counselling (and potentially, advice on the use of an SSK). To this extent, guidance 
suggesting that pre- and post-test discussions are not entirely necessary is not universally 
accepted by service providers or non-specialists (62). In all focus groups and several 
interviews there were those who made it clear that their preferred testing pathway involved 
direct contact and risk assessment discussion with a skilled service provider, followed up by 
immediate on-site POCT. Such individuals considered SSKs to be a ‘poor relation’ to POCT. 
One participant queried, “If you're going to start offering it as an anonymous kind of thing 
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that's not connected to services, well, what's the reason for doing that? What problem are you 
trying to solve by offering that?” [Glasgow service provider interview 1]. 
Those who thought testing should be delivered with interpersonal engagement said it seemed 
peculiar to distribute SSKs when POCT afforded immediate sample and results collection, 
with full support and advice on offer.  
Essentially, these findings highlight participants’ ambivalence to SSKs. On the one hand, 
they expressed enthusiasm about the freedom and autonomy that this technology offers. 
However, they were also concerned that this comes at the sacrifice of immediate results, 
professional contact, support and clinically robust procedures. It was widely held by most 
participants that SSKs needed to be embedded in larger support interventions that involved 
discussions with skilled professionals. 
4.3 SSK distribution options 
The privacy afforded to individuals in each potential SSK distribution setting was ultimately 
the overriding factor in participants’ assessments of their suitability. However, for every 
setting, there were disagreements as to whether privacy and confidentiality could be 
guaranteed. Therefore, while some saw GP surgeries as providing an ideal combination of 
privacy and medical expertise, others worried that Home Office officials could be notified of 
an outcome via the medical facility, and there were concerns that even the discussion of an 
HIV test could persist on a medical file with negative consequences.  
Furthermore, while some argued that ordering such a kit to be delivered through the post at 
home might be ideal, this suggestion was almost always vetoed by others who felt that most 
black African people did not live alone, and the arrival of such a kit in the post (or even the 
carrying of a package that is distributed in the community) would always elicit questions 
about what is inside.  
I worry that we're not understanding the home environment in which this will land in 
enough. That needs to be understood. There are so many other issues going on with 
our communities that the context in which this lands, it needs to be understood 
[London service provider group 3]. 
Many participants favoured voluntary pick up of SSKs in key community sites (similar to 
what has been done with chlamydia self-sampling kits), rather than service provider-initiated 
distribution, as this affords greater privacy while simultaneously reducing the potential for 
black Africans to feel targeted and potentially stigmatised. At the same time, it was 
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recognised that promotion of the kit to reluctant or unfamiliar users would be required. 
Indeed, there was considerable support for the proposition that first-time users should be 
shown how to use the kit, in order to ensure efficiency in SSK use and uptake.  
Some participants delineated the need for a user-led approach within a fuller HIV prevention 
paradigm, starting with a discussion about HIV awareness, elevated prevalence among black 
Africans in the UK, individual risk-perception, and the importance of prompt access to 
antiretroviral treatment for people with HIV, prior to a potential offer to take away an SSK. 
To this extent, it was agreed that assumptions of universal willingness (or indeed need) to use 
SSKs among all black African people were problematic, and that on balance, it was 
recommended that often a user-led and needs-led approach involving some dynamic 
interaction with a skilled distributor would be required. To this end, service providers 
suggested that such distribution would be best placed within existing service specifications, 
with additional resourcing to ensure adequate staffing and promotion. 
In terms of the best sites for accessing SSKs in the community, there was near uniform 
support for distribution of the kits to black African people through GP surgeries. The 
confidentiality and privacy afforded in a GP setting was seen by many as a ‘gold standard’ 
option for SSK distribution. However, there was concern about the capacity of surgery staff 
to appropriately target black Africans while avoiding racist and stigmatising approaches.  
[Interviewer: Do you think it’s possible to target these [SSKs] mainly, or exclusively 
at black Africans?] 
Participant 1: I think in General Practice that would be quite difficult. 
Participant 2: Yes, it’s difficult from the point of view that you shouldn't discriminate 
[Glasgow service provider group 3]. 
Some were confident that developing cultural competence training for GP practice staff could 
help to overcome this risk. Furthermore, it was thought that on balance, the strong 
accessibility of the setting could outweigh the perceived shortcomings of distributors.  
Other concerns, voiced particularly by service providers, included the time that such an 
intervention would take during the brief ten minute appointments typically allocated in 
primary care, given that raising the topic of HIV requires some sensitivity, and the complex 
TINY vial kits (in particular) needed to be explained and demonstrated. There was 
considerable variation opinion on the role that various GP surgery staff could play in 
active/passive distribution of SSKs, with a consensus on the fact that a specific appointment 
should not be required to acquire a kit. Some favourable comparisons were made with the 
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way in which chlamydia self-sampling kits were made discreetly available in such locations. 
However, the majority of service providers took the view that nurses and general practitioners 
should actively target and initiate distribution in order to increase cost effectiveness by 
sharing information and assessing the likelihood of need, and increasing motivation. 
There was also nearly universal approval of HIV specialist community organisations 
distributing SSKs alongside current outreach work. This workforce was deemed to have the 
expertise required to target this population sensitively, with less risk of causing offense or 
generating responses that might exacerbate HIV related stigma  
You can say: You know what? We've got these kits and you can test in your home. The 
results won't come back to me. I don't really need to know until maybe you are 
confident enough maybe to discuss it with me. So I think it's a good opportunity 
[Glasgow service provider group 2]. 
In the main, SSK distribution by African-focussed HIV-specialist community service 
providers was regarded as having the potential to work seamlessly with community HIV 
promoters’ existing skills and approaches, as well as benefitting from existing relationships 
and infrastructures for setting access and referrals. 
Further discussions were prompted about the appropriateness of pharmacies, faith-based 
organisations, higher education institutions, dental surgeries, hairdressers and salons with 
high proportions of African users, as well as targeted online ordering systems for home 
delivery of kits. While the ‘normalisation of HIV’ was regarded as a potential strength of all 
of these distribution sites, the overriding response from service providers and non-specialist 
participants alike was that clinical governance concerns ruled out these options.  
It’s because in a pharmacy it’s not like a GP. There’ll be someone else picking up 
different drugs or waiting behind you or whatever. So that’s where you feel, “God, 
there’s someone right here….”. There’s no, like, privacy in the pharmacy. You’re not 
going into the little room; you’re going to a counter  
[Glasgow non-specialist group 1]. 
I would say nobody would be courageous enough, especially if they are married or 
even if they want to get married in the next year or so to go to your pastor and ask for 
an HIV test kit, that's almost impossible [London service providers group 3]. 
Lack of privacy (including the arrival of a kit through the post), and lack of appropriate HIV 
expertise, impartiality, or guarantees of confidentiality amongst other distributors were at the 
forefront of participants’ rejection of using such settings for targeted distribution of SSKs to 
black African people.  
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4.4 Summary  
The data from this stage of research fed directly into the process of intervention development, 
described in section 2.4. In particular, these findings are perhaps best summarised in relation 
to the COM-B model of behaviour change(36) which was ultimately applied to determine the 
best way forward for the intervention development for Stage 2 which is described in Chapter 
5 below.  
With regard to capability of service users and providers to distribute and use the SSK, 
concerns were highlighted about the amount of time that service providers had (particularly 
general practitioners) to initiate discussion and encourage use, and furthermore there was also 
a fundamental concern raised in all groups about the amount of blood required to provide a 
TINY vial sample.  
On the other hand, targeted distribution of SSKs was seen as a broadly positive means of 
expanding the range of opportunities for black African people to test for HIV. There was 
widespread enthusiasm about SSKs as one of many new technologies that comprise an 
improved array of HIV testing options for black Africans. There was specific support for the 
fact that SSKs could provide an opportunity for the initiation and follow through of an HIV 
testing discussion in a setting that black African people were already accessing, so 
convenience was regarded as a significant gain.  
Finally, these findings offer us considerable insight into the potential motivation issues 
arising with targeted offers of SSKs. Participants advised that targeted offers (particularly 
those made in healthcare settings and/or made by non-black Africans to black African service 
users) needed to be couched in clear terms, using epidemiological evidence to help people 
consider their likely risk, and to work to avoid the perception that offers were being made 
because of racist or xenophobic sentiment. Instead, it was deemed of utmost importance that 
distributors were regarded as trustworthy, knowledgeable, non-judgemental and that they 
could encourage a realistic degree of reflection about HIV risk among those to whom they 
encouraged SSK use. There was a universal view that SSK distribution needed to actively 
resist HIV stigma rather than potentially reinforce it.  
Ultimately, this data demonstrates that we cannot underestimate the extent to which 
considerations of privacy (and its limits) are at the centre of considerations for SSK 
feasibility and acceptability among black African people in the UK. Central to this concern is 
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the pervasive presence of HIV-related stigma, impacting on service providers and black 
African people alike. Finding the correct mechanisms for highlighting epidemiological 
realities among members of ethnic minority communities, without engendering feelings of 
imposed stigma and blame, are not easy. 
4.4.1 Strengths and limitations 
Although limited in scope and scale, the range of recruitment methods used for our FGDs 
helped to ensure that we had a diverse mix of non-specialist participants, most of whom were 
unlikely to have taken part in similar research previously. We started to approach data 
saturation by the time of the latter focus groups and interviews, demonstrating that our use of 
purposive sampling for both specialist and non-specialist participants had helped to achieve a 
balanced range of perspectives and experiences. The decision to make some of the non-
specialist groups more homogeneous (all male; younger; HIV positive) was a benefit overall, 
as it helped to ensure careful consideration of distinct subject positions during both data 
collection and analysis. Although the decision to hold one to one interviews with HIV 
clinicians and other decision-makers ultimately resulted in divergent and multiple data 
sources for this phase, the option of mixing them in groups with other specialist providers 
was not only less feasible in terms of availability to attend, but it was also clear that given the 
strongly divergent insights expressed by those in this sample (influenced by clinical 
experience and policy involvement), it was ultimately best to collect their data separately.  
Ultimately, the use of these qualitative methods to collect data in two geographically distinct 
locations enabled the study team to: triangulate findings across study populations and 
geographic areas; compare and contrast specialist / non-specialist perspectives on SSKs and 
their targeted distribution, and their rationales for these viewpoints; and to directly address 
these perspectives in the design of the intervention to be assessed in Stage 2 of the study. 
4.4.2 Conclusion 
While the introduction of this new technology is meant to assist in circumventing the 
problems of low HIV testing uptake among black Africans, these findings remind 
implementers to be cautious about not introducing new problems while trying to address 
existing ones. The next Chapter builds upon the findings presented in this Chapter to develop 
the intervention which was implemented in Stage 2 of this study. 
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Chapter 5: Intervention development  
This Chapter addresses the first aim of Stage 1, to develop an SSK-based intervention to 
increase the provision and uptake of HIV testing among black Africans using existing 
community and healthcare provision.  
The methods for intervention development comprising a four-step process, informed by the 
behaviour change wheel are described fully in section 2.3. The four-step process is as 
follows:  
 Step 1: Delineate key intervention components 
 Step 2: Map barriers and enablers of the implementation of intervention components 
in relation to theoretical domains 
 Step 3: Identify potential intervention components that can overcome modifiable 
barriers and enhance the enablers within a future intervention;  
 Step 4: Ensure viability of the intervention using APEASE criteria.  
The sections below discuss the results at each point of this process.  
5.1 Step1: Delineate key intervention components 
The research team identified eight key intervention components:  
1. Setting and location  
2. The targeted offer of an HIV SSK to black African people  
3. Participant personal information collection 
4. The self-sampling kit itself 
5. The appearance and packaging of the HIV SSK 
6. Information leaflet and instructions for correct use of SSK 
7. Kit return, and 
8. Result communication.  
In order to facilitate focused consideration of the key intervention components, each 
component and its implications for the research team, participants, and service providers are 
presented in Table 6. Each component is then explored in detail within step 2. 
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Table 6: Key intervention components 
Intervention 
components 
Requirements  Notes regarding component and associated behavioural domains 
1.  Setting and location 
2.  
Research team needs to engage with professionals and 
black African, non-specialist, members of the public to 
assess relative opportunities presented by a range of 
potential testing settings and their acceptability and 
assess the pragmatic aspects of intervention delivery 
within these diverse settings.  
 
Not a behavioural domain per se  
 Raises questions of the scale of locations and smaller places within 
them (e.g. reception are of GP practice)  
 Needs to be explored by both a range of health professionals and 
black African members of the public 
 Presents a central question for subsequent acceptability and 
feasibility study if multiple settings are compared 
3. The targeted offer of an 
HIV SSK  
Two distinct behavioural domains for health provider 
suggested:  
i) identifying black Africans 
ii) and subsequently offering the HIV SSK 
 
 Which health providers could implement this approach?  
 How would the offer work within their routine practice? Or should the 
interaction be specific rather than within routine practice? 
 Amenable to an analysis of theoretically relevant barriers and 
facilitators to imagined implementation 
4. Participant personal 
information collection  
Participant must provide accurate information to enable 
processing of sample and provision of results 
 
 
 Scope for health provider to intervene here or relevant documentation 
to be considered as an active part of the intervention 
 High degree of sensitivity required given HIV related stigma and for 
some, issues relating to migrant status 
 Amenable to an analysis of theoretically relevant barriers and 
facilitators to imagined implementation  
 Central to both the acceptability and feasibility aspects of the 
intervention 
5. The self-sampling kit 
itself  
Use of a CE approved kit - not amenable to change or 
modification  
 The choice of SSK is subject to relevant regulations.  
 Central to both the acceptability and feasibility of the intervention 
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Intervention 
components 
Requirements  Notes regarding component and associated behavioural domains 
Or seek permission to proceed with non- CE marked kit  
6. The appearance and 
packaging of the HIV 
SSK  
Participant and outreach distributor must transport the 
SSK without damaging it and may wish its content to 
remain unknown to others  
 The participant must transport the kit from the site in which it was 
offered to the site in which they intend to use it.  
 Given the stigma of HIV and HIV testing within these communities the 
appearance of the kit has particular sensitivities 
 There is scope for the packaging to be considered as an active part 
of the intervention, particularly if it was also used to deliver behaviour 
change techniques that could boost uptake and engagement or 
compliance with the kit. 
 Amenable to an analysis of theoretically relevant barriers and 
facilitators to imagined implementation 
 Central to the acceptability of the intervention  
7. Information leaflet and 
instructions for correct 
use of SSK 
Participant must comply with kit instructions and 
understand result process and meaning. 
 Compliance with kit instructions is complex and involves multimodal 
sequential behaviour domains 
 High levels of literacy required (although visuals are also provided) 
 Central to the acceptability of the intervention 
8. Kit return  The participant must return the kit to get it processed 
within the lab and to enable results to be communicated 
 Amenable to an analysis of theoretically relevant barriers and 
facilitators to imagined implementation 
9. Result communication Researchers and providers to give results in acceptable 
ways and specify patient pathways where relevant 
 
 The decision for choice of return options is subject to best practice 
and standards of care. 
 Central to both feasibility and acceptability of the intervention. 
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5.2 Step 2: Intervention barriers and enablers and relation to theoretical 
domains 
Key theoretical domains (see Table 1, Chapter 2) were important for most, if not all, 
intervention components. Skills, beliefs about consequences, social influence and 
environmental context and resources were particularly important theoretical domains across 
many of the intervention components and their target populations. Below, we map the key 
barriers and enablers that we identified for each intervention component; these could relate to 
the service provider (SP), user (U) or both (B). 
Setting and location: Not a behavioural domain but important to secure locations that 
maximise opportunities to reach African communities, and settings that could facilitate trust 
in the intervention process. Also the limited amount of time with a potential user in some 
settings may prohibit intervention delivery on top of meeting the individual’s presenting 
needs. 
The targeted offer of an HIV SSK: A central dimension of the intervention outline contained 
within the NIHR’s commissioned call was the specificity to black Africans. It was imperative 
to reflect upon which person or persons would be most appropriate to make a targeted 
approach. It was also important to consider the point in the path of the patient/client journey 
through routine services was the most appropriate time to make an offer of a self-sampling 
kit. It was equally vital to address risks about the potential implementation of the targeted 
offer to minimise harm and maximise uptake. 
Key barriers in relation to relevant TDF domain:  
 Knowledge: Lack of knowledge as to why would target HIV testing at black Africans 
(SP) 
 Skills: Lack of skills in initiating conversations about targeted self-sampling (SP) 
 Social/professional identity: Service providers may or may not see routine or 
universal testing as part of their day to day role (SP) 
 Beliefs about capabilities: Sense of low self-efficacy and capability concerning 
targeted offer of a kit (SP) 
 Beliefs about consequences: Perceptions a targeted offer will be perceived as racist 
and this may compromise their relationship with person they have targeted and other 
community members and lead to damaged reputation (SP) 
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 Intentions: Potential service users and providers may have prior intentions of testing 
through other routes (not self-sampling) (B) 
 Environmental context and resources: Population level exposure to targeting of black 
African populations may lead to heightened stigma and disincentivise testing (B) 
 Social influences: Strong social norms concerning the avoidance of conduct which 
can be perceived as racist and discriminatory within a cultural context of xenophobia, 
racism, intergroup conflict, identity and social identity (SP) 
 Emotion: Service providers distress and negative affect will be a barrier to targeted 
offer of a test (SP) 
Participant personal information collection: Recipients of SSKs must provide accurate 
personal information to enable their sample to processed and results returned to them. This is 
central to facilitate the later communication of negative, unsuitable sample, or reactive test 
results and secure an entry into HIV care for anyone who obtained a reactive result. Although 
providing this information is within the behavioural domain of the participant, the service 
provider who makes the targeted offer of the SSK may be instrumental in explaining or 
reassuring the participant of the need and safety of disclosing personal information within the 
context of the HIV test 
Key barriers in relation to relevant TDF domain:  
 Beliefs about consequences: Personal details may not be confidential and be seen by 
others or shared across agencies impacting negatively upon future health and social 
care (U) 
Key facilitators in relation to relevant TDF domain:  
 Beliefs about consequences: Clear information detailing exactly how personal 
information would be used and why it was required would reduce perceptions of 
negative future consequences (U) 
 Environmental context and resources: Use minimal information to enable the lab to 
contact the participant (U) 
 Environmental context and resources: Use online systems for completing study 
procedures and data collection (U) 
The testing kit itself: While not a behavioural domain the choice of self-sampling kit 
represents a central component of the intervention. Regulatory and clinical standards limit 
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options and create challenges if wanting to use non-CE approved kit or enhance current kit 
options (see section 5.3.1).  
The appearance and packaging of the HIV SSK: There were three particularly important 
dimensions to consider. First, how to ensure that the kit was packaged in a way to lessen the 
risk of damage during transport from the setting in which it was offered to the setting in 
which it was used. Second, the team considered how to address and minimise the effects of 
social stigma associated with being seen to be in possession of an HIV test. Third, the team 
reflected on how the intervention packaging could support the recipient in their testing 
behaviour.  
Key barriers in relation to relevant TDF domain:  
 Beliefs about consequences: The packaging may be recognised as an HIV SSK and 
the users ‘reputation’ within their communities may be damaged (U) 
 Environmental context and resources: Use of any external label/packaging that 
mentions HIV or test kit (B) 
 Environmental context and resources: Concerns relating to the safety of the kit and 
potential damage to it (B) 
 Social influences: Perceived HIV stigma shaping interpretations of carrying a kit if it 
is recognisable to others (U) 
Key facilitators in relation to relevant TDF domain:  
 Environmental context and resources: Use brown paper bags (or other generic 
material) to distribute/carry kit (B) 
 Environmental context and resources: Use non transparent materials to 
distribute/carry kit (B) 
 Environmental context and resources: The kit has to be convenient to carry (B) 
 Environmental context and resources: Tight, secure packaging that will not 
break/open/tear prior to use of the kits (B) 
Information leaflet and instructions for correct use of SSK: Given that SSK recipients 
were likely to use the kit without the support of the service provider who distributed it, 
potentially days after this interaction and predominantly in a domestic setting, it was 
important to optimise the information on the participant information sheet and kit instructions 
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for acceptability and usability. Irrespective of the complexity of the intervention components, 
the correct use of the kit represents a complex multidimensional behavioural domain as it 
involves 13 distinct steps (see supplementary information).  
Key barriers in relation to relevant TDF domain:  
 Skills: Lack of English language skills could hamper use of kit (U) 
 Skills: Lack of perceived skill in compliance with complex instructions (U) 
 Beliefs about capabilities: Concerns that test instructions may be too complex and 
difficult to follow (U) 
 Beliefs about capabilities: Concerns that language used will not be understood (U) 
 Memory & decision processes: Perception that instructions are too difficult and 
complex to follow (U) 
 Memory & decision processes: The medical language concerning test results may be 
confusing and impact negatively on testing decisions (perceptions of test efficacy) (U) 
 Environmental context and resources: Perception that readability and font size of 
instructions are too small to read (U) 
 Environmental context and resources: Medical language and terminology could be 
alienating to participants (‘Lancet’, ‘non-dominant hand’) (U) 
 Emotion: Words/Graphics on the printed instructions or instructional video could 
increase anxiety and fear and may lead to avoiding the kit (U) 
 Emotion: Anxiety levels and fear of test results may influence compliance with 
instructions (U) 
Key facilitators in relation to relevant TDF domain:  
 Skills: Video/Voice provision of test instructions to facilitate compliance with test 
instructions (U) 
 Beliefs about capabilities: Use of clear simple messages and pictures (U) 
 Beliefs about capabilities: Translate into other languages (U) 
 Environmental context and resources: Having additional on-line video of someone 
using the kit (U) 
 Social influences: Perceived need for the service provider to have used the test 
themselves (U) 
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 Social influences: Perceived need for the service provider to explain the test process 
in person (U) 
 Social influences: 24 hour access to pre- and post-test counselling service may 
facilitate uptake (U) 
 Social influences: Signal clearly sources of and easy access to social support 
regarding testing within instructions to facilitate testing (U) 
Kit return: A further core component was the process of the participant returning the 
collected sample with sufficient information to enable processing and result communication. 
This element again represented a relatively complex self-managed behavioural domain. 
Having used the kit, the participant must properly enclose the sample along with an 
identification label and sample return form within the protective packaging and ensure that it 
is posted via the supplied postage-paid, addressed envelope.  
Key barriers in relation to relevant TDF domain:  
 Beliefs about consequences: Perception that participants will not return the kit if they 
believe it will get lost or spoiled within the postal system (U) 
 Environmental context and resources: Royal mail system would disincentivise kit 
return through widespread perception of distrust with the system (U) 
 Social influences: Returning kit to community setting, eg Faith leaders (as potential 
distributor) linked to privacy concerns and disincentivising kit return (U) 
 Emotion: Concerns about the affective impact of information if the testing process 
was not confidential (U) 
Key facilitators in relation to relevant TDF domain:  
 Skills: Previous competence with on-line tracking systems may facilitate kit return 
(U) 
 Beliefs about consequences: Participants should be given a choice of how to return 
the kit to accommodate beliefs about consequences (U) 
 Intentions: intentions to test in situ at distributor venue may enable uptake (U) 
 Memory & decision processes: Having choices of ways of returning the kit was seen 
as facilitating test kit return (U) 
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 Environmental context and resources: Post boxes are ubiquitous and can enable kit 
return with minimal effort (U) 
 Environmental context and resources: Medical facilities such as GP surgeries were 
trustworthy with management of samples (U) 
Result communication: The final component of the intervention related to the processing 
and communication of test results. These processes are subject to clinical governance 
regulations and identifying mechanisms by which best practice would be delivered was 
crucial (see section 5.3.3).  
5.3 Step 3: Intervention components to overcome the modifiable barriers and 
enhance the enablers 
Table 7 illustrates the mapping of the key barriers and facilitators to potential intervention 
implementation against COM-B elements and the concomitant specific behaviour change 
theory (BCT) that could enhance implementation. The intervention components each present 
different foci in relation to the COM-B elements, for example, some highlighting the need for 
focus upon capability (the targeted offer of a SSK and compliance with kit instructions) and 
some with a focus upon opportunity (the appearance and packing of the SSK). The table also 
highlights how different components demand the use of different intervention functions (i.e. 
the way that the intervention content should be delivered). For example, the table shows that 
much of the proposed intervention content relating to the targeted offer of a test should be 
delivered within training and education of providers. In contrast, much of the active 
intervention content regarding the appearance and packaging relates to the redesign of the 
pack and persuading people to use the kit.  
Finally the table addresses the particular behaviour change techniques that could be used 
within an intervention (adding much more specificity in relation to the broad and more 
generalised COM-B elements). The numbers provided relate to behaviour change technique 
taxonomy (63). For example, the motivational elements of training providers to deliver a 
targeted offer of the test, can be achieved through the specific use of techniques which 
increase motivation to offer the test, i.e. technique ‘Provide information about health 
consequences (5.1)’- wherein, within training sessions, providers are given detail about the 
consequences of late diagnosis for potential test users in order to motivate them to overcome 
 86 
 
Table 7: Intervention components, COM-B intervention functions and selection of BCTs for intervention implementation 
Requirement  COM-B Analysis Broad function for 
training and 
intervention and  
 
Potential behaviour change techniques  
(Numbers refer to behaviour change techniques taxonomy) 
The targeted offer 
of an HIV SSK 
Capability 
Major psychological 
Some physical 
 
 
Opportunity 
Some physical 
Some social 
 
 
Motivation 
Major reflective  
 
 
Some Automatic 
 
C- Education, 
training, persuasion 
and modelling, 
enablement  
Environmental 
restructuring 
O- Training, 
restructure 
environment  
 
 
M- Training, 
incentivisation, 
coercion, 
environmental 
restructuring 
 
Within training sessions  
 Instructions on how to perform targeting via individual risk assessment. Advise 
and agree on how to do targeting (4.1) 
 Demonstration of the behaviour – provide an observable performance of 
targeting (6.1) 
 Behavioural practice/rehearsal- increase habit and skill though rehearsal of 
targeting (8.1) 
 Verbal persuasion about capability- within training - tell providers they can 
perform targeting and argue against self-doubts, asserting that they can succeed 
(15.1) 
 Provide information about health consequences- provide detail about late 
diagnosis information (5.1) 
 Salience of consequences –use methods designed to emphasize the 
consequence of performing targeting (5.2) – e.g. reduced new infections, future 
health of some patients instead of disability  
 Feedback on outcomes of behaviour – let providers know if any patients have 
tested positive to encourage more targeting within trial (2.7) 
 Behavioural experiments- Ask providers to test their hypotheses about targeting 
and see how people respond (4.4) 
 Verbal persuasion about capability- within training tell providers they can perform 
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Requirement  COM-B Analysis Broad function for 
training and 
intervention and  
 
Potential behaviour change techniques  
(Numbers refer to behaviour change techniques taxonomy) 
targeting, and/or risk assessment and argue against self-doubts, asserting that 
they can succeed (15.1) 
 Anticipated regret – raise awareness of expectations of future regret about not 
performing targeting via risk assessment – so how will providers feel if they know 
they avoided offering a test and later found out someone had an AIDS diagnosis 
or long term problems through late diagnosis (5.5) 
 Verbal persuasion about capability- within training tell providers they can perform 
targeting, and/or risk assessment and argue against self-doubts, asserting that 
they can succeed (15.1) 
Homework –post training 
 Behavioural experiments- Ask providers to test their hypotheses about targeting 
and see how people respond (4.4) 
Within trial 
 Feedback on behaviour – give providers information and evaluation of their 
recruitment within trial (2.2) 
 Social comparison – draw attention to other providers performance to allow 
comparison with providers own performance (6.2) 
Participant 
personal 
information 
disclosure  
Capability 
Minor physical 
Minor 
Psychological 
 
 
 
 
In provider script: 
 Ask the person to affirm statements indicating commitment to supply personal 
information (1.9) 
 Social comparison – draw attention to other patients provision of information to 
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Requirement  COM-B Analysis Broad function for 
training and 
intervention and  
 
Potential behaviour change techniques  
(Numbers refer to behaviour change techniques taxonomy) 
 
Opportunity 
Major Physical 
Minor social 
 
 
Motivation 
Major reflective  
No automatic 
 
O- Training, 
restructure 
environment (design 
a process to 
minimise perceived 
barriers) 
 
M- Education, 
persuasion and 
modelling (to improve 
disclosure) 
allow comparison with the persons own performance (6.2) 
 Present verbal communication from a credible source (provider?) in favour of 
providing personal information (9.1)  
 Advise the patient to identify and compare the reasons for wanting and not 
wanting to provide the personal details (9.2) 
 Focus upon past success- provider asks patient to think about or list previous 
successes in providing personal information (15.3) 
 Prompt observations of the consequences for others of giving personal details – 
i.e. test results (16.3) 
 Restructure the physical environment by simplifying the instructions, using easier 
language, simple messages and pictures and providing information in a number 
of languages (12.1) 
Appearance and 
packaging  
Capability 
Minor physical 
Minor 
Psychological 
 
Opportunity 
Major Physical 
Minor social 
 
 
 
 
O- Training, 
restructure 
environment (design 
pack) 
 
M- Education, 
 Restructure the physical environment by ensuring that non transparent materials 
are provided, that generic commonly used materials are used, that they are 
secure and they can be easily carried (12.1) 
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Requirement  COM-B Analysis Broad function for 
training and 
intervention and  
 
Potential behaviour change techniques  
(Numbers refer to behaviour change techniques taxonomy) 
Motivation 
Major reflective  
No automatic 
persuasion and 
modelling (to take kit 
and carry) 
Participant must 
comply with kit 
instructions  
Capability 
Major Physical 
Major 
Psychological 
 
Opportunity 
Minor Physical  
Minor Social 
 
Motivation 
Major reflective  
 Minor Automatic 
 
C- Training, 
education, 
environmental 
restructuring, 
enablement, 
modelling (redesign 
kit instructions) 
 
O- Training, 
restructure 
environment  
 
 
M- Education, 
persuasion, 
modelling and 
enablement  
Design of kit 
 Restructure the physical environment by simplifying the instructions, using 
simple language and pictures, providing information in a number of languages 
and add an instructional video s (12.1) 
 Add objects to environment – provide new kit instructions (compared to one in 
FGs) as well as instructional video (12.5) 
Within interaction with provider  
 Credible source – the provider should be credible and trustworthy (9.1) 
 Problem solving –analyse or prompt patient to analyse factors influencing the 
use of the kit and generate strategies to overcome barriers to using kit (1.2) 
 Social support (practical) – provide practical help for performance of the 
behaviour (3.2) 
 Instructions on how to perform the behaviour. Advise and agree on how to do 
use instructions (4.1) 
 Demonstration of the behaviour – provide an observable performance using the 
SSK instructions (6.1) 
 Behavioural practice/rehearsal- increase habit and skill though rehearsal using 
kit instructions (8.1) 
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Requirement  COM-B Analysis Broad function for 
training and 
intervention and  
 
Potential behaviour change techniques  
(Numbers refer to behaviour change techniques taxonomy) 
 Verbal persuasion about capability- within interaction tell patient they can utilize 
the instructions and argue against self-doubts, asserting that they can succeed 
(15.1) 
Within interaction with provider  
 Identification of self as role model (13.1) 
 Draw attention to others performance (the providers own) to allow comparison 
with the persons own performance (6.2) 
 Problem solving –analyse or prompt patient to analyse factors influencing the 
use of the kit and generate strategies to overcome barriers to using kit (1.2) 
 Within interaction with provider  
 Advise on ways of reducing negative emotions to facilitate compliance with kit 
instructions (11.2) 
 Advise on, provide, emotional social support for compliance with kit instructions 
(3.3) 
Within kit itself/and or with provider 
 Information about emotional consequences – provide information about 
emotional consequences of performing the behaviour (5.6) 
Participant kit 
return  
Capability 
Minor Physical 
Minor 
Psychological 
 
 
 
 
 Goal setting – Agree that the return sample will be returned (1.3) 
 Restructure the physical environment by not holding details on GP records, or 
within a distributor, to facilitate an alternative reminder mechanism (12.1) 
 Behavioural contract (1.8) - Sign a contract with the patient that she will return 
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Requirement  COM-B Analysis Broad function for 
training and 
intervention and  
 
Potential behaviour change techniques  
(Numbers refer to behaviour change techniques taxonomy) 
 
Opportunity 
Major Physical 
Minor Social 
 
Motivation 
Major Reflective 
Minor automatic  
 
O -Restructure 
environment  
 
 
M- Education, 
persuasion, 
modelling and 
enablement 
the kit (1.8) 
 Prompt detailed planning of performance of sample return from home –ask 
patients to state an implementation intention (1.4) 
 Restructure the physical environment by simplifying the instructions, using 
simple language and pictures, providing information in a number of languages (if 
went to full trial) and add an instructional video (12.1) 
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their perceived barriers for the targeted offer of a test. Equally motivating the providers to 
overcome their perceived barriers could be achieved by using the technique ‘Salience of 
consequences (5.2)’. In this way motivation to overcome perceived barriers for the targeted 
offer of a test is achieved by highlighting the consequence of effectively performing 
targeting– e.g. reduced new HIV infections, or detail regarding the future health of patients 
rather than their future disability. Using the behaviour change wheel thus enables a range of 
highly specific potential intervention elements that can be used in relation to each of the 
intervention components. 
5.4 Step 4: Viability of the intervention  
5.4.1 Challenges to the development of an optimal SSK intervention 
One of the key components of the HAUS intervention is the SSK itself. The type of specimen 
(saliva or blood) can have implications on its acceptability and on the accuracy of test results. 
The following section presents an overview of the UK regulations for medical devices for 
HIV testing and its implications for development and viability of an optimal SSK 
intervention for HIV testing.  
Current UK regulations for HIV testing and diagnostics  
SSKs are required to meet the legal criteria aimed to ensure quality and performance of these 
kits. They have to be approved by the Medicines and Healthcare Agency (MHRA) and the 
European Medicines Agency. They cannot be sold without the Conformité Européene (CE) 
mark, which indicated that the manufacturer has met the required standards in relation to test 
performance, directions for use and labelling.  
HIV SSKs can appear in many forms, employing dried blood spot, saliva, and blood 
collection devices. This is because the diagnosis of HIV infection is usually made on the 
basis of a serological test; the detection of HIV-1/2 antibodies (Ab) or simultaneous detection 
of HIV-1/2 Ab and HIV-1 p24 antigen (Ag). In the UK, HIV testing using ‘fourth generation’ 
assays (i.e., combined antibody and HIV p24 Ag detection) is recommended over ‘third 
generation’ assays that detect only Ab against HIV.(37) The ability to detect HIV-1 p24 Ag 
has enabled the reduction of the window period between exposure to HIV and detection of 
infection from three months to one month, thereby enabling detection of recent infections. 
Currently, all saliva-based testing options and a lot of Point of Care Tests using whole blood 
are third generation only. 
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Although we did not formally assess the acceptability of various HIV self-sampling methods 
in FGDs (as we did not believe we would have a choice) strong concern about the proposed 
TINY vial collection device arose (see Chapter 4).  
5.4.2 Discordance between acceptable self-sampling methods among study 
participants and UK regulations for HIV testing and diagnostics 
The discordance between preferences of black African communities, service providers and 
UK regulations for HIV testing had several implications on development of an optimal 
intervention.  
Preference for oral specimen collection compared to blood collection device among users 
and service providers 
Stage 1 of the project elicited significant concerns about the only CE marked SSK available 
currently available in the UK. This SSK relies on the collection of 400ul of blood into a vial. 
A finger is pricked with a lancet and droplets of blood are collected. Collecting a blood 
sample was viewed as a significant barrier to HIV testing for this population in community 
settings. As set out in section 4.2 concerns about the volume of blood required, the fear of 
needles, presumed difficulty in using the kit, fear of contamination of the vial, and fears about 
contaminating others were expressed. Among those familiar with SSKs, collection of an oral 
specimen using a swab was identified as an easier alternative to the TINY vial - both in terms 
of use, acceptance and the amount of support required to promote its use. Due to these 
reasons, the study team perceived usage of the TINY vial device constituted a barrier to the 
successful delivery of the intervention.  
Lack of availability of CE marked assay for saliva HIV testing and implications for 
development of HAUS intervention 
Due to the concerns over the TINY vial, the study team proposed to use an oral self-sampling 
device such as OraSure which is commercially available and CE marked in order to optimize 
testing in the study population. However, there is currently no CE marked saliva-based HIV 
assay available in the UK. In the original grant application, we proposed to use the 
GENSCREEN™ ULTRA Ag-Ab assay for HIV testing. This test is CE marked for use on 
human blood serum and plasma but not saliva. When used with plasma and serum, it is 
considered a fourth-generation assay, and has a sensitivity of 100% (93.2% in the 
seroconversion scenario) according to the manufacturer (64).The test is a reliable indicator 
when a result is negative, which is important to consider as incident infection in the black 
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African population in the UK is likely to be low.(1) However, when used with saliva it is 
regarded as a third generation assay as it is unable to reliably detect HIV-1 p24 Ag. This 
means it is less sensitive to very recently acquired infection and can detect HIV that was 
caught more than 14 weeks ago. The performance of the GENSCREEN™ ULTRA Ag-Ab 
assay with saliva has been evaluated and is considered appropriate for use.(65) All people 
with indeterminate and reactive results are strongly advised to attend confirmatory testing 
using serum or plasma (according to standard practice of NHS centre that they attend) so any 
false positives would be identified.  
Given that the GENSCREEN™ ULTRA Ag-Ab assay for testing saliva for HIV is not CE 
marked, we obtained MHRA guidance on whether we would be able to use the assay on 
saliva within our research study. The MHRA responded positively on the proviso that a NHS 
Trust would accept liability for using a product ‘off-label’ for research purposes. Indeed, due 
to user and provider demand for kits that use saliva, there are commercial and NHS services 
throughout the UK who are willing to take on this liability and use saliva-based HIV SSK 
(66). Exploring these options took up a considerable amount of time at a key point in our 
intervention development.  
UCLH NHS Foundation Trust agreed to be our clinical partner organisation and assume the 
liability for using the GENSCREEN™ ULTRA assay off label, conditional to the study team 
obtaining permission from the NIHR to use the assay. However, The Doctors Laboratory 
(TDL) – the processing laboratory for this study - declined to assume liability to test saliva 
specimens in the context of a research study, even though they provide saliva testing for some 
NHS services and the SSK could not be seen as NHS service provision (as UCLH do not 
offer a saliva-based self-sampling service).  
UCLH also stipulated that the only way they could accept the clinical responsibility for 
proceeding with a saliva option was if a formal evaluation of the kit was included in the study 
design as this was not a test the service was providing and therefore not evaluated previously. 
This would entail participants being provided both sampling options (blood and saliva) and 
both needing to be returned to TDL for processing. This was not a viable option as it would 
represent a significant shift in the original research question and design. Further, the 
requirement for both samples raised ethical issues about what to do should only a saliva kit be 
returned. Following consultation with the study steering committee, the research team 
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decided that such a radical alteration in our proposed study design was not an appropriate 
option for HAUS. 
The steering committee advised that Stage 2 of the study proceed, despite not being able to 
proceed with the optimal kit in terms of user and provider preference. Thus, it was agreed to 
continue with TINY vials as part of the HAUS intervention. This decision was also supported 
by the NIHR because it was felt that that the usage of the TINY method would not comprise a 
shift in the research design of the study. The Stage 2 evaluation was also considered 
worthwhile because a national HIV prevention initiative in the UK is based on HIV SSK 
using TINY vials, with currently little evidence to support its effectiveness or cost-
effectiveness, in particular for black African communities. The Stage 2 study would 
demonstrate whether the approach and distribution methods were feasible and acceptable, 
along with the return rate. Additionally, the evaluation plan (which included qualitative 
interviews both with people returning and with not returning kits) would assess kit 
acceptability. 
5.4.3 Aligning study protocol with quality care and research governance framework  
The best practices for provision of sexual health care in England are outlined in the 
‘Standards for the management of sexually transmitted infections’ developed by the British 
Association of Sexual Health and HIV.(67) These clinical recommendations also apply to 
Wales and Northern Ireland. Sexual Health service standards for Scotland were published by 
NHS Quality Improvement Scotland in 2008.(68) Both these standards provide guidance for 
achieving safe, high quality services for management of STIs. According to these guidelines, 
development of clear care pathways to be utilised by all STI service providers both statutory 
and non-statutory is vital component of STI management. Specialist GUM providers are 
advised to have an explicit leadership role for clinical expertise and clinical governance in the 
management of STIs. Provision of results as quickly as possible to service users, whether 
positive or negative, is emphasised for effective clinical management of infection and for user 
satisfaction. The recommended time-period between consultation and receipt of results is 
ideally no more than 14 working days, taking account of the laboratory turnaround times. The 
guidelines emphasise that people accessing non-specialist or outreach services should receive 
the same standard of care as those accessing any other service for the testing and treatment of 
STIs. The Research Governance Framework for Health and Social Care outlines the 
responsibilities of researchers and care providers that apply to all research within the remit of 
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Secretary of State.(69) Ensuring confidentiality and quality of care provided to research 
participants is at the core of this framework. 
In the context of SSK for HIV testing, clear and robust pathways of care are needed for 
participants: to send specimens for testing; delivery of test results; offering retest to those 
with indeterminate results and confirmatory tests to those with reactive results; and linking 
those who test HIV positive to care. In order to align with the principles of the governance 
framework and given the sensitivities around HIV, the research team felt it important that an 
organisation with previous experience of managing HIV results, and ideally SSKs, were 
involved – this organisation would also need to be willing to assume the liability for the 
quality of care provided. Establishing collaboration with an organization willing to accept 
duty of care for all study participants and not just those with reactive (positive) results took 
considerable time and led to substantial delay. The reasons for the delay are described 
below.  
The study team collaborated with TDL for the provision and processing of SSKs. An NHS 
Trust initially agreed to take responsibility for duty of care for all study participants. 
However, this arrangement was complicated by the fact the team intended to use an ‘off-
label’ assay to test for HIV. Although this Trust had previously provided the same saliva-
based SSKs using the GENSCREEN™ ULTRA Ag-Ab assay as part of outreach work to 
increase HIV testing in the gay community, they were unwilling to assume liability in the 
context of a research study. Eventually the Trust withdrew their support to fully partner the 
study and in particular to take responsibility of care for those participants that did not require 
direct personal contact. Cost pressures within the Trust leading to reduction of staff due to 
restructuring of commissioning of sexual health services also made involvement problematic. 
Besides, for a NHS trust to assume liability for the assay, the assay would need to be 
supported by a performance evaluation. This was not feasible, since the Trust did not house 
the required laboratory. 
Similarly, other NHS Trusts with SSK experience approached by the study team were 
unwilling to provide duty of care to participants testing negative because they would 
effectively have no contact at all with the individual (the kits being distributed in the 
community, processed by TDL and informed of the result via text message sent by TDL). 
Eventually UCLH agreed to be the ‘organisation providing care’ for all study participants; 
with laboratory services provided via a sub-contract with TDL and a sub-contract with 
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Central & North West London NHS Foundation Trust (CNWL) to deliver all results requiring 
direct contact with participants given UCLH did not have prior experience or services in 
place to provide this service. The process of establishing the clinical care pathways and 
necessary contracts took over 10 months, which adversely affected the ability to deliver the 
study on time and at scale. 
5.4.4 Collaborating with GP/CBOs  
One of our study aims was to assess the feasibility of using existing services for an SSK 
intervention for future Phase III evaluation. Based on results from Stage 1, the study team 
decided to distribute HIV SSKs targeted at black African people in (GP) surgeries and CBOs 
working in HIV prevention in both London and Glasgow. Unfortunately, implementation of 
the Haus study in Glasgow and collaborations with CBOs in London did not occur as 
intended.  
Recruitment of GP sites in Glasgow 
Recruitment of GPs surgeries for research purposes in Scotland is carried out by the Scottish 
Primary Care Research Network (SPCRN). Due to the SPCRNs previous experience of 
delays in gaining ethics approval and its impact on the willingness and interest of surgeries in 
participating in research, the SPCRN now declines to make contact with GP surgeries without 
ethical and NHS Research and Development (R&D) approvals being in place. In fact, no 
information on research projects can even be sent to GP surgeries prior to these approvals 
being in place, making it difficult to gauge interest and likelihood of support for a project. 
The NHS R&D approvals in Scotland were also dependent on an agreement between GP 
practices in Glasgow and UCL – something not required in London as no financial 
reimbursement would occur between London GP sites and UCL. Because CRN support 
differs between England and Scotland, there was a need for some reimbursement to Glasgow 
practices from UCL to ensure they received the same support as their London counterparts. 
Despite beginning the contracting process in November 2015 it took until the end of April 
2016 before these were in place.  
The SPCRN were provided with an introduction letter to the project which was distributed to 
17 GP surgeries across three regions within the Greater Glasgow and Clyde health board, 
namely Glasgow City, Clydebank and Paisley. Unfortunately, none of the surgeries 
responded to either accept or decline the request to participate. Due to the lack of response, 
another letter was distributed, which did not yield any responses from surgeries. It is not 
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possible to know the reasons behind this lack of willingness to participate. Anecdotally, staff 
at the SPCRN believed recruitment would be low due to the low numbers of black Africans 
attending GP nurse appointments within the Greater Glasgow and Clyde region. Due to lack 
of research sites yielded in Scotland, the Haus intervention could not be implemented through 
GP surgeries in Glasgow. 
Recruitment of CBOs 
A total of 10 CBOs were intended CBO partners in London, however several declined to 
participate because at the time of setting up this study these organisations had to cease their 
services that had previously delivered HIV prevention that targets black African people due 
to funding cuts. This meant that the burden of recruiting the required sample size for the 
study had to be shared by fewer CBOs than originally planned. 
Waverly Care in Glasgow were involved in the project from its inception. One of the first 
exploratory focus groups (see section 2.1.2) was held on their premises and many of their 
staff attended as they had a great interest in the development of and participation in the 
intervention. Unfortunately, due to the delays in getting REC approval, they withdrew as 
distributors in order to work on developing their own HIV testing intervention which was to 
be implemented for World Aids Day in 2015. As such, the HAUS intervention could not be 
implemented through CBOs in Glasgow  
5.4.4  Final intervention content 
Table 8 illustrates the intervention functions and behaviour change techniques that were 
agreed across the team to become part of the HAUS intervention. These are the core 
components to be used within the intervention manual and within intervention training. As 
described in section 2.3 (step 4) they were derived after systematically having applied the 
APEASE criteria (Affordability, Practicability, Effectiveness and cost-effectiveness, 
Acceptability, Site-effects/safety, and Equity).(32) These criteria assess the viability of 
intervention function and behaviour change techniques for a real world intervention 
implementable within the UK. In this way the content of the HAUS intervention was finally 
agreed and drafted. 
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Table 8: Final intervention content following application of APEASE criteria 
Intervention component  Following application of Appease criteria:  
Intervention function and BCTs to be used within the HAUS intervention within both training and manual 
The targeted offer of an HIV 
SSK 
Intervention functions 
Education of health professionals, Training of health professionals, Persuasion and modelling to health professionals  
Behaviour Change techniques to be employed within training  
 Demonstration of the behaviour – provide an observable performance of targeting (script provided within manual) (6.1) 
 Behavioural practice/rehearsal- increase habit and skill though rehearsal of targeting (8.1) 
 Provide information about health consequences- provide detail about late diagnosis information within  training session (5.1) 
Participant personal 
information disclosure  
Intervention functions 
Persuasion  
Behaviour change techniques employed  
Present verbal communication from a credible source (service provider) in favour of providing personal information (9.1) 
The appearance and 
packaging  
Intervention functions 
Environmental restructuring  
Behaviour change techniques  
Restructure the physical environment by ensuring that non transparent materials are provided, that generic commonly used 
materials are used, that they are secure and they can be easily carried in a neutral bag provided to people (12.1) 
Compliance with kit 
instructions  
Intervention functions 
Persuasion, modelling and enablement 
Behaviour change techniques  
Credible source – the service provider should be credible and trustworthy (9.1) 
Problem solving –analyse or prompt patient to analyse factors influencing the use of the kit and generate strategies to 
overcome barriers to using kit (1.2) 
Instructions on how to perform the behaviour. Advise and agree on how to do use instructions (4.1) 
Verbal persuasion about capability- within interaction tell patient they can utilize the instructions and argue against self-doubts, 
asserting that they can succeed (15.1) 
Demonstration of the behaviour – provide an observable performance using the instructions (and via video link) (6.1) 
Kit return  Intervention functions 
Persuasion 
Behaviour change techniques  
Prompt detailed planning of performance of sample return from home –ask participants to state an implementation intention 
(1.4) 
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5.5 Conclusion of the development of HAUS Phase 2 
A theoretically informed and implementable intervention was developed specifying the active 
ingredients of the intervention content. It focussed upon the targeted offer of an HIV SSK 
distributed by both Practice Nurses in GP clinics and by Community Workers from 
community organisations. The study recruiters were trained using the training manual to offer 
black Africans a SSK using a scripted discussion that provides a rationale for HIV testing and 
explains how the kit is to be used. Use of the script would ensure consistency of approach 
across distributors. Intervention recipients were given a brief explanation of how to take the 
sample. They were asked to return their sample within two weeks using a stamped, addressed 
envelope provided with the kit. Using a structured approach to intervention development 
enabled a high degree of specificity regarding the content of the intervention training, and 
intervention manual and enabled clarity of focus for both process and outcome measures 
within trial evaluation. The intervention manual and training materials are available upon 
request. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 101 
Chapter 6: Study design and methodology for Stage 2 
The aim of Stage 2 was to assess the feasibility, appropriateness of settings and optimal 
intervention design for future Phase III evaluation. The objectives of Stage 2 were addressed 
through three main research activities: 
1. A feasibility study 
2. A process evaluation 
3. An economic analysis. 
This chapter focuses on the study design and methodology for the feasibility study (section 
6.1) and the process evaluation (section 6.2). The methodology and findings of the economic 
analysis are presented separately in Chapter 11. 
Ethical approval was obtained from the East of England- Cambridge South Research Ethics 
Committee (REC reference 15/EE/0412; IRAS project ID 184223). 
6.1 Methodology and design of the feasibility study 
6.1.1  Study settings 
The intervention was intended to be offered in GP surgeries and CBOs in both London and 
Greater Glasgow. Unfortunately for the reasons described in section 5.4.4, implementation 
of Stage 2 of the Haus study in Glasgow did not occur. London GP surgeries  
Recruitment was to be focussed on areas with relatively large black African communities. 
South London, particularly Lambeth, Lewisham, and Southwark, Croydon and Bexley were 
identified via 2011 census data. Many GP surgeries within East London had recently 
participated in an HIV point of care testing intervention (70), so this area was initially 
excluded from recruitment despite having a large black African population.  
In mid-November 2015, staff at the South London Clinical Research Network (CRN) 
introduced the HAUS Study via email to Practice Managers whose surgeries were members 
of the ‘Research Sites Initiatives’ scheme. This was followed by email communication to 
contacts at practices not part of the scheme in late November. In December 2015, the chief 
investigator of HAUS delivered a presentation on the study at a research event at Guy’s 
Hospital, London, to an audience of GP Practice Managers (PM) located in south London. 
This event introduced the study to a wide variety of practices, and resulted in interest in 
participation in HAUS from GP surgeries outside of the initial target boroughs. As practice 
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recruitment was slower than expected, the geographical recruitment area was expanded to 
include all areas in South London excluding Richmond, Kingston, Sutton, and Bromley, and 
eventually to North London. The study team were careful to ensure the HAUS intervention 
would not interfere with recent interventions aiming to increase POCT.(70)  
Twelve GP surgeries agreed to deliver the intervention. These sites were trained over a period 
spanning from mid-March to mid June 2016 (training materials are available upon request). 
All attendees evaluated the training received. All training sites received a Trial Site File, 
which contained the study protocol and study instruments.  
London Community-Based Organisations 
CBOs involved with HIV prevention in London were also recruited as distribution settings. 
Only organisations with experience of targeting black African people, and whose existing 
scale and scope of work with this population was strong were approached for involvement in 
the study.  
A longlist of 10 London-based HIV CBOs that serve African people was drafted based on the 
extensive contacts held by members of the study. Of these, those with a predominant focus on 
HIV prevention were shortlisted (n=8) and approached to attend Phase 1 focus group 
discussions. This enabled the study team to identify four well-placed CBOs to be potential 
distributors, and one further was identified at that stage to make a total of five. Ultimately, 
because two of these CBOs lost funding to undertake HIV prevention activity prior to the 
start of fieldwork (following a pattern that unfolded across the HIV sector during our study), 
we ultimately had three CBOs recruited as study distributors: Positive East 
(http://www.positiveeast.org.uk), NAZ Project London (http://naz.org.uk), and KwaAfrica 
(http://kwaafrica.org). Initial training sessions occurred in February 2016 before appropriate 
contracts outlining their involvement and obligations to the study were finalised. There was a 
delay of several months between the training session and the signing of the contracts (see 
section 5.4.3). As such, the CBO sites required re-training due to the delay and staff turnover. 
These training sessions were delivered in April and May 2016 and focussed more on data 
processing.  
Each attendee was invited to evaluate the training sessions (the results of which are reported 
in section 9.3.1). Each CBO received a Trial Site File that contained the study protocol and 
study instruments.  
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6.1.2 Inclusion and exclusion criteria 
To be eligible, potential participants needed to consider themselves to be ethnically black 
African, 18 years of age or older, and able to provide informed consent. Potential participants 
were excluded if they were unable to read and understand English and or could not provide a 
means of contact for result notification.  
6.1.3 Statistical Methods and Sample size calculation  
The sample size is based upon the precision of the estimate of the return rate (eg the width of 
the confidence intervals).  The numbers were estimated using the well known Wald 
Approximation.  As the primary measure is based upon attrition (the return rate) no further 
allowance has been made for precision. 
 
HIV SSK projects in the UK (which primarily target MSM online) have achieved return rates 
in the region of 60% (20). Given that in the UK HIV testing rates tend to be lower in black 
African communities the study team assumed a return rate of 50%. Distribution of a total of 
600 kits per setting would enable a precision rate of at least ±4.0%, and distribution of a total 
of 380 kits per setting would enable a precision rate of at least ±5.0%. Should the return rate 
be lower or higher with a fixed sample size the size of the standard error would be smaller 
and the resulting confidence intervals narrower.  
More SSK were to be distributed in London than in Glasgow because the former has a larger 
population of black Africans and recruitment was limited in Glasgow to GP surgeries. We 
planned to distribute 600 SSKs in each site (GP surgeries and CBOs) in London and 380 in 
GP surgeries in Glasgow. Prior to the commencement of SSK distribution, it became clear 
that no SSKs would be distributed from Glasgow sites (for reasons outlined in section 5.4.4). 
Accordingly, the recruitment target was reduced from 1,580 to 1,200. 
Proportions were described using the number and percentage, and continuous data are 
described using the median and IQR.  The relationship between baseline characteristics and 
enrolment is described using simple univariate logistic regression models.  All analyses were 
conducted in SAS 9.4 (SAS Institute; Cary, North Carolina) 
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6.1.4 Self- sampling Kit 
The TINY collection device in conjunction with ROCHE HIV Combi assay was used to test 
for the presence of HIV antibodies in participants who consented to take part in this study. 
The ROCHE HIV Combi is a 4th generation assay, used for the detection of HIV p24 antigen 
and antibodies to HIV-1 (Groups M and O) and HIV-2. It can detect HIV that was acquired 
more than 4 weeks ago and is CE marked. The ROCHE HIV Combi has a sensitivity of 100% 
(lower 95% CI 99.8%) and a specificity of 99.63% (95% lower CI 99.42).(71) This test 
requires collection of 400 ul of blood (obtained by pricking a finger with the supplied lancet) 
in a small collection tube. The test enables the specimen to be transported to a lab, by post, in 
a vial that contains preservatives which stabilize the sample for up to 21 days if temperatures 
are between 4° C and 37° C.  
The package distributed to participants included: the TINY kit sample collection device 
(including self-retracting lancets); a sample data form (see supplementary documents) which 
required three unique sample identifiers from the participants in order for the laboratory to be 
able to process the sample and to enable result notification; the acceptability questionnaire 
(see Appendix J); a paid return envelope for sample and questionnaire return to the lab, and 
the sample collection instruction sheet. The instruction sheet provided information on how to 
collect the sample, a link to a video demonstration (www.haus.org.uk), information on 
labelling the sample and postage, information on how the result would be communicated and 
why they may be contacted, and a reminder about completion of the acceptability 
questionnaire. Both the instruction sheet and the video demonstration used black African 
imagery. 
The Doctors Laboratory (TDL), a CPA accredited pathology provider who take part in 
NEQAS (National External Quality Assurance Scheme), supplied the kits each featuring a 
unique identifier. Sites were instructed to store the kits in a locked cupboard until distribution 
to avoid tampering and theft. Kit distribution to all sites was tracked by the project manager.  
6.1.5 Screening Procedures  
GP Surgeries  
The plan was for Practice Nurses (PNs) at GP surgeries to go through their patient list each 
morning and identify potentially eligible patients. Ethnicity information is often routinely 
gathered for new patients at GP surgeries in London and available on the electronic patient 
record, thus enabling identification of eligible patients; this information was recorded on an 
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enrolment log. Where ethnicity information was not available, or patients attended 
unexpectedly, recruiters were also encouraged to offer the intervention to others who were 
potentially eligible and to record this retrospectively.  
Community-Based Organisations 
Details of all potential participants were also to be listed by CBO workers on the enrolment 
log, regardless of whether or not the potential participant ultimately enrolled into the study. 
CBOs did not always have the information required for the enrolment log such as age for all 
potential participants (especially those who did not enrol into the study). The study team 
asked community workers to insert approximate age ranges where exact ages could not be 
ascertained.  
6.1.6 Participant recruitment 
An intervention script was provided to distributors in both GP surgeries and CBOs to 
introduce and initiate discussion about the study. This was supplemented by an aide memoire 
in the form of key bullet points derived from the longer script. It was anticipated that this 
scripted interaction with potential participants would occur during routine consultations at GP 
surgeries, or regular outreach activities undertaken by CBOs. Interested eligible potential 
participants were given the Participant Information Sheet (PIS), asked to read it, and given 
the opportunity to ask any questions. At this point potential participants were invited to enrol 
in the study, and if accepted eligibility established. 
If the participant declined, distributors were instructed to state, “That’s absolutely fine. We 
would really like to understand why people do not want to participate in the study. On this 
card are some of the common reasons why people say no”. They then showed them a card 
with nine reasons why people may not want to participate. The listed reasons were:  
1. I have recently tested for HIV 
2. I do not believe I am at risk of HIV 
3. I would prefer to test elsewhere 
4. I would prefer not to use a self-sampling kit 
5. I would prefer not to know my HIV status 
6. I do not like being offered an HIV test just because I am black African 
7. I already know that I am HIV positive 
8. I would prefer not to say 
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9. Another reason 
If asked what was meant by the term ‘black African,’ distributors were instructed to clarify 
that this category included anyone who identified themselves as black African, whether they 
were migrants from Africa, African descendants or African nationals. A ‘frequently asked 
questions’ section was provided in the intervention manual to support distributors in fielding 
any questions they may receive about HIV or the study process. If the potential participant 
was ineligible, the distributor thanked them for their interest, explaining that they did not 
meet the eligibility criteria, and suggested an alternative method of HIV testing.  
Consent process 
Informed consent was obtained from all participants. Though the study team intended for the 
majority of consents to be obtained via the tablets, most sites used paper forms. In the case of 
GP surgeries, there was overwhelming preference for paper forms. Reasons for this 
preference usually centred on the lack of dependable wifi at GP surgeries, and concern that 
the tablets would be stolen. As such, only the CBO sites were provided with study tablets, 
though the CBOs also relied upon paper forms when the tablets were not feasible. Responses 
entered via tablets were automatically recorded and stored in the study database. Completed 
paper consent forms were sent to the trial manager via secure fax or email.  
The consent forms contained both mandatory and optional components. For those participants 
recruited from GP surgeries, notification of general practitioner of HIV test result was an 
optional consent item. If consent to this item was granted, the general practitioner was 
notified via letter from the chief investigator. The general practitioner was not informed if 
consent was not obtained for this item, and were not informed if a participant decided not to 
return the kit to the laboratory for analysis. Participants recruited at both sites were given the 
option of consenting to be contacted for follow-up telephone interviews.  
Baseline data 
Participants were asked to complete a short baseline questionnaire (see Appendix H) in situ 
either on paper or via tablet. The baseline questionnaire collected demographic data and a 
brief assessment asking country of birth, duration of UK residence, HIV testing history and 
sexual activity within the last 12 months. The baseline data was for research and 
governance purposes and was not intended to be used or seen as a risk assessment 
screening toolDistribution of the kit 
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The distributors then gave the participant a SSK and briefly explained the processes involved 
with kit use. Distributors also explained how results would be communicated. Additional 
information on how to use the self-sampling kit, how to access the online video of someone 
using the kit, the importance of posting the sample to the laboratory for processing and the 
use of reminder texts to participants should the sample not be received at the lab was 
highlighted in the PIS and instruction sheet.  
6.1.7  Sample Collection and Analysis  
Participants who self-collected a sample were also required to complete the sample form with 
three unique identifiers (initials, date of birth and unique ID number) to enable the sample to 
be processed at the laboratory. The ID number was pre-populated on both the sample form 
and the acceptability questionnaire.  
6.1.8 Follow-up of participants 
Acceptability questionnaire: Every kit included an optional brief acceptability questionnaire 
(see Appendix J) which was completed and returned with the sample. The questionnaire 
explored the acceptability of being offered an SSK in the setting, acceptability of targeting, 
and the process of using the kit. The unique ID number enabled linkage with test results and 
baseline data.  
Telephone interviews: At enrolment, participants were asked if they would be willing to take 
part in optional follow-up telephone interviews. The study team initially aimed to complete 
30 interviews, purposively sampled to include participants across age ranges and genders and 
to ensure a balance between who did and did not return a sample, in each of the intended 
study cities, as well as those recruited through each distribution setting (CBO or GP surgery). 
Because the overall recruitment target was not met, and this stage did not ultimately take 
place in Glasgow, the number of participants targeted for interviews was revised to 20. We 
sought to maintain a balance between those who did and did not use the kit. Furthermore, as 
this stage of the study progressed a substantial proportion of kits were returned with 
insufficient samples so we expanded our purposive sample to ensure we interviewed a 
balanced sample between three groups: those who accepted a kit but did not return a sample 
those who used a kit and received a negative result, and those whose sample was unable to be 
processed due to under-filling of the blood vial. Interviewing those with reactive results was 
never part of our purposive sampling strategy as we felt this would likely cause distress, as it 
was no reactive results emerged from within the study sample. This revision of the purposive 
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sampling strategy enabled us to be responsive to the conditions and realities faced by our 
study population as they emerged in real-time. 
A topic guide (see Appendix C) exploring kit distribution, kit use and return, and implications 
of the intervention was used for the interviews. Participants provided verbal consent to 
proceed with the interviews at a mutually convenient time. Interviews lasted approximately 
30 minutes and interviewees were sent a £10 voucher for their time. Interviews were recorded 
and transcribed. Detailed notes were taken during non-recorded interviews in lieu of 
transcription.  
Anonymised transcribed interviews along with notes from non-recorded interviews were 
imported into an NVivo 10 file for coding and analysis. The interviews were analysed using a 
thematic approach.  
6.1.9 Results communication and management 
Anonymised results were communicated from TDL to the project manager at UCL on the 
same day that sample analysis occurred, via secure encrypted email. There were three 
possible test results: HIV not detected, reactive sample, or insufficient sample (due to either 
under filling of TINY vial or gross haemolysis). UCLH provided duty of care to all 
participants who returned a self-sampling kit, regardless of whether they were recruited at GP 
surgery or a CBO. However, duty of care was passed to CNWL for reactive results, 
insufficient samples, and those without a mobile number. This arrangement arose because 
UCLH does not currently provide a self-sampling or HIV result notification service for 
patients. CNWL do and have clinical expertise in the provision of HIV results. If a participant 
were to require confirmatory testing duty of care would pass to the health care institution 
attended.  
Non-reactive results 
In line with standard practice in most NHS sexual health clinics, non-reactive results were 
delivered via text message. TDL, under contract to UCLH, was responsible for the delivery 
of these messages. If a participant only provided alternative contact means (landline) then the 
study team tasked a Health Advisor (HA) at CNWL to notify the participant as per normal 
clinic practice. 
Reactive results, and insufficient samples  
 109 
Participants with reactive results or insufficient samples were notified by telephone by 
CNWL HAs. Health advisors attempted to make contact directly with participants, rather than 
leaving a message for the participant to call back.  
TDL notified the project manager at UCL of any reactive or insufficient results on the day of 
the sample analysis via secure encrypted email. At this stage, the names of participants with 
reactive samples are unknown to all parties as only initials are required with SSK return. The 
study manager would link the study ID number to the associated consent form and baseline 
questionnaire, thus obtaining their name. This information was passed to the HA in person, 
enabling them to contact the participant. Should any reactive results have been obtained, the 
HA would also have made follow-up phone contact with the participant to ensure linkage to 
care had occurred. It was anticipated that this would also provide an opportunity to identify 
any unexpected consequences of the testing process. 
For those with reactive results, the study team planned to offer follow-up for confirmatory 
testing within 24 working day hours of the test result. As postal code information was 
gathered, HAs were enabled to contact the sexual health clinic nearest any participant with a 
reactive result, to arrange for confirmatory testing. Thus, there was a process in place to 
ensure that any participant with a reactive result would be linked to specialist care.  
For those with insufficient samples a process identical to that in the case of reactive results 
was followed. The participant with the insufficient sample was offered three options via 
telephone communication: to have a second SSK posted, to be advised on where to access 
alternative HIV testing, or to discuss alternative testing options with their GP.  
For both reactive results and insufficient samples, the HA was responsible for documenting 
the pathways into care, to record follow-up attempts and next steps including linkage to care. 
A schematic of the HAUS fieldwork process is provided in Appendix I.  
6.2 Methodology and design of the process evaluation    
6.2.1 Purpose and scope of the evaluation 
An understanding of what was implemented and how it was implemented are integral to 
explaining how an intervention works, in order to address questions of feasibility; or whether 
it was possible to deliver the intervention as planned in the chosen settings.  
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The principal concern of early process evaluation frameworks was capturing what was 
delivered in practice in order to avoid dismissal of sound intervention theories due to a failure 
to implement them effectively.(72) Most frameworks focus on the precise ‘form’ of delivery 
in terms of whether this represents fidelity to what was intended to be delivered, as well as 
measuring the reach of delivery (the dose). There is debate about whether adaptations in 
programme delivery, decided locally, enhance intervention effectiveness or lead to poorer 
outcomes.(72, 73) 
Advocates of strict fidelity(74) argue that fidelity is essential if effective interventions are to 
be replicated, especially when an intervention’s ‘active ingredient’ may not be known. 
Advocates of local adaptation argue that interventions need to be tailored to local 
circumstances.(73) Durlak and DuPre (2008) propose a compromise whereby the ‘core 
components’ of an intervention should be delivered in standard form, but less central 
intervention components or features can be modified to fit local needs.(75) They present 
research that suggests a balance between fidelity and adaptation is likely to be most effective, 
with the precise balance dependant on the specific intervention. 
The process evaluation was informed by MRC guidance(76, 77) and the wider 
implementation science literature.(78-80) It investigated not just implementation of the 
intervention (that is, fidelity, reach and acceptability) but also considered mechanisms of 
action (impact in context) and potential future normalisation of the intervention. These three 
areas of exploration are described in fuller detail below.  
i. Implementation  
• Were standardised intervention components implemented with fidelity of form? 
• Where deviations from fidelity of form occur, do these reflect intentional adaptation 
(and if so with what motivation), unintentional drift or simple omission? 
• What was the reach of the intervention? 
• How did reach and acceptability vary across key sub-groups of African people and 
what contextual factors appear to affect this? 
ii. Mechanisms of action 
• Does the intervention increase access to HIV testing (opportunity) 
• Does the intervention provide an acceptable and viable option to establish HIV status 
(capability) 
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• Does the intervention increase motivation to test for HIV 
• Are any potential harms suggested by qualitative data 
iii. Normalisation 
• Is the intervention likely to be supported by key stakeholders in future funding and 
delivery of SSK? Do they: 
a. view the intervention as coherent? 
b. commit to future participation? 
c. commit to collectively take on the work arising from the intervention?  
d. review progress implementing it? 
 
To address these areas the process evaluation collated information from the inception of 
Stage 2. Figure 4 contains a flowchart of the data collection points relevant for the process 
evaluation. The following data were intended to be collected:  
1. Study diaries – the study team routinely recorded challenges and issues encountered by 
in all aspects of the implementation of the feasibility study. 
2. Training evaluation - distributors were asked to complete a before/during/after survey 
assessing the value of the training, the extent to which the training meets its stated aims, 
and their comfort and confidence in delivering the HAUS intervention 
3. Screening and recruitment logs - This data assisted in monitoring progress during 
recruitment and facilitated early intervention if support in recruitment was required.  
4. Distributor weekly log - Distributors were asked to complete a weekly log to monitor 
their recruitment progress and report any problems with recruitment (see Appendix I). 
They were asked to rate how they felt about recruiting people to the HAUS study, their 
confidence level in targeting black African people and in answering questions about the 
study, and whether they used techniques provided in the training session or study 
manual.  
5. Site Visits - Up to two site visits were planned with each distributor to support 
implementation of the intervention. Detailed notes were taken during the visits to aid 
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with understanding of the environments and circumstances in which the intervention was 
being delivered.  
6. Data flow - The speed and success of data flow through all elements of Stage 2 was 
monitored to assess intervention feasibility. 
7. Support queries and responses - Any contact with the study team by distributors or study 
participants was logged.  
8. Site summaries - Throughout the distribution period, data from distributors was collated 
and synthesised into a one-page intervention summary for each site, describing their key 
successes, challenges and experiences along the way. Each summary was cross-checked 
by the project manager, and then emailed to each distributor in turn for their 
consideration and comment.  
9. Site close-down interviews – the site summaries were used as the basis for undertaking a 
final face-to-face interviews with distributors at each site. Focus groups were originally 
planned however, as few individuals at each site undertook distribution (in many cases, 
only one individual), one-to-one or small group interviews were a more feasible format. 
Interviews lasted for approximately 30 minutes (range 5 to 60 minutes). A semi-
structured topic guide (see Appendix K) was used to structure these discussions. The 
focus of the interviews was to gauge acceptability of the intervention, distributors’ 
experience of undertaking targeting, recruitment and consenting procedures, and fielding 
questions. The interviews were recorded where possible, and notes were taken 
throughout. Annotations formed the basis of analysis, with recordings providing backup 
where needed 
10. Qualitative interviews with study participants - The process evaluation also drew upon 
the qualitative follow-up interviews with participants described in section 6.1.8 above.  
The raw and synthesised data was then coded and analysed with a focus on eliciting themes 
relevant to the organising principles of feasibility (fidelity) and acceptability. 
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Figure 4: HAUS process evaluation plan 
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Chapter 7: Results 
The recruitment period for London-based CBOs and GP surgeries was reduced from 6 to 4 
months (April to July 2016) due to delays caused by the kit selection and governance issues 
(see section 5.4). As such, the study team anticipated that recruitment would fall short of the 
revised target of 1,200 SSKs.  
7.1 Overall results 
The recruitment rate from all sites (even when accounting for truncated recruitment period) 
was substantially slower than expected, with only 349 eligible persons approached in total; 
229 from GP settings and 120 in CBO settings. Of those approached 125 (35.8%) agreed to 
participate. Six participants however, all who returned their SSK, subsequently had to be 
excluded due to errors with the consent process, providing a final total of 119 participants. 
Figure 5 illustrates the participant flow from screening to enrolment for GP and CBO 
settings. 
Figure 5: Participant flow from screening to enrolment per recruitment setting 
 
 
 
 
 
 
 
 
The most common reason for declining to participate was that the person had recently tested 
for HIV (25%), followed by lack of perceived risk (18.7%) (see Table 9). Six (2.7%) people 
stated they did not like being offered an HIV test just because they were black African and a 
further 17.4% declined as they wanted to either test elsewhere or not use a SSK. We were 
unable to assess whether reasons for declining varied according to whether recruitment was 
120 Screened in CBO settings 229 Screened in GP settings 
90 Declined 
to participate 
30 Enrolled 95 Enrolled 134 Declined 
to participate 
119 included in final analysis 1 
Excluded 
5 
Excluded 
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in a GP or via a CBO due to the number of reasons presented and insufficient degrees of 
freedom.  
Table 9: Reasons for declining to participate (as specified by respondent) 
Reason for declining to participate Frequency (%) 
I have recently tested for HIV 56 (25.0%) 
I do not believe I am at risk of HIV 42 (18.7%) 
I would prefer to test elsewhere 19 (8.5%) 
I would prefer not to use a self-sampling kit 20 (8.9%) 
I would prefer not to know my HIV status 15 (6.7%) 
I do not like being offered an HIV test just because I am black African 6 (2.7%) 
I already know that I am HIV positive 4 (1.8%) 
I prefer not to say 19 (8.5%) 
Another reason (unspecified) 43 (19.2%) 
Total 224 (100%) 
Eligible people visiting their GP were significantly more likely to be recruited than those 
approached via a CBO (odds ratio [OR] 1.96 95% CI 1.21 to 3.19). There was no observed 
relationship between gender or age and enrolment status (OR for greater recruitment among 
women 1.12 95% CI 0.72 to 1.75; and OR for greater recruitment with increased age 1.02; 
95% CI 0.997 to 1.034). 
Table 10: Socio-demographic characteristics of HAUS participants 
Characteristic 
Overall (%) 
N-119 
SSK returned 
Yes (%) 
n=66 
No (%) 
n=53 
Age median (Inter-quartile range) 42.6 (32.7, 51.7) 41.6 (32.7, 51.6) 44.6 (36.7, 53.7) 
Male (%) 58 (48.7%) 33 (50.8%) 25 (46.3%) 
    
Recruitment site (n=119)    
GP 90 (75.6%) 45 (50.0%) 45 (50.0%) 
CBO 29 (24.4%) 21 (72.4%) 8 (27.6%) 
    
Country of birth (n=109)    
Africa 89 (74.8%) 45 (50.6) 44 (49.4) 
Elsewhere including UK 20 (16.8%) 12 (60.0) 8 (40.0) 
    
Time in UK (n=113)    
Less than one year 6 (5.0%) 3 (50.0%) 3 (50.0) 
1-2 years 1 (0.8%) 0 (0%) 1 (100) 
2-5 years 7 (5.9%) 4 (57.1%) 3 (42.9) 
5-10 16 (13.4%) 8 (50.0%) 8 (50.0) 
 >10 years 6 (5.0%) 36 (52.9%) 32 (47.1) 
Born in UK 15 (12.6%) 9 (60.0%) 6 (40.0) 
    
Time since last HIV test (n=113)    
 116 
Never previously tested 30 (26.5%) 12 (40.0%) 18 (60.0) 
< 1 year ago 19 (16.8%) 10 (52.6%) 9 (47.4) 
1-2 years 17 (15.0%) 12 (70.6%) 5 (29.4) 
2-5 years 17 (15.0%) 11 (64.7%) 6 (35.3) 
>5 years 22 (19.5%) 12 (54.5%) 10 (45.5) 
Prefer not to say 8 (7.1%) 3 (37.5%) 5 (62.5) 
    
Sex in the past months (n=113)    
I have not had sex 21 (18.6%) 15 (71.4%) 6 (28.6) 
With both men and women 1 (0.9%) 1 (100%) 0 (0) 
Only with the opposite sex 86 (76.1%) 41 (47.7%) 45 (52.3) 
Unsure or prefer not to say 5 (4.4%) 3 (60.0%) 2 (40.0) 
In total 119 participants were correctly enrolled: median age 42.6 (range 18-79 years); 58 
(48.7%) were men; the majority (90 (75.6%)) recruited from GP practices (Table 10). The 
SSK return rate was 55.5% (66/119); 95% CI 46.1% to 64.6%. 
There was a reduced odds of SSK return with increasing age although this was not 
statistically significant (OR 0.98, 95% CI 0.96-1.01; p= 0.212). Similarly, there was a non-
significant reduction in the odds of returning a kit among women compared to men (OR 0.84 
95% CI 0.41 - 1.72; p= 0.627). Kit return may vary according to whether recruitment 
occurred in a GP compared to a CBO (OR 2.63 95% CI 1.05 - 6.54). Twelve people who 
returned a kit had never previously tested for HIV, and a further 12 had not tested over five 
years.  
The majority (83.1%) of tests returned HIV negative. However, 11 samples (16.9%) were 
unable to be processed due to the vial being under filled or sample grossly haemolysed. There 
were no reactive results. Of the 11 participants who returned insufficient or grossly 
haemolysed samples, only one requested a further SSK be mailed to them (unfortunately  this 
was also returned as an insufficient sample). Three were unable to be directly contacted and 
after three attempts, a text message informing them of the outcome was sent. Most (n=5) 
opted to discuss alternative testing options with their GP when they next attended. 
7.2 Acceptability data  
Of the 65 participants who returned a SSK, 62 (95.4%) also returned the acceptability 
questionnaire (see Appendix I). The offer of the test directly helped 79.0% of respondents 
decide to test for HIV. The overwhelming majority (93.7%; 59/62) also reported that the 
person who offered the kit helped them feel more confident about knowing their HIV status. 
Just under a third (32.2%, 19/62) reported watching the video online; of these 19 people all 
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found the video helpful, and 14 (83.3%) felt it made them feel more confident. The majority 
of kit returners (73.2%) reported that they would be willing to use one of these kits again. 
Participants were asked to rank how they found aspects of the intervention (Table 11) using a 
visual scale (see Figure 6).  
Figure 6: Visual scale used with acceptability questionnaire 
 
The least acceptable aspect of the intervention was the targeting of black Africans with just 
over a third (34.5%) reporting it was unacceptable. No one felt the location in which they 
were offered the kit was unacceptable. The majority (82%) found the SSK instructions easy 
to understand and most (67.7%) felt comfortable with taking the sample themselves.  
Table 11: Acceptability of the intervention as reported by SSK returners (n=62) 
Item Unacceptable  
(-2) 
(-1) Neutral (+1) Acceptable 
(+2) 
Acceptable to be offered an HIV 
test in this manner  
0 
(0%) 
3 
(4.8%) 
7 
(11.3%) 
9 (14.2%) 
43 
(69.4%) 
Acceptable to be offered an HIV 
test because you are African 
(n=61) 
18 
(29.6) 
3 
(4.9%) 
13 
(21.3%) 
3  
(4.9%) 
24 
(39.3%) 
Location where offered the kit 
(n=60) 
0 
(0%) 
0 
(0%) 
4 
(6.7%) 
10 
(16.7%) 
46 
(76.7%) 
 
Very difficult 
(-2) 
(-1) Neutral (+1) Very easy (+2) 
Instructions in the kit easy to 
understand (n=61) 
4 
(6.6%) 
2 
(3.3%) 
5 
(8.2%) 
17 
(27.9%) 
33 
(54.1%) 
Item 
Uncomfortable 
(-2) 
(-1) Neutral (+1) 
Comfortable 
(+2) 
How felt about taking the sample 
themselves (n=61) 
10 
(16.4%) 
4 
(6.6%) 
10 
(16.4%) 
14 
(23.0%) 
23 
(37.7%) 
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7.3 Limitations 
The small sample size limits our ability to make associations and draw conclusions as to who 
did and did not participate and or return their sample. The baseline demographic and 
behavioural data of participants however suggests the the intervention was reaching a black 
African population at risk of living with undiagnosed HIV and four people approached to 
participate disclosed they were already known to be HIV positive.  
Acceptability data in this format is only provided on those who returned their sample and by 
definition, this is the group most likely to have found the intervention acceptable. Further 
qualitative data exploring acceptability with participants who did and did not return their 
sample is provided in Chapter 9. Finally the failure of intervention implementation in 
Glasgow means we were unable to assess whether acceptability or feasibility may vary across 
the UK. We had specifically wanted to test the intervention in two distinct health care 
systems, which differed in the proportion of Africans within their population, and in the 
provision of HIV and community services, in case this impacted on the acceptability and cost 
effectiveness of the interventions.  
 
 
7.4 Summary 
Our findings demonstrate that users of the SSK liked being able to access HIV testing in this 
manner and in the locations provided. The proactive opportunistic offer of the kit was directly 
responsible for the majority of kit users deciding to have an HIV test. Although numbers are 
small there is a suggestion that distribution of HIV SSK in these settings could help increase 
HIV testing in black African communities as 12 (18.5%) of kit returners had never previously 
tested, and a further 12 (18.5%) had tested over 5 years ago. However, recruitment was low 
with only 128 (35.8%) of people approached consenting to participate. While it is reassuring 
that 56 (25%) declined as they had recently tested,  42 (18.7%) did not perceive themselves to 
be at risk and a further 15 (6.7%) did not want to know their HIV status - both potentially 
reflecting the impact of HIV related stigma. A further 39 (17.4%) may have tested if an 
alternative method or location were available. 
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Although acceptability of the intervention is likely higher in those returning a kit over one 
third still reported that it was not acceptable to be offered an HIV test because of their 
ethnicity. It is unclear as to whether these participants were aware that they had been 
explicitly targeted as a black African as the findings from the follow up interviews (see 
section 9.1.4) suggest not all participants had realised this. Only six (2.7%) of those declining 
to participate indicated that targeting was responsible for their decision. 
The kit return rate of 55.5% is in keeping with similar projects (66) and somewhat 
concerningly, so is the proportion of samples received that were unable to be processed due 
to under filling or gross haemolysis. Our finding that 16.9% (11/65) of samples were unable 
to be processed is similar with the 15.4% reported by the national HIV self-sampling service 
among their 1125 black African users to date.(81) This suggests that an alternative to the 
TINY vial is required if HIV SSK are to be an effective means to increase HIV testing in 
black African communities. There is also the potential that a negative experience with a SSK 
may put people off alternative or future HIV tests - therefore choice of SSK and its 
acceptability to participants should not be compromised in future research. 
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Chapter 8: Process evaluation - Intervention fidelity and reach  
The HAUS study aimed to establish whether it was feasible and acceptable to distribute and 
monitor the distribution of HIV SSK to black Africans using GP surgeries and community 
outreach services. This chapter describes findings from key elements of the process 
evaluation, which linked to the feasibility trial allow fuller interpretation of the findings for 
potential further application  
There were three broad areas of interest within the purview of the process evaluation related 
to the implementation of the HAUS intervention: fidelity, reach, and acceptability. This 
chapter addresses fidelity and reach; the acceptability of the intervention for kit users and 
service providers is explored in Chapter 9. 
8.1 Purpose and scope of process evaluation 
8.1.1 Fidelity 
The HAUS intervention was designed to be implemented with highly standardised inputs and 
processes with little or no site-specific tailoring. However, in practice substantial local 
tailoring was observed. Therefore, our approach to evaluating implementation focuses both 
on fidelity of form and fidelity of function. Fidelity of form refers to the extent to which the 
intervention follows the standardised structures and processes developed for Stage 2 of the 
HAUS study, as described in Chapter 6. This process evaluation examines the extent to which 
these standardised intervention components were implemented with fidelity of form. Where 
we observe deviations from fidelity of form we assess whether these were intentional 
adaptations (and if so, what motivated them), unintentional drift or simple omission; and 
whether the adaptation runs with or against the logic of our theory of change (that behaviour 
is an outcome of three necessary conditions - capability, opportunity and motivation). This is 
a substantial issue in HAUS as the intervention was delivered across 12 GP practices and 
three African CBOs throughout London. We also examine fidelity of function, that is the 
extent to which locally decided adaptations to the intervention processes were consistent with 
the overall theory of change.  
8.1.2 Reach 
Reach is the extent to which the target audience come into contact with the intervention. 
Moore et al. (2015) recommend that process evaluations should include quantitative 
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assessments of reach, in terms of, for example, proportions of the target audience who are 
aware of and come into contact with the intervention (76).  
Assessing awareness reach of the HAUS intervention across the whole population of black 
African people in England and Scotland was not appropriate or feasible within the context of 
this study. Unfortunately, we were also unable to accurately determine what proportion of 
eligible persons in contact with the recruiters were actually exposed to the intervention. It 
was intended that the enrolment log would capture this information but in reality these were 
often poorly completed. The data we have shows that 349 people were offered the 
intervention with 125 agreeing to participate. In excess of 37000 black Africans are resident 
in the borough of Lambeth alone .  
8.1.3 Normalisation 
A further component of this process evaluation is to better understand the process by which 
interventions might best become embedded in distributors routine policies and systems of 
service delivery. This is often described in terms of ‘normalisation’ or ‘sustainability.’ 
There are a variety of frameworks which help evaluators assess intervention normalisation 
(e.g. the RE-AIM framework (82, 83). However, the study team chose to use normalisation 
process theory (78). The focus of this theory is to consider how implementers can enable the 
embedding of interventions within institutions and social contexts so that they are ultimately 
integrated (78). The theory suggests that whether this happens depends on the following four 
“generative mechanisms” that those working on implementation engage in individually and 
collectively:  
• coherence (how people make sense of a new practice); 
• cognitive participation (the willingness of people to sign-up and commit to the new 
practice);  
• collective action (their ability to take on the work required of the practice); and 
• reflexive monitoring (activity undertaken to monitor and review the practice).  
8.2 HAUS fidelity and feasibility 
We start by examination of those areas where fidelity to the intended ‘form’ (by this we mean 
the structural and procedural issues) of the intervention either proved difficult or required 
adaptations to the agreed protocol. The second part of this section relates to aspects in which 
fidelity to key aspects of the intervention ‘function’ proved difficult for some distributors 
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and/or participants. Intervention function relates to the central mechanisms that underpin the 
intended study and intervention design. Quotes are taken from the weekly distributors’ 
experience survey, from emails to the Project Manager, and the final distributor interviews. 
8.2.1 Distributors 
Within CBO settings it was intended that community outreach workers would be the 
distributors of the SSKs, and this was what was reported from these distributors. While the 
distributors within GP settings were intended to be Practice Nurses (PNs) during the training 
it became clear that this was not always going to be feasible. A range of GP locations told the 
Project Manager from the outset that other staff members in the surgery would be 
undertaking study recruitment and distribution, including: General Practitioners, Health Care 
Assistants (HCAs) and Practice Managers. In all, eight of the 12 practices used one or more 
of these alternate members of staff as recruiters and distributors for the study.  
Discussions during site visits established that each practice took a different approach to 
managing staff workloads. This sometimes meant that HCAs were regarded by their senior 
colleagues as having more time to devote to research tasks than others, even if that was not 
actually the experience of HCAs. Alternatively, in a number of cases, GPs with a particular 
interest in sexual health took on responsibility for recruitment and distribution themselves. 
Though they were working under time pressures to stay within the typical 10-minute 
appointment schedule, they distributed the SSKs as they had a particular commitment to the 
issue. The following quote is from a GP surgery where two GPs participated as distributors: 
[Interviewer: Why was it you two who did this? 
GP1: Because we volunteered for it! We were the ones who were interested 
GP2: You got the email, didn’t you? 
GP 1: Yeah, and I knew you would be keen 
GP2: Because we are doing a lot of gynae, and sexual health generally. So, it’s an 
area of interest. 
In the main, we can conclude that in the majority of GP surgeries, it was not PNs (or not PNs 
alone) who recruited participants into the study and distributed kits. This action, while 
deviating from study intention, facilitated recruitment by increasing the opportunities in 
which it could be delivered, and as such should be considered a logical adaptation. 
The intervention was designed to work alongside distributors’ existing commitments. 
However it was reported to us by one GP practice that staff members’ days off were used to 
attend HAUS training, and in another instance, a GP came into the surgery on her days off in 
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order to undertake recruitment. Other distributors explained that it took a lot of additional 
time in the day (including overtime and loss of breaks) to fit in study recruitment, kit 
distribution and the associated research tasks. 
8.2.2 Targeting  
Within CBO outreach settings it was intended that community workers would identify black 
African people whom they encountered in their routine outreach activities and locations to 
approach for study participation, and this is what was (in the main) what was reported by 
these distributors. In some cases, they also undertook special outreach events at settings such 
as barbershops, in order to specifically recruit to the study. 
Within GP practices it was intended that eligible individuals would primarily be identified 
from patient lists (using recorded ethnicity and/or country of birth data) at the start of the day, 
prior to the initiation of appointments. That way, a prepared enrolment log could be in front 
of each distributor, ready for when the patient came to them, and they could log the patient’s 
reason for refusal, or their agreement to take part on the enrolment log. This method was also 
intended to eliminate the need for practice staff to try to identify a patient’s ethnicity visually, 
or to ask them their ethnicity prior to offering them the intervention.  
Five GP surgeries informed us that there was usually or always insufficient data available to 
them to identify potential participants’ ethnicity in this way. As a result, practices resorted to 
a variety of alternate means of targeting black Africans. Staff in at least four practices 
described using visual cues (both in the waiting room and in the consultation room) to 
identify potential participants. One practice in particular reported that this meant that many of 
those approached were ultimately found to be ineligible, as the majority were black 
Caribbean rather than black African. Other tactics were additionally used to identify potential 
participants, in particular knowledge of patient backgrounds especially for those recruited in 
primary care. Having a range of practices to assess potential eligibility could cause confusion, 
as indicated by this comment: 
Dr X asked the patient, who was happy to participate. I'm not sure if this particular 
patient fitted into the category though so was a little confused. The patient was born 
in the UK, so I could not remember whether this mattered or not. 
Some practices did effectively use ethnicity data contained within their databases to identify 
some or all those eligible for participation. One practice designed a prompt to remind the 
distributor to introduce the study to come up on the practitioner’s screen when that patient 
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was being seen. Another practice wanted to initiate such a system, but was ultimately unable 
to do so.  
One GP practice used the ethnicity data that they held on patient lists to screen for eligibility 
and then contacted patients to invite them to make an appointment so that the HAUS study 
could be introduced and discussed. This represents a considerable departure from the 
intention that the intervention was to take place alongside existing routine service delivery in 
GP settings when patients presented for other reasons. 
8.2.3 Script to introduce the study 
It was intended that distributors in CBO and GP practice settings would use the agreed script 
to present the study to eligible participants. The script and its importance were underlined at 
all training events, and laminated cards with the script wording were made available in each 
site manual.  
When asked at follow up about the extent to which they had adhered to the script, eight study 
sites said they had not used the script consistently. Most said that they had used either the 
script or the Participant Information Sheet (PIS) to become familiar with what information 
was to be communicated, and then they summarised it in their own words. One distributor 
remarked, “I used my own words, because it’s something I do on a daily basis. I just use my 
words, and the statistics are very important, they don’t lie. As well, I try to find out what part 
of Africa they are from”. Another clarified that s/he did not follow the script work for word, 
preferring to memorise the key facts and stating it in their own way.  
It was felt that reading from a card could undermine confidence in the distributor, and one 
distributor said he was “not a robot” and therefore needed to put things into his own words.  
It was clear that in most cases, the number of approaches made by each distributor in a single 
day or even a single week was too low to expect them to have committed the script to 
memory. Furthermore, at many GP practices, study paperwork (including the site file) may 
not have been in the same room as the distributor, so they needed to raise the issue 
opportunistically and then find the relevant Participant Information Sheet and Consent form 
afterwards. None of the CBO distributors reported adherence to the intervention script, as 
once again, they had found it more comfortable to summarise and put things into their own 
words. Again, this can be regarded as a purposeful deviation from the intended intervention 
design, based on the practicalities of delivering it in busy settings, and the professional 
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expertise of healthcare staff to put things in language most appropriate for a particular patient 
or situation. 
When asked to confirm that they had all introduced the study in a way that made it clear that 
black African people were being targeted for distribution due to higher prevalence in this 
population, all distributors agreed that they had made this clear in their tailored introductions 
to the study. 
8.2.4 Recruitment process 
In the intervention protocol, it was intended that one single distributor took the participant 
through the entire recruitment process themselves, and that this all happened within one 10-
minute time period. Research paperwork (consent form and baseline questionnaire) was to be 
completed within this period, along with kit distribution and answering of any questions. 
In the main, all CBO distributors attempted to adhere to this process and all struggled to keep 
required components to a 10-minute timeframe. On at least one occasion during distribution 
at a barbershop, the barber first introduced the study to potential participants and sent 
interested participants to community workers at the back of the shop 
This practice of ‘funnelling’ potential study participants to other distributors who would then 
take them through the eligibility criteria and the study documentation was also evident in a 
few GP practices. In these cases, a PN or a GP would introduce the study, and then send 
interested individuals on to a designated colleague to complete the process. This was 
regarded as a means of extending reach, while utilising time and expertise efficiently. One 
distributor explained, “It was easy to do in surgery as another member of staff does the 
consent.” 
Another variation, applied in a few practices, was for staff to break the recruiting process 
down into distinct stages, in order to avoid appointments backing up. For example, GPs at 
one surgery introduced the study during the appointment, and then asked interested 
individuals to go out into the waiting room to review and complete the study documentation 
on their own. These patients were then called in between appointments until all questions 
were answered and all documents completed. Again, this represents an opportunistic 
departure from intervention fidelity as an attempt to undertake at least some recruitment in 
this setting. 
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At another practice, an HCA approached patients who looked to be black African and 
introduced the study to them in the waiting room (rather than in private as had been 
intended). Individuals were left with a copy of the PIS and invited to approach the HCA in 
her consultation room if they wanted to take part, and the rest of the process was carried out 
there. Finally, a HCA at a third practice said he tended to introduce the study at the start of 
the consultation, and then based on their response gauged the remaining consultation time. If 
they seemed interested, the distributor tried to make sure he had time to go through all the 
stages of study recruitment by the end of the appointment. He felt that this tactic helped to 
prioritise the patients’ presenting health needs over the needs of the research study, while also 
ensuring that they did not leave the consultation without his having mentioned it. 
Although in CBO settings it was suggested that the instruction video could be shown to 
potential participants as a part of the recruitment process, this option was not often utilised 
due to time pressures, internet connectivity problems and because it was felt it could be “off-
putting” by at least one distributor. 
8.2.5 Study procedures 
It was intended that the introduction and recruitment components of the study, including 
sharing of the PIS, and completion of the consent and baseline questionnaires would take no 
more than 10 minutes. Feedback from almost all distributors indicated that it took 
considerably longer to get through the entire process, which in the particular case of 
oversubscribed GP surgeries caused major feasibility issues.  
The only problem is the time, as no extra time has been allocated for this study while 
some minutes are needed to provide the information to patients as well as when 
patients asked questions to understand more about the study. 
Difficult time wise to fit/ add into a 10 min. GP consultation when all the time has 
already been used up with the patient’s agenda/ symptoms. 
There was a considerable burden of data management and data tracking expected of each 
distributor. A few sites (particularly CBOs) found it difficult at first to keep a log of those 
that they had approached who had refused, partly because of the perception that the study 
team needed an age and other data for each person who had refused, as well as a reason for 
refusal. Once the study team intervened to suggest that estimates and null values were 
acceptable entries in the enrolment logs, tracking of refusals improved.  
Furthermore, it was essential that in all cases an identical kit ID number was attached to the 
paperwork an individual had completed, which matched with the kit ID number on their SSK. 
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In at least one case, the SSK kit ID did not match that on the paperwork received by the study 
team. 
There was a range of dataflow that was essential to the smooth running of the research study, 
including electronic or faxed copies of consent and baseline forms and enrolment logs being 
sent to the Project Manager, and completion of weekly distributor logs to identify and 
respond to emergent challenges. Both sets of data were generally very slow to be returned to 
the study team. This introduced a number of unintended challenges, as the Project Manager 
was frequently not in possession of the consent form or contact details of a participant who 
had, for instance, sent back an insufficient sample, and who therefore needed to be called by 
telephone to be advised of their options (see section 6.1.9). In this way, the participants, the 
Royal Mail and TDL were able to jointly act with far greater efficiency than the distributors 
and the study team in terms of relaying required information through to one another. These 
logjams occasionally meant results could not be clearly communicated to individuals until the 
paperwork had caught up. Occasionally these logjams took a number of weeks to resolve, and 
in a small number of cases the paperwork never materialised, so the individuals had to be 
excluded from the study. All individuals who returned a sample were informed of their 
results regardless of whether they were subsequently included in study. 
8.2.6 Connection to other HIV testing interventions 
The HAUS study was not intended to be delivered alongside (either as a follow-on from or 
pre-cursor to) any other HIV testing interventions being undertaken by the distributing 
agencies. However, it was reported by one CBO that following an event where the SSKs had 
been introduced, a group of interested people accompanied the individual back to the CBO 
office to undertake a POCT HIV test, because they regarded this testing option as more 
acceptable than the SSK on offer in the HAUS study. 
8.2.7 Distributor support to take blood sample  
The study was designed to assess the acceptability and feasibility of the targeting and use of 
HIV SSKs among black African people. However, two distributors (one CBO and one GP 
surgery) described assisting participants with the blood sample collection. In the case of the 
GP surgery, the Practice Manager decided that the kit was so difficult to use, she would 
support every single participant she recruited, and reported that the entire time spent with 
each participant was between 30 and 40 minutes. The following excerpt is from an enrolment 
log: 
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I helped another patient today, and again the whole process took ages to complete. 
This was because the patient’s blood wouldn’t flow from her fingers, we used all the 
lancets in the box plus another 4, in the end the nurse came in to help but the patient’s 
blood seemed to be clotting the minute it started to flow. I’m not sure whether there is 
enough blood in the bottle to test. We really persevered and the patient said that if she 
was at home she would have discarded the whole thing. For me it’s becoming a very 
time consuming exercise. 
Two further GP practices reported that they had requests from participants to support them 
with use of the kit, due to its complexity, but each of these distributors refused, owing to a 
desire to maintain fidelity with the research protocol. 
There was further data emanating from one CBO (and the participants whom they recruited) 
that during one distribution event in a barbershop, at least some participants took their blood 
samples together at the same time, with support from the distributor.  
8.2.8 Location for sample return 
There was one reported instance where a sample was returned to a GP surgery rather than 
being posted by the participant to TDL via Royal Mail. Because the distributor in this 
practice was not working on the day the sample arrived, it was stored in the practice 
refrigerator until a few days later when that staff member returned to work and was informed 
about the sample. The distributor then posted it. 
Further data collected from distributors and participants at the CBO also leads us to infer that 
after this event at the barbershop, it is likely that the distributor posted the samples via Royal 
Mail, rather than the participants doing this themselves. 
8.2.9 Communication with participants after sample return 
There were a number of occasions when participants and distributors reported that a two 
week text reminder to return a sample was sent to people who had already returned their 
sample. This created some concern among participants about the potential for lost samples, 
and made some doubt the veracity of their results.  
Although it was intended that a HA at CNWL would have access to the secure database to 
enable them to directly obtain contact information for those participants with reactive or 
insufficient results, this did not occur as sites predominantly used paper forms so there was 
delay in getting this information onto the database. Instead, the Project Manager notified the 
HAs directly when an insufficient sample had been received at TDL. Occasionally due to 
missing or delayed consent and baseline data forms, there was a delay in access to sufficient 
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information to contact the participant immediately. Furthermore, due to the HAs’ working 
context, there were occasionally further delays between notifying the HA team and 
communication of result to a participant. The protocol does not state a time limit for these 
activities, but in the training distributors were told to inform participants that it could take up 
to 5 days for them to receive a result.  
It was also reported that in at least a few cases, a negative result was received by participants 
via text from TDL within 24-48 hours of a sample being posted, which appears to have 
caused concern among some participants that the result may not be trustworthy as it had 
arrived more quickly than anticipated.  
8.3 Summary 
The planned SSK intervention was not feasible in GP surgeries or during outreach from 
CBOs and progression to a future Phase III evaluation is not supported. While some form of 
the intervention was delivered by almost all distributors, most distributors found it difficult to 
recruit to and almost all found it too time consuming to deliver in the context of a busy GP 
surgery or during community outreach. The research process attached to the intervention was 
the principal driver of this barrier.  
Totally fidelity in relation to the proposed intervention structures was not the norm as local 
adaptations were common in most of the GP surgeries and all of the CBOs. While these 
adaptions were not always agreed in advance almost all might be considered reasonable 
tailoring of the intervention to the specific local context in which it was being delivered.  
Most local adaptions maintained the fidelity of form for the intervention, in that they followed 
the standardised structures and processes developed for Stage 2 of the HAUS study. 
Examples include broadening the range of staff recruiting to the intervention within a GP 
surgery or breaking up the offer and sign-up of patients into smaller blocks of time to better 
suit the workflow of GP staff. The exception of this was the routine distributor support 
offered at two sites.  This  fundamentaly changed the structure of the interventio  from one of 
routine offer and self-completion of SSK to a fully assisted intervention. Almost all the 
deviations from the proscribed fidelity of form for the intervention were intentional, and were 
motivated by a desire to speed up the process of recruitment or offer the intervention to a 
larger proportion of patients. 
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Chapter 9: Acceptability of Haus Intervention  
This chapter seeks to address the objective for Stage 2 of establishing the acceptability of the 
intervention to black Africans and service providers. The chapter is divided into two sets of 
findings; acceptability of the intervention to participants, followed by acceptability of the 
entire study process and the intervention among distributors. For each we discuss findings 
related to those aspects of the intervention which compromised acceptability, followed by 
aspects which promoted acceptability. In quotes from study participants, the age, sex, and 
HIV test outcome are stated in the square brackets. A range of data sources were used in this 
analysis, including interviews with a sample of study participants and with staff from all 
distributing organisations, study team diaries and site visit notes, emails exchanged with 
distributors, and weekly distributor experience surveys. 
9.1 Acceptability to black African community 
9.1.1  Descriptive results 
The total number of study participants interviewed was 21, median age was 40 (range of 18 
to 67); 12 were women. Of the 21, nine had received negative results, four sent samples that 
were unable to be processed (due to the samples being under-filled), and eight had not 
returned their sample. Seventeen interviewees were recruited at GP surgeries and four at 
CBOs. Approximately half of the interviewees (n=9) had previously had an HIV test. 
However, the majority were unaware that SSKs existed prior to participation in the study. 
Some interviewees had a notion that a kit could be ordered online, but did not have a more 
specific knowledge of either SSKs or self-testing kits before enrolment.  
9.1.2 Barriers to acceptability of SSKs 
There were five interrelated themes which emerged as barriers to the acceptability of the 
SSKs. The first three all pertained specifically to the kit used (fear of needles, insufficient 
blood flow, and issues with the vial). The latter two meant several interviewees submitted an 
under-filled sample, resulting in their being contacted by HAs who explained their sample 
could not be processed and described future testing options (see section 6.1.9 above). Those 
who experienced this problem reported several concerns which impact the acceptability of the 
intervention. Finally, interviewees identified stigma, fear, and taboo surrounding HIV and 
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HIV testing as a barrier not only to SSKs but to all methods of HIV testing. Each of these 
themes are discussed in greater detail below.  
9.1.3 Fear of needles 
Of the interviewees who had not returned their sample, fear of needles and pricking one’s 
own finger were commonly-mentioned obstacles to using the SSK. One interviewee 
recounted that she opened her SSK when she returned from her GP appointment and could 
not bring herself to prick her own finger. She explained, “I opened it, but I can’t do it by 
myself. I can’t use the needle to pinch myself. I can’t do it” [45-year-old female, non-
returner]. She subsequently returned to her GP surgery for a health check, and requested 
assistance from two nurses in drawing blood for the SSK. They apparently stated that they 
could not help, so the interviewee brought the SSK back home and did not try to use it. 
Another interviewee shared,  
The reason why I didn’t [use the SSK] is because even though the Doctor explained 
that it was really simple, I’m scared of needles, so I was actually waiting for someone 
to be with me to do it, in case, like, I started freaking out. [...] I’d prefer, like, a friend 
to do it, rather than me, ‘cause if I see a needle I’ll, like, freak out. Even though it was 
explained that it’s really easy. But I don’t know what’s easy in [GP’s] terms. Like, for 
me, it’s not easy at all to, like, prick myself [23-year-old female, non-returner]. 
When asked whether they would consider using a SSK in the future, a number of participants 
replied that they would not consider future use due to a lack of comfort pricking one’s own 
finger and seeing one’s own blood. However, not all interviewees were squeamish about the 
lancets, and many found the lancets acceptable.  
9.1.4 Insufficient blood flow  
The interviews were replete in accounts describing the difficulties faced in maintaining 
sufficient blood flow to fill the vial. One woman who had consecutively submitted two 
insufficient samples expressed dissatisfaction and frustration with the process of drawing 
blood. She recounted,  
The first time when I used it I thought the blood was enough and then […] I posted it 
and they called that the blood wasn’t enough and then I got another [SSK] and then 
they said still the blood wasn’t enough, so I just couldn’t be bothered [26-year-old 
woman, insufficient sample]. 
This interviewee recalled that it had taken approximately a half an hour each time she took 
the sample. She described being offered alternative HIV testing via a sexual health clinic near 
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her home during a phone call from a HA, but was discouraged due to her negative 
experiences using the SSKs. She shared,  
They explained I can go and get a HIV test in [an area in London] or in where I live 
but I said, I say I can’t be bothered. They wanted to give me another home test but I 
say no, ‘cause two times, shew. 
One interviewee, a 52-year-old female, attributed issues in getting blood to flow to a pre-
existing nerve problem. Her sample was under-filled, even though she used all of the lancets 
and “tried everything” to get the blood to flow, including milking her finger.  
9.1.5 Issues with TINY vial 
Frustration was also expressed regarding difficulty in getting blood to drop into the vial 
provided in the SSK. Lack of clarity over the best angle to hold the finger to facilitate the 
flow of blood into the vial was voiced, along with feedback that the vial was too narrow to 
allow the blood droplets to collect at the bottom. A few interviewees reported that the process 
was quite messy due to these issues.  
This is where the flaws come into it. You know like you use the lancet, and then you 
try to get the droplets of blood to go in at a certain angle […] it’s very hard to get the 
blood to drop freely as well, and it doesn’t collect enough. [39-year-old woman, 
insufficient sample] 
Another interviewee recounted,  
It took me a while to get the rhythm of it. I mean basically the first finger was a dud. I 
completely mucked it up. Blood was everywhere and I think it was partly the nerves. 
[…] I couldn’t get it into [the vial]. […] So I basically abandoned that finger and 
moved onto the second one and that one was much better. Yes.  
[Interviewer: Why do you think it went better?] 
I don’t know. Because I had a second go at it and probably made mistakes the first 
time around I would have been more aware the second time round. Like I didn’t 
handle my finger right in terms of how it was sort of placed above the little one tube. 
So when I changed the angle the blood was more prone to coming out in droplets that 
way than the other way. The other way was sort of messy […] With the little bottle 
thing, the blood had a tendency not to go all the way down. It would sort of float at 
the top. [25-year-old man, negative].  
The issues of inadequate blood flow and difficulty in collecting blood droplets into a narrow 
vial were echoed in the following account:  
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The most difficult part was trying to get the blood out of my finger and I managed to 
put blood all over the table, and my mom came in and she thought that I was not 
doing it properly, so she helped me to do it, and I think that was just the most difficult 
part getting the blood to come out my finger and put it into that little tube [18-year-
old woman, negative].  
When asked whether they would be willing to consider using an SSK in the future, the vial 
was frequently cited as a factor that discouraged participants from future use. It was viewed 
as ‘tricky’ to use and a few interviewees specifically recommended providing a wider vial to 
improve the ease of blood droplet collection. 
Despite such comments, not all interviewees reported problems in filling the vial. For 
instance, a 67-year-old man reported that his blood flowed very easily. In fact, he reported 
that taking his sample had been a very positive experience: “It was so easy. It’s stress free. I 
really enjoyed it.” Similarly, an 18-year-old female reported that she had trouble stopping her 
finger from bleeding, even after she had filled the vial. A 49-year-old female whose first 
sample was indeterminate, and second was negative, recounted that the second time drawing 
blood had been much easier than the first.  
Many interviewees, especially those who did not return their sample or returned an 
insufficient sample, felt that issues regarding needle squeamishness, blood flow, and 
collection in the vial could be overcome by having GPs and other health staff assist 
participants in taking their blood samples. One young female interviewee stated,  
If they had been offered to me in the Doctor’s and then he, sort of, helped me do it, I 
think it would’ve been a lot easier. But I think sometimes, when you take things away 
it’s, sort of, kind of, like, it’s a lot harder to get round to doing it, if that makes sense, 
and then there’s the whole hassle of having to send it off. That, sort of, factors in and 
it’s just… it might not be the best way to get, like, someone like me to do something 
[23-year-old woman, non-returner]. 
Another participant, who did not return her kit, was uncomfortable drawing her own blood, 
and similarly would have preferred a health care professional to take the blood for her. She 
shared,  
It would be good if you invite the person in the hospital or somewhere and then do it 
for them, because if you give it to me like this I can’t use the needle to pinch my 
finger. It’s very hard for me to do it. […] If someone is doing it for me I would do it, 
but doing it for myself I can’t. […] It would be better if they can do it in the surgery 
or hospital. They invite you. You know, when you go and they can take your blood and 
then do it. That would be better if it was possible for that [45-year-old woman, non-
returner]. 
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This was echoed in a suggestion offered by a 52-year-old female who returned an insufficient 
sample. She thought that the aspect of the patient posting the kit could be retained, but that 
the sample collection could be assisted by a health care professional for those who had 
difficulty maintaining blood flow. Another interviewee, whose sample was indeterminate, 
suggested that providing a walk-in option where people could go to receive assistance using 
the SSK would be beneficial. She stated, “perhaps have a place within each locality where 
one could just walk in and do the test and have someone to assist them with the test as well. 
That could be another alternative as well” [39-year-old woman, insufficient sample].  
9.1.6 Issues with follow-up for insufficient samples 
Several of the interviewees whose samples were unable to be processed due to being under-
filled were critical of the way in which they received their result, and the options offered for 
further testing. One such interviewee was distributed two kits consecutively. The first one 
was never received by the laboratory. After receiving a reminder text from the study team to 
send in her sample, she returned to her GP surgery to obtain a second kit and presumed that 
the first one had been lost in the post. The second sample was insufficient as it was under-
filled. She recalls being contacted by a HA:  
Someone called me from the study. Said there wasn’t a sufficient sample, and then I 
did a sample, I did the test twice. One, the study never received it, then the second one 
they didn’t get in time or something like that, and then they didn’t send me another kit 
or anything like that again. And I just thought okay, well, can I come in to do a face to 
face or, if need be, can I not just come in face to face and get it done as well, and that 
wasn’t offered. […] I think going forward what would be useful would be to have the 
option of coming into a centre, not necessarily…like any of the hospitals, whichever 
was in that locality, or even up to the GP to obtain a sample [39-year-old woman, 
insufficient sample]. 
As the HAs were instructed to offer another SSK to anyone producing an insufficient sample 
it would appear to conflict with the interviewee’s statement that an offer to send another kit 
was not made. Notably, she attributes the problem with the second kit to the study team not 
receiving the kit in time, which was not the case – the problem was that the vial was under-
filled. She also stated that she was not offered a face-to-face test, although according to the 
records kept by the study team she was advised by the HA to discuss alternative testing 
options with her GP upon her next visit. These anomalies demonstrate the gap between the 
process outlined in the study protocol for handling indeterminate samples and the process as 
perceived by the study participant.  
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This interviewee also referenced the delay she experienced between sending in the sample 
and hearing the result:  
[Results notification] takes five days and no one knows what’s happening in between 
that five days before they call you, and then they’ll call you to say…I mean, I had two 
calls where I was told that they hadn’t received and I sent a text back and nobody 
actually replied back to that actual text, but you phoned back and said actually I did 
send it. […] So I think maybe a better communication will be better as well. Also five 
days, depending on some people […], they would feel more anxious. I wasn’t, but 
some people might have been. So, to alleviate that kind of anxiety, […] if there’s 
another number for people to call. Because I got a call from somebody and they left a 
mobile number and, again, it wasn’t clear enough. Sometimes, it’s very hard to say 
what you want to say in a more succinct way. So, maybe better communication in 
terms of who calls and when they call, etc., and if there’s a standalone number that 
someone can leave a message and say call me back. Sorry, not a standalone number, 
but an actual mobile that’s actually manned as opposed to just you leave a message 
and then whoever will come back to you at a time that’s even more inconvenient 
because it’s convenient for them [39-year-old woman, insufficient sample].  
Contained in this passage are several learning points for future interventions featuring SSKs 
and/or text messaging to participants. The respondent points out that no one responded to her 
text, which is accurate; the study protocol did not plan for study staff to respond to text 
messages received from participants who were sent reminder text messages by the study 
team. As this participant may have been comforted by receiving a text message back from the 
study team, future interventions may be improved by adding this capability into the process. 
Moreover, she suggested that an improved communication pathway with the HA is needed, 
as there was a lot of back-and-forth and leaving of messages by herself and the HA in this 
particular scenario.  
Despite these experiences, other interviewees with insufficient samples found the follow-up 
process unproblematic. No participants had a reactive sample so pathways for linkage to 
confirmatory testing remained untested.  
9.1.7 Stigma, taboo, and fear regarding HIV and HIV testing  
Many interviewees cited stigma, taboo, and/or fear around HIV testing in general as a barrier 
to acceptability of the SSK. Several felt that others would rather remain ignorant of their HIV 
status than be tested (via a SSK or otherwise) and potentially face the stigma associated with 
an HIV positive status, even when they recognised their behaviours may have put them at 
risk. One interviewee stated that some African people would never willingly be tested, based 
on a belief that HIV only becomes problematic once it is diagnosed.  
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9.1.8 Facilitators to acceptability of SSKs 
The convenience of the SSK emerged as a very salient theme in the data. The comprehensive 
kit was thought to have many positive features, including the lancets (perceived by many 
interviewees as non-threatening) and clear instructions - features which were frequently cited 
as making the SSK acceptable to use. Additionally, participant trust in the SSK distributor 
facilitated SSK acceptance. Each of these facilitators is discussed in the sections below.  
9.1.9 Convenience 
Comments on the convenience of the SSK were widespread, and centred on related themes 
regarding ease of use, speed and the delivery mechanism of results, flexibility on when and 
where to use the kit, and privacy afforded by the kit. An 18-year-old female whose test was 
negative remarked on the convenience of not having to provide a blood sample at a medical 
facility, supervised by staff: “I would not need to come back another time to come and redo 
the test, and I could do it in the comfort of my own home, without anyone pestering me, or 
having to watch me do the test.” The privacy afforded by the test was recognised even by an 
interviewee who did not return her test, who stated “It’s not like you going to a centre, 
standing there they take your blood, other people are watching; so you do it yourself. And 
then you post it” [41-year-old female, non-returner]. 
Though some potential participants voiced preference for point-of-care testing due to 
immediacy of results, those who used the SSKs recognised that the SSK process delivered 
results quicker than some sexual health clinics.  
Sometime before, two years ago, when I did it they just told me that they wanted to try 
using a pack to do a HIV test and I said I’m interested and they asked me to go to 
King’s College for the blood and they send the result to them and the nurse phoned 
me and said that I was negative. It took almost a week to get the result. This one it 
does not take, it’s almost within 24 hours I got my result. [Interviewer: And you 
didn’t have to travel to the hospital or anything like that?] 
Exactly. I would have to take a bus to the hospital. [66-year-old male, negative] 
Several interviewees appreciated that using a SSK negated the need to schedule time 
specifically for an HIV test at a clinic. Coupled with the speed of the result, the lack of need 
to travel to give the blood sample was cited as an attractive feature of the SSK. Related to this 
is the convenience of posting the sample once complete, though a minority of interviewees 
voiced concerns over the sample going missing in the post or felt that posting a sample was a 
‘hassle.’ One shared, “I worried, because I did not know if it was going to get delivered to the 
right place” [18-year-old female, negative]. In at least one case, a participant erroneously 
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received a text message prompting her to return their kit when she had already returned it, 
causing the participant to wonder whether the kit had arrived at its intended destination. She 
later received a phone call from a HA as her sample was insufficient, which relieved her 
anxiety over whether the SSK had gone missing. She received and used another SSK, and 
was more confident about it not going missing in the post the second time as it had arrived 
the first time.  
Convenience of receiving the result via text message was frequently linked to the speediness 
of this result notification method. The majority of those who received negative results via text 
message were comfortable with this method. In fact, some specifically stated that they were 
more comfortable with a text message than with a phone call, as the latter method would have 
made them feel more nervous. When prompted to elaborate why he felt this way, an 
interviewee explained,  
I probably would have felt more awkward if it was like a phone call. I probably 
would’ve gotten more nervous with a phone call. […] Because you try to read into it. 
You try and read into the person’s tone and how they sound over the phone. And you 
try to like guess what it is before they say it [25-year-old male, negative]. 
Some interviewees specifically commented that the content of the text message was clear, 
and due to its format as a text message could easily be sent to others if desired. For instance, 
one interviewee recounted:  
I did not expect [the test result] so soon. […] I was happy because it was negative. So 
I was very happy. It was very straightforward and I sent it to my girlfriend […] so 
that she would know that I am free [64-year-old male, negative].  
However, one respondent felt that the message reporting the negative result could be 
misconstrued or misunderstood by some, as ‘negative’ may be interpreted as meaning ‘bad 
news’ rather than the absence of HIV antibodies.  
Interviewees received a texted reminder if more than two weeks passed between obtaining an 
SSK and reception of the SSK at TDL. This appeared to be an effective method to remind 
participants to use and post their SSKs. One interviewee recounts how the texted reminder 
prompted him to use the SSK:  
I was reminded because you know I got the kit – I put it somewhere where I can 
usually see it. But I received a text message to remind me of it. […] So that was when 
– it is like oh, I have been reminded now I think I have to do it [50-year-old male, 
negative].  
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The majority of interviewees, including those who submitted insufficient samples, stated that 
they were willing to use a SSK in the future, based on the convenient nature of the kits.  
I’d be willing to use something similar to this, yeah. Definitely. […] Because I just 
think the privacy is definitely like a win-win situation. I would prefer to not have to go 
somewhere I think. Yeah, I'd rather just do it in my own environment. If you do it 
where you're comfortable as well, if you need the support of someone else close to 
you, you can do it with them. It's just, yeah, I think it's a really good idea [18-year-old 
female, negative]. 
One interviewee felt that the SSKs could be made even more convenient by storing them 
behind the counter at GP surgeries, and have them available upon request to anyone who 
wanted one without having to book an appointment with health staff.  
9.1.10 Non-threatening lancet  
Though some interviewees (especially those who did not return their samples) were fearful of 
pricking their own fingers to draw the blood sample, many other interviewees found the 
supplied lancets acceptable and less ‘scary’ than other types of needles used to draw blood. 
One 25-year-old male liked the lancets because the sharp needle was not visible (it only 
emerged when the device was pressed against the finger, and then it retracted). Another man 
favourably compared the SSK lancets to needles used at hospitals to draw blood, and reported 
that having blood drawn by the latter method was “very painful” and “caused anxiety” for 
him. He viewed the lancets, in contrast, as “very easy and simple.” He recounts,  
I pressed [the lancet against the finger] and there was blood coming out. It was very 
easy and very simple. Simple, easy, anxiety free, painless. I’m okay. I did enjoy it. If I 
had to do it every week I would do it [66-year-old male, negative]. 
Similarly, a male 26-year-old explained that he was motivated to use the SSK as it seemed a 
“less inconvenient and less painful” HIV testing option compared to other testing methods. 
The lancets were also deemed acceptable by a 39-year-old woman, who recounted her first 
impression of the lancets in the following: “Then I looked at the lancet, and it wasn’t 
something that I was like oh it’s going to hurt me or anything like that, and I just did it.”  
9.1.11 Clear instructions 
Several interviewees opined that the instructions, both the paper version included with the 
SSK and the online version, assisted them in using the SSK. One young woman felt that the 
process seemed very complicated initially, until she referred to the instructions. She 
recounted her impression when she first opened her SSK at home:  
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Well, it looked very complicated because there was so many things inside the kit. But 
once I laid it out into where it is meant to go and read the instructions, it was actually 
a lot less than I expected, because most of it was just packaging and some of it I did 
not even have to use. It was just extras [18-year-old female, negative]. 
General comments about the video were positive, with one interviewee speculating that it 
would particularly appeal to young SSK users. One interviewee shared the following positive 
opinion: “I liked the video – you had the video which helped to go through the instructions a 
lot easier” [18-year-old female, negative]. 
A minority felt that the written instructions were too complicated, and could have been 
simplified or made less ‘wordy.’ The small text of the instructions was also referenced as a 
potential area of improvement.  
9.1.12 Trust in distributor 
A small number of interviewees mentioned that a high level of trust and regard for the 
distributor who offered the test motivated them to accept a SSK. Examples of this were 
evident in recruitment from both CBOs and primary care. One interviewee who was offered 
the SSK via a CBO at a barbershop and was encouraged by his trusted barber to take the test. 
Similarly, a GP-surgery recruited participant referenced his high level of comfort and rapport 
with the HCA as motivating him to enrol into the study. One interviewee, a 50-year-old male, 
suggested that having black African distributors who had personally used an SSK may 
increase trust in distributors and thereby increase acceptability of the kits and HIV testing 
more generally.  
9.1.13 Awareness-raising of HIV testing and treatment 
Increasing awareness of HIV testing and treatment options arose as a major theme when 
interviewees were prompted to suggest other or better ways to encourage black African 
people to be tested for HIV more regularly. One woman provided several suggestions on how 
to increase awareness:  
Well, there’s like family planning clinics, church groups, invite people from various 
communities, from the Black community, talk a bit more, put it into music, into sports, 
into drama, just get it out there and just try and…just try and talk to people in the 
community where you can do. You can do it with like a part of a general health thing, 
like if they’re doing a health focus on diabetes and other blood borne viruses and 
other things, pneumonia, keeping well, health awareness sort of programme. Why not 
attach this along with it? [39-year-old female, insufficient].  
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A 36-year-old male suggested that the SSKs and/or point-of-care testing could be offered out 
of health vans, or at events organised by African organisations.  
Another interviewee argued that increasing awareness could ‘normalise’ discussions about 
HIV, to decrease fear and stigma and thereby facilitate HIV testing efforts, including SSKs.  
9.1.14 Acceptability of targeting to African people in London  
Over half of the participants interviewed indicated that they did not mind that the intervention 
targeted black African people specifically. One interviewee commented that the way she was 
offered the kit was non-discriminatory, even though it was made clear that the intervention 
was targeting only black Africans. Another interviewee mentioned that he liked the way his 
doctor approached him about the SSK, mentioning that his doctor ‘invited’ him to take part 
and he felt privileged to be given a kit. Several interviewees thought that the intervention was 
a good idea and should be expanded to be offered to other ethnic groups, even if they were 
not offended that it was limited to black Africans. One pointed out that sexual relationships 
are not necessarily formed within ethnic boundaries, so the intervention should similarly not 
be limited according to ethnicity. She stated, “It becomes an African thing, like you know this 
test, there is intermarriages of different nationalities. […] What about those who are married 
with the Africans, or those Africans who are married with the whites?” [45-year-old female, 
insufficient sample]. Only one interviewee, a 26-year-old male whose sample was negative, 
felt offended that he had been offered the test due to his ethnicity. He stated that the targeting 
of black Africans was “quite racist,” and surely the SSK could have been beneficial for other 
groups as well.  
Though the majority of the interviewees were not personally offended by the targeted aspect 
of the intervention, some participants speculated that the targeting of black Africans may 
offend other African people. For instance, a 50-year-old male speculated that some would 
react to the offer of a SSK by thinking,  
Oh, why Africans, why not other people? […] They may get the message wrongly thinking oh it is just 
for Africans, why not for Americans, why not for other people from other races. […] Some people 
might feel offended. Oh, why Africans, oh, they have come again, why Africans. No. You see such 
people might need some maybe literature to read [50-year-old man, negative] 
He suggested that informing black Africans of the reasoning behind the targeting would help 
in acceptance of the SSKs. He recommended, “Such people need to be informed, need to be 
lectured so that they understand why it is being carried out, otherwise they will get the 
message wrong.” 
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A minority of interviewees stated that they were unaware that the intervention was targeted at 
all. This may reflect the nervousness expressed by some sites to make clear that the 
intervention was targeted exclusively at black Africans, or simply misunderstandings 
amongst the interviewees about the targeted nature of the intervention. One interviewee 
described the interaction with a practice nurse when he was offered the kit which appears to 
support the former:  
Interviewer: How did you feel about being offered the HIV test because you were 
African? 
I didn’t think about that. Because it was on the sign up form so it was generic and for 
everybody. It never crossed my mind that it was because I was African or anything. 
You know?  
Interviewer: Right. So no one specifically said that this was a program that had 
been set up for the African community? 
No [25-year-old man, negative]. 
In cases where interviewees were apparently unaware about the targeted nature of the 
intervention, the project manager contacted the sites from where the interviewee was 
recruited to inquire whether the distributors were fully informing potential participants of the 
targeting aspect of the study. In all of these instances, the distributor reported that they were 
indeed informing all potential participants that the SSKs were being offered only to black 
Africans.  
9.2 Acceptability to service providers 
Thirteen GP surgeries and three CBOs in London judged the HAUS SSK intervention as 
likely to be acceptable to their staff and clients when they volunteered for the study and all 
but one GP surgery maintained this judgement through the process of training prior to 
implementation. That London surgery withdrew from the study during training when 
substantial opposition was voiced by a range of staff, both on the grounds of insufficient time 
and as a consequence of concerns about targeting black Africans.  
9.2.1 Acceptability and utility of training 
All distributing organisations undertook mandatory training prior to the initiation of 
fieldwork. In total 18 training sessions were delivered across London. These were delivered 
in the premises of 12 GP practices and three community–based organisations (CBOs) that 
participated, with the CBOs receiving two training sessions each. Some distributors asked for 
and received follow up sessions, either to review key elements, or to catch up staff that were 
unable to attend the first training. 
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In total 70 people attended the training sessions following which 47 (67%) people voluntarily 
completed and returned an evaluation form anonymously. The participants identified their job 
roles as follows: professional health worker including GPs, GP practice nurses, pharmacists, 
health care assistants (n=33); peer support worker (n=4), community based organisation 
service manager (n=8), and other (n=2).  
Training sessions typically lasted around 2 hours, and participants were asked to complete an 
evaluation form at the outset and following the training. These brief evaluations were 
primarily intended to be used iteratively to improve subsequent training sessions, but they 
also help assess the overall value that the training makes to intervention delivery.  
Participants were asked to rate components of the training on a scale of 1 to 5, where 1 was 
“no benefit” and 5 was “great benefit” (see Table 12). Each of these components  received an 
average score of between 4 or 5, with the two highest rated items being the overview of self-
sampling kits and study paperwork, as well as the clarification of study inclusion criteria. 
Some feedback demonstrated that a few participants were less confident about the benefit of 
the training to help them describe and model use of the kit, and to explain to participants how 
their sample results will be delivered, but these views were very much in the minority. 
 
Table 12: Training evaluation components rated 1= no benefit to 5=great benefit 
Component of Training Average score 
Clarification of inclusion criteria 4.6 
Overview of self-sampling kits and study paperwork 4.5 
Overview of the intervention 4.45 
Explaining how results will be delivered 4.44 
Alleviating concern and motivating potential participants 4.42 
How to target individuals and gain consent 4.36 
How to describe and model use of kit 4.29 
Building confidence in potential participants 4.1 
The vast majority (96%) agreed that the range of topics covered within the training was good. 
When asked, “Did you get what you were looking for from the training event?” One third 
(n=16) said they had “completely” got what they wanted, with half (n=23) saying that they 
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had “mostly” got what they wanted. Four were ambivalent in their responses with 
“somewhat”. All those who responded to “The training has increased my understanding of 
the HAUS study and what is expected of me as a distributor” agreed with this statement 
(n=45, 2 missing). Similarly the majority (87%) reported that any questions or concerns they 
had at the start had been answered, with the remaining 6 people neither agreeing or 
disagreeing. 
Each individual was asked to summarise what they understood the HAUS study to be about 
and their role within it both at the start and at the completion of training. Following the 
training all participants gained a stronger understanding of the study aims and objectives, and 
clarity about their roles and responsibilities also became more pronounced. A range of other 
responses further reflected on the excitement participants felt at having a new way to 
encourage HIV testing, and a comment that this could be a helpful route to ensure ongoing 
support for African people with diagnosed HIV.  
The clear shift in participants’ responses indicates that participation helped to increase 
knowledge about the study and their roles as recruiters. Indeed several GP distributors at the 
subsequent exit interviews (see 9.2.2) indicated that prior to the training they were unaware 
of the epidemiology relating to HIV in the UK in general and to HIV and black African 
communities in particular. 
9.2.2 Acceptability of HAUS intervention to primary care staff 
Broadly speaking, the acceptability of the intervention to staff at GP surgeries remained 
relatively high even after, in many cases, a relatively unsuccessful period of intervention 
implementation.  
The only universal impediment to the acceptability of this intervention in primary care was 
the time it took to recruit to the study. In the context of 10-minute consultations the research 
requirements of the study were the major impediment. Moreover, some felt there was 
insufficient time to describe and execute the SSK intervention without causing a backlog of 
other patients. All the GP surgeries struggled to find sufficient time to implement the 
intervention routinely and most offered the intervention to far less patients than they had 
hoped due to pressure of time. Problems with the time it took to deliver the research 
requirements were exacerbated by concerns about the kit itself among some distributors, 
especially among those surgeries that allowed the patient to take the sample on site. However, 
there did remain a degree of enthusiasm about the potential use of SSKs in GP settings as 
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‘add-ons’ for patients, especially where phlebotomy was based off site or POCT was not 
perceived as feasible. In our closing interviews, a number of GP based distributors talked 
about the way that an SSK could benefit some of the people they see, and in the main it 
tended to be the research process that prevented timely distribution. There was even more 
support for SSKs that used an oral sample, or a blood based sample provided it would be 
simpler to use than the TINY vial (for African people and for all potential users).  
The other key issue in the perceived acceptability of the intervention was targeting. The 
majority of recruiting staff found the concept of targeting black Africans acceptable at least 
during training and relatively few reported adverse reactions from patients once the 
intervention was implemented, though some patients required an explanation as to why they 
were being targeted. One distributor noted, “The black community are more receptive and 
recognise [HIV] is an issue. Don’t take it personally, not a slight.” 
Some surgery staff found the process of targeting difficult, usually because it was not feasible 
to establish the ethnicity of patients from the patient database as this were often incomplete, 
contained erroneous data, or because they did not have the time to check through patient 
notes. In the absence of pre-existing data, clinics adopted a range of strategies to identify 
potentially eligible patients that often varied between staff even in the same clinic. In some 
settings, there was discomfort with the concept of targeting based on visible race because this 
often led to a discussion about the intervention with patients who were not ultimately eligible. 
This was especially pertinent in areas where the majority of black patients were of Caribbean 
rather than African origin.  
In up to half of clinics some (but often not all) distributors felt some unease with targeting 
black African patients. The concept of targeting black Africans raised concerns about 
exacerbating both HIV-related stigma and xenophobia. In three clinics, the proposed 
targeting based on ethnicity was accepted during HAUS study training but rejected once the 
distribution period began, resulting in little or no recruitment occurring at these sites. In all 
these sites most recruiters seemed uncomfortable with the concept of targeting black Africans 
largely for fear of causing offence.  
In one clinic, after training staff decided that discussing the study openly with patients or 
even asking patients whether they were black African could be considered offensive and give 
rise to accusations of racism. In other surgeries, there was some mild concern that targeting 
migrants and visible ethnic minorities might exacerbate racism and xenophobia. One 
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distributor noted, “I am always a bit cautious about offering based on ethnicity because of 
what has been happening, in our country, and people feeling a bit uneasy about the colour of 
their skin and where they are from.” 
9.2.3 Acceptability of HAUS intervention to staff of CBOs 
The acceptability of the intervention to staff at CBOs remained high throughout the study, in 
spite of substantial recruitment difficulties. CBOs maintained that SSKs were a useful 
additional intervention for their menu of services when targeting black Africans. They also 
felt that the SSKs were considered convenient by their clients, though HIV stigma clearly 
presented a barrier to some enrolment. Broadly speaking, SSKs remained acceptable to CBO 
staff in spite of evidence that SSKs were not necessarily a feasible add-on intervention to the 
outreach activities that formed a large part of their existing funded work. For all CBOs, pre-
existing commitments to funded interventions meant they had limited capacity to recruit to 
HAUS. Among CBO staff, perceived acceptability among black African people was variable 
with concerns about HIV stigma, the time required to complete research processes and 
process of using the kit itself.  
While the staff and volunteers at one of the CBOs struggled to implement the intervention 
they reported it “felt good” to be able to offer SSKs as an option for their clients. Further, 
they reported that participation in HAUS increased morale among staff, partly because “they 
had something concrete to give out to people” but also because it allowed them to have a 
dialogue with clients about HIV testing. Staff at this CBO had hoped to integrate the SSK 
offer into the standard outreach work they are funded to provide to black Africans, but this 
proved difficult because the HAUS process was too time consuming. They reported trialling 
the intervention at three “events” at barbershops in Lambeth, but that there was some 
resistance to their activities in these settings with a high volume of refusals, which they 
assumed was a consequence of a lack of privacy in these settings.  
Staff from another CBO had a little more success with recruitment but still found it difficult 
to implement the intervention. In spite of difficulties, the intervention remained acceptable to 
the organisation and its staff and they reported less acceptability concerns for their clients 
compared to staff from the first CBO described above. They were comfortable targeting 
Africans (they too were black African) and were comfortable with the element of providing 
information required alongside the intervention, though this could be time-consuming. Staff 
at both CBOs felt participating in HAUS was a good experience as it filled gaps in their 
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existing range of services. For instance, even though they had a mobile testing unit, HAUS 
allowed them to distribute kits where the mobile unit could not go.  
Staff at the third CBO expressed considerable enthusiasm about the HAUS study during 
initial contact and training. Like staff at the other participating CBOs, they felt the HAUS 
SSKs would give them an important new tool to engage with service users, and would help to 
supplement their office-based POCT HIV testing service. Distributors felt that their service 
users had benefitted from the intervention, although not many kits were distributed, they felt 
that awareness of testing had increased due to the discussions prompted by the SSK offer.  
All CBOs reported that they approached many eligible people who refused to participate. 
CBOs reported two key barriers to participation which might be considered evidence that the 
intervention was not acceptable to the intended target audience. The primary acceptability 
problems identified by the CBOs were very similar to the GP surgeries, with the added 
complication that the CBOs’ recruitment tended to focus their recruitment efforts on outreach 
interventions rather than selecting among their existing clients.  
While CBOs had no initial qualms about targeting only black African people, they 
subsequently reported that some people approached were hostile about being targeted and 
even aggressive. African men were reported as especially challenging to engage. Given all 
three CBOs have experience of recruiting Africans to other HIV prevention interventions all 
expressed surprise that there was still so much stigma associated with HIV among the wider 
community of African people in London. They felt disappointment that the intervention was 
limited to black Africans, as it disqualified other black groups from participation. This issue 
was a bit off-putting to some black people approached, as they would indicate interest in the 
SSK only to be turned away due to black Caribbean status. This issue became especially 
problematic when the SSK was offered to a group of people, some of whom were eligible for 
participation and some not. One CBO also reflected that the usual users of their office-based 
HIV testing service were highly self-selecting, in that they were already primed to consider 
HIV testing, which was not the case in the wider community. The extent of disengagement 
from HIV, framed in hostile or suspicious responses was described as being difficult to bear 
during kit distribution. Some staff felt that ignorance of HIV (including beliefs that HIV was 
a conspiracy, or could be cured with prayer), were a barrier to using a SSK but this is likely 
to be a disincentive to all types of HIV testing.  
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The second major barrier to recruitment was the amount of time it took to explain the study, 
fill out the paperwork, and go over the kit contents. All CBOs intended to distribute SSKs in 
outreach sessions already scheduled for other funded projects, but this was not always 
feasible as it took much more time than they expected to explain the study to potential 
participants, especially if they showed the video to potential testers.  
As in the GP surgeries, CBO distributors reported problems with the actual intervention, 
including the amount of blood needed to fill the vial, the requirement to provide personal 
details to receive the result, and the preference of some people to know the outcome of the 
test immediately. Some distributors reported that potential participants felt that they should 
be paid to participate in the research study.  
 
9.3 Summary  
The interviewees widely reported that the targeting of black Africans specifically was 
acceptable. This was in contrast to the experience of distributors at GP surgeries, who despite 
the training and provision of a script to initiate this discussion often felt unease at targeting 
black African patients only. Concerns about exacerbating HIV-related stigma and xenophobia 
were expressed. Lack of willingness to target black Africans ultimately led to little or no 
recruitment at three GP surgeries. Despite these misgivings, many primary care staff felt that 
the intervention was worthwhile and expressed disappointment when the distribution period 
finished. Distributors at GP surgeries also reported having been unaware of the HIV 
epidemiology in relation to black African communities in the UK prior to participation in the 
study. Provision of this information did facilitate the targeting process for many. 
Some distributors at GP surgeries noted that targeting was complicated as information on 
ethnicity on patient databases is sparse, and moreover there was limited time to check this 
data prior to appointments. These issues manifested in a large variety of methods employed at 
GP surgeries to select patients to offer the intervention.  
The acceptability of the intervention to staff at CBOs remained high throughout the study, 
with the SSKs generally viewed as a valuable add-on to service menus. However, significant 
barriers to recruitment were noted, including stigma around HIV testing and limited time and 
capacity to conduct the intervention.  
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The acceptability of the HAUS intervention was also compromised by the specific SSK used, 
as well as issues with follow-up for insufficient samples, and stigma, fear, and taboo around 
HIV and HIV testing. Conversely, acceptability was supported by the convenience and 
privacy afforded by the use of SSKs, clear instructions and trust in the distributor. In a broad 
sense, users felt that acceptability not only for SSKS but for all HIV testing could be 
increased through awareness-raising activities.  
Based on these findings, suggestions to improve the acceptability of the SSK specifically 
include development of a more user friendly SSK and ideally the option of both saliva and 
blood based kits.  
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Chapter 10:  Cost effectiveness 
The aim of the economic model was to determine if offering an HIV SSK is a cost-effective 
means to increasing the provision and uptake of HIV testing among black Africans in the UK 
compared to current practice from  health care perspective. The model assessed the lifetime 
cost per quality adjusted life year (QALY) gained of SSKs compared to current practice in 
black Africans in the UK. 
10.1  Methodology 
We developed a hypothetical cohort of 8,000 individuals of black African descent to populate 
the model. The hypothetical cohort was representative of the current black African population 
in the UK in regards to age, gender and HIV status. The cohort size was chosen so that 
sufficient cases of HIV were present in the model to test the hypothesis but not so great that 
the model could not run due to computational load. All patients were aged 18 to 80 years, and 
proportioned according to current sex and age-band distributions as defined in Table 13. 
Sex-specific prevalence rates of HIV, including diagnosed and estimated undiagnosed, were 
used to determine the baseline number of HIV cases in our model population.(1) Data from 
Public Health England also provided information on proportion of individuals in early and 
late stage HIV, and proportion on ART(1) (see Table 13). 
10.1.1 Population  
Table 13: Population characteristics of black Africans in the UK 
 Male Female 
Male and 
Female 
Reference 
Age Distribution (black African population 
in the UK) 
    
0-15 137,565 140,073  (84) 
15-24 80,175 80,468  (78) 
25-49 205,934 230,281  (78) 
50-64 39,182 40,322  (78) 
>=65 10,500 13,241  (78) 
Total 335,791 364,312  (78) 
Black African Population HIV positive     
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 Male Female 
Male and 
Female 
Reference 
Diagnosed  8 312 17 730  (1) 
Undiagnosed 1 530 2 380  (1) 
Percentage at each CD4 count     
< 350   20% (1) 
350 - 499   25% (1) 
> 500   55% (1) 
Proportion on ART - all   85% (1) 
Proportion on ART and CD4 <350   89% (1) 
Average viral load for people infected with 
HIV (log copies/ml) 
  4 (85) 
10.1.2 Model structure 
A patient level simulation was developed to assess the cost-effectiveness of SSKs in black 
Africans in the UK, compared to current practice. The model was developed using published 
data and results from the HAUS trial to predict individual’s transitions, costs and health 
outcomes. The model was created in Microsoft Excel 2010 according to methodological 
recommendations for evaluations of new health care technologies and interventions.(86, 87) 
The same hypothetical cohort of 8,000 patients was tested under two different HIV screening 
arms, similar to the trial: (i) intervention (SSK); or (ii) comparator (current practice) (see 
Figure 7). 
The patient level model is a lifetime patient level simulation with the following three 
components: 
1. Simulation of HIV disease progression  
2. The probability of HIV transmission from HIV positive to HIV negative patients 
3. Effectiveness of SSKs in increasing HIV testing and reducing the number of 
undiagnosed and untreated cases of HIV in black Africans in the UK. 
The model consists of cycles of 3 months duration. In each cycle patients are in one of 6 
health states or 2 death states (see Figure 8). All patients enter the model alive and in one of 
the six health states. There is a 10-cycle run in period to stabilise the model during which no 
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outcomes are measured. After the 10th cycle patients that are not dead and not in the state 
“diagnosed HIV” are offered a SSK when they are in the SSK screening arm. 
Figure 7: Decision tree of patient movements through the model 
  
During each cycle patients can remain in their current health state, or move to a new one 
based on the following rules:  
• Only sexually active patients can move from HIV negative to new HIV positive.  
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New HIV positive patients move directly into “HIV undiagnosed” in the next cycle. Patients 
can only move from “HIV undiagnosed” to “HIV diagnosed” if: (i) they are in the SSK arm 
and accept and return a SSK test; (ii) through current screening practices in both arms. 
Figure 8: Model structure for health states 
 
• Once a patient is “HIV diagnosed” they have a probability of being either on anti-
retroviral therapy (ART) or not on ART. In both regimes patients that are 
diagnosed as HIV positive receive ART, in line with HIV best practice guidelines 
where all patients start ART following diagnosis regardless of CD4 count(88)  
• Diagnosed and undiagnosed HIV patients have a 3-month probability per cycle of 
either HIV related causes or death from other causes. HIV negative patients have a 
risk of death from other causes only. This was taken from Office of National 
Statistics (ONS) life tables.(84) 
• All patients continue to cycle through the model until they reach an absorbing state of 
dead. 
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In the primary analysis, the SSK screening tool was only offered at one time point (baseline). 
A secondary analysis evaluated offering SSK screening tools at multiple time points 
(annually).  
10.1.3 Effectiveness of screening tools 
Our model assessed two HIV screening tools: (i) SSKs and current practice and (ii) current 
practice only. 
The effectiveness of screening tools is dependent on  
- The percentage of HIV negative and undiagnosed HIV patients that are given an HIV 
SSK (acceptance rate). 
- The percentage of patients given a SSK that return the SSK (return rate). 
- The percentage of returned tests that provide a complete result. 
- The percentage of patients with undiagnosed HIV that are diagnosed as HIV positive 
after using the screening tool (dependent on the sensitivity of the screening tool used) 
The SSK screening tool employed in this study, was a blood test sampling kit, with a 
sensitivity and specificity of 0.999 (95% confidence interval (CI), 0.999 to 1) and 0.992 (95% 
CI, 0.982 to 0.998) respectively.  The percentage of patients that are given a SSK and return 
the SSK are based on data from the HAUS trial. A range of values of acceptance and return 
rates were tested within sensitivity tests of the model. 
HIV screening tools in current practice settings such as sexual health clinics, GP clinics and 
antenatal services are typically blood tests. The sensitivity and specificity of current practice 
screening tools was assumed to be the same as SSKs. The probability of testing was taken 
from the National Survey of Sexual Attitudes and Lifestyles survey 3 (NATSAL 3) where the 
5 year rate of HIV testing in black African men and women was 43.9% (95%CI, 30.3 to 
58.6%) and 46.1% (95% CI, 35.6 to 57.0%) respectively. The probability of having a test in 
the past 5 years was based on HAUS trial data in a sensitivity test. 
All individuals in the model who are diagnosed using a SSK receive confirmatory testing in 
current practice settings. In addition, all those that are not diagnosed as HIV positive and are 
sexually active could have additional testing in current practice settings as per current 
practice testing rates. 
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10.1.4 Transition probabilities 
In our model, events were assumed to have occurred when the patient specific probability of 
an event was greater than a random number generated in Excel. For example, if an individual 
who was HIV negative had a probability of HIV infection in a cycle of 0.4% and the random 
number generated was 0.001 (0.1%), the individual would move to the “new HIV” state. If, 
however, the random number generated was 0.553 (55.3%), the patient would stay in the HIV 
negative health state. Events for patients were carried over cycles and hence the model has 
memory of past health states for each patient. 
The probability of being infected with HIV was determined by four factors; 
i. The transmission rate of HIV to HIV negative patients for HIV positive patients on 
ART(89) 
ii. The transmission rate of HIV to HIV negative patients for HIV positive patients not 
on ART(89) 
iii. The prevalence of HIV in the model population during that cycle. 
iv. The probability that HIV negative patients are sexually active. This was taken from 
the African Health Survey 2013-14 that reported 84.2% of men and 73% of 
women had a sexual partner in the previous year(26). A sensitivity analysis was 
conducted using the percentage sexually active reported in the HAUS study. 
A weighted average risk of HIV infection was applied to all those that were HIV negative and 
sexually active in the model. 
Those that were HIV positive progressed through the stages of HIV (Stage I, Stage II, Stage 
III, Stage IV: death from HIV). At baseline, individuals with HIV were proportioned to stage 
of disease. The proportion of individuals in early and late stage of disease was equal to the 
proportions of patients in each group reported by Public Health England in 2015(90) (see 
Table 14). Individuals who were free of HIV at baseline and subsequently infected with HIV 
during the model, entered stage I of disease upon infection. Progression through the stages of 
HIV was determined by changes in CD4 count, where Stage I, II, and III was given by a CD4 
count of >499, 350 to 499, and <350 respectively. Baseline CD4 count for those newly 
infected and change in CD4 count was calculated using the algorithms reported in an 
economic model of lifetime outcomes and costs of HIV in men-who-have-sex-with-men in 
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the UK.(85) Those that were HIV positive and receiving ART and compliant, change viral 
load and CD4 count in line with the algorithm set out in Nakawaga et al. (2015) based on 
treatment strategy and adherence.(85) 
The probability of dying from HIV was applied to all HIV positive patients. Risk was 
stratified by sex and CD4 count, where risk increased 10-fold for those in late stages of HIV 
(CD4 count <350). One-year probabilities were converted to three month rates and then 
probabilities.(91)  
The probability of dying from non-HIV related causes was calculated from the ONS 2015 
data,(84) where death from non-HIV causes was equal to total mortality minus HIV related 
mortality (ICD-10 codes B20 to B24 as per ONS guidelines). As mortality is higher in those 
with HIV, the probability of death from non-HIV related causes was increased by 50%.(85) 
The risk of death from non-HIV related causes was age and sex specific. We conducted a 
sensitivity analysis increasing the probability of death by 100% for non-HIV related causes. 
10.1.5 Effectiveness of ART 
The effectiveness of ART was applied to the transmission probability of HIV, where those on 
ART were at lower risk of transmitting HIV than those who were not. All those newly 
diagnosed with HIV were assumed to be prescribed ART in line with current guidelines. 
Adherence with ART was based on the rate of adherence from PHE HIV statistics (90) (see 
Table 14). 
10.1.6  Costs 
Costs included in our model were the cost of the HIV screening tool and the cost of HIV. The 
cost of the HIV screening tool included the cost of SSK’s and/or current practice screening 
tools, the cost of confirmatory testing, any additional testing, and pre- and post-test 
counselling.  
Table 14: Data inputs for cost-effectiveness model 
Variable Value Reference 
Effectiveness of SSK   
Specificity 99.24% (92) 
Sensitivity 100% (92) 
Effectiveness of confirmatory/other testing of HIV   
Rate of HIV testing in previous 5 years   
Male 44% (93) 
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Variable Value Reference 
Female 46% (93) 
Specificity 99.24% (92) 
Sensitivity 100% (92) 
   
1 year probability of Death from HIV causes   
Early stage (CD4 count >3501)   
Male 0.005 ONS 2015 
Female 0.003 ONS 2015 
Late stage (CD4 count <350)   
Male 0.05 ONS 2015 
Female 0.03 ONS 2015 
Death from non-HIV related causes   
On ART 0.03 (89) 
Not on ART 0.022 (89) 
Compliance with ART 0.85 (90) 
Proportion of population sexually active   
Male 0.842 (26) 
Female 0.73 (26) 
Viral load2 for people newly infected with HIV 4 (85) 
Viral load change for all those with HIV and not on ART   
0 - <3 0.11 (85) 
3 - <3.5 0.13 (85) 
3.5 - <4 0.14 (85) 
4 - <4.5 0.15 (85) 
4.5 - <5 0.17 (85) 
5 to <5.5 0.18 (85) 
5.5 - <6 0.20 (85) 
6 - <6.5 (max) 0.21 (85) 
   
CD4 count change for all those with HIV and not on ART    
0 - <3 -0 (85) 
3 - <3.5 -0.016 (85) 
3.5 - <4 -0.04 (85) 
4 - <4.5 -0.12 (85) 
4.5 - <5 -0.04 (85) 
5to <5.5 -0.08 (85) 
5.5 - <6 -1.6 (85) 
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Variable Value Reference 
6 - <6.5 (max) -2 (85) 
Costs   
Current practice/confirmatory testing   
Of those tested, percentage tested in each setting  (38) 
GP Clinic 10%  
Sexualhealth clinics 61% (38) 
Antenatal clinics 29%  
Cost per test for each setting   
GP Clinic £8.67  
Sexual health clinics £9.12  
Antenatal clinics £8.90  
Cost Behaviour counselling/hour £41.06  
HIV events on ART    
CD4 > 200  £11,960 (94) 
CD4 < 200  £7,307 (94) 
HIV events not on ART    
CD4 > 200  £3,145 (94) 
CD4 < 200  £7,307 (94) 
Undiagnosed HIV £3,145 (94) 
Utility scores for QALYs   
Healthy 0.82  
HIV positive utility decrements   
On ART, VL < 50, CD4 < 200 -0.13 (95) 
On ART, VL < 50, CD4 > 200 -0.11 (95) 
On ART, VL > 50, CD4 < 200 -0.15 (95) 
On ART, VL > 50, CD4 > 200 -0.11 (95) 
Stopped ART, CD4 < 200 -0.18 (95) 
Stopped ART, CD > 200 -0.13 (95) 
Never started ART, CD4 < 200 -0.17 (95) 
Never started ART, CD > 200 -0.04 (95) 
1 CD4 count is in cells/mm3 
 2 Viral load is presented on the log10 scale 
The cost of the SSK was calculated from the HAUS study and includes the cost of the test kit 
itself as well as the time to deliver the kit. The cost of the current practice screening tool was 
calculated as £9.33.(38) In addition, pre- and post-test counselling was valued at £46.45 per 
test. 
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The cost of HIV was extracted from an economic analysis of early access to HIV 
services.(94) The cost of HIV included the cost of hospital inpatient, outpatient and day ward 
services, determined by the mean number of days spent in each service. The cost of HIV was 
stratified by CD4 count and presence of ART. For undiagnosed HIV, the cost was estimated 
to be equivalent to individuals with early stage HIV (CD4 count >200) and not on ART as 
these individuals are likely to have more illnesses/visits to the doctor than HIV negative 
individuals. 
All costs were inflated to 2015 values using relevant national price index conversion rates 
(96). 
10.1.7 Outcomes 
The outcomes assessed in this analysis included societal and individual level outcomes. 
Societal outcomes included the number of HIV cases prevented, whilst individual level 
outcomes included the impact of HIV on mortality and morbidity. 
The mortality and morbidity impact was evaluated using QALYs as recommended by NICE 
in the UK (97). QALYs are calculated by multiplying a preference based value of a health 
state (a utility score) by the amount of time spent in that health state, where 1 represents 
perfect health and 0 represents death. All individuals who were HIV negative were assumed 
to be in a ‘healthy’ state with a utility score of 0.824. If an individual had HIV, a utility 
decrement was applied (95). This was applied at the time of infection as well as every cycle 
thereafter until the individual died. The utility values were taken from a cross-sectional study 
of health-related quality-of-life of people with HIV compared to the general population. 
Utility decrements were dependent on viral load, CD4 count, and use of and adherence with 
ART. As individuals progressed through disease stages, and/or use of ART changed, the 
utility decrement applied was updated accordingly. 
Cost-effectiveness was evaluated as the mean incremental cost per QALY gained of 8,000 
patients over a life-time time horizon.(98) The incremental cost effectiveness ratio (ICER) for 
HAUS is defined as the total discounted cost of the intervention (SSKs) less the total 
discounted cost of current practice, divided by the total discounted QALYs of the 
intervention less the total discounted QALYs of current practice. An ICER of £30,000 per 
QALY is generally reported as the maximum value that NICE is likely to approve the 
implementation of a new technology. Claxton et al. (2015) though have calculated that it 
currently costs £12,936 to generate an additional QALY in the English NHS.(99) As a result, 
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it has been argued that this value may represent a more appropriate cost-effectiveness 
threshold to use.  
The random numbers in the model meant that each run of the model would result in a 
different result. As such, we took the average of each parameter in the ICER from 10 runs of 
the model. A Monte Carlo Error from the 10 runs of the model is reported to provide an 
estimation of the precision of 10 runs of the model.  
All future benefits (QALYs) and costs were discounted at 3.5% per annum, converted to a 
three month rate.(97)  
10.1.8 Sensitivity analyses 
We conducted a number of sensitivity analyses. The analysis was conducted in line with the 
Decision Support Unit guidance (100).  
10.2 Results 
The average age of the hypothetical population in the model was 37 years old and 53% of the 
population were female. This compares with the HAUS population from the trial with an 
median age of 42.6 and 51.3% female. In the baseline population the prevalence of HIV 
positive was of 4.2% or a total of 335 HIV positive cases per 8,000 patients. Of the 335 HIV 
positive 48 patients (14%) are undiagnosed. 
As reported in section 7.1 of the report, 125 out of 349 (35.8%) patients approached agreed to 
partake in the HAUS trial. Of those six were excluded from the trial as a result of problems 
with the consent process. For the purposes of this analysis the patients excluded for consent 
reasons are considered to have “accepted to use SSK” as the consent process is separate to 
accepting to take a SSK. Removing the six participants left 119 eligible participants 
remaining in the trial, 65 (54%) of whom returned the SSK. Of those 11 (16.7%) were 
incomplete and contacted for a retest. In the model we assume that 100% of the patients who 
have incomplete tests are contacted to retake the test. 
Qualitative investigation of the research process suggested that of the 15-20 minute 
appointment that the nurses, community worker or health care assistant had with patients to 
conduct the study, the majority of time was spent on the research process (explaining the 
study, taking consent and administering baseline questionnaires) with only a few minutes 
dedicated to explaining the SSK and how to use it. As a result a conservative estimate of 5 
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minutes with the patient per kit was used. The cost of the highest paid professional, a practice 
nurse, to give the test to the patient and explain how to use it was estimated as £4 for the 
35.8% of patients that agreed to use a SSK. The test itself cost £3.24 if not used and a 
returned kit cost £13.24 or £15 if including the cost of retest for incomplete tests.  
In addition to the conservative estimate of time, and staff with a lower cost per minute 
dispensing the kit, there was discussion as well of the possibility of patients being able to 
collect the kit from reception or pharmacies, further reducing the cost of dispensing SSK. 
This was tested as part of a sensitivity analysis. 
The results of 10 runs of the model for SSK versus current practice are reported in Table 15. 
There were 8 new cases detected using SSK, with a cost per case detected of £6,431. SSK 
dominated current practice resulting in an additional 24 QALYs and a cost saving of £17,208 
over 8,000 patients and a maximum of 75 years or until they died. The Monte Carlo error for 
the difference in QALYs was 735. As a result the 95% confidence interval for the difference 
in QALYs between SSK and current practice is -432 to 480 QALYs. The Monte Carlo error 
for costs was 515,078, with a 95% confidence interval for a difference in costs of -£336,451 
to £302.035. 
Table 15: Number of HIV cases, costs, QALYs, and ICERs per 8,000 black Africans in the 
UK for SSK compared to current practice averaged across 10 runs of the model. 
Outcomes SSK Current Practice Difference 
Total tested using SSK 1502 0 1502 
Total HIV positive diagnosed using 
SSK 
8 0 8 
Diagnosed other services 57 60 3 
Total new HIV infections 37 39 2 
Costs SSK test £48,883 0 £48,883 
Cost of other screening £1,530,123 £1,528,834 £1,289 
Cost of HIV treatment £39,425,225 £39,648,006 -£222,781 
Total Cost (undiscounted) £41,004,231 £41,179,840 -£172,609 
Total Cost (discounted) £21,319,574 £21,336,782 -£17,208 
Total QALYs (undiscounted) 1, 1,107,969 274 
Total QALYs (discounted) 509,704 509,680 24 
Incremental cost-effectiveness ratio 
(discounted) 
  Dominant 
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To test the robustness of some of the values used in the model values from completion of the 
questionnaires completed as part of HAUS were used in the model instead. In HAUS 50% of 
patients report having been tested for HIV in the past 5 years. This is similar to the value 
reported in the National Survey of Sexual Attitudes & Lifestyles 3 who report 45% of black 
Africans have been tested for HIV in the past year. In HAUS 81% of patients reported being 
sexually active. This is compared to 79% as reported in African Health Survey 2013-2014 
(26). Changing the values in the model to those reported in HAUS does not result in 
significant changes to the results.  
The results of the sensitivity tests are reported in Table 16. None of the changes made to the 
model had an impact on the results 
Table 16: Sensitivity analyses of SSK compared to current practice per 8,000 black Africans 
in the UK for each HIV screening tool averaged across 10 runs of the model 
Results Updated 
for 
results of 
trial 
65% 
accept 
SSK test 
75% return 
the test 
5% of tests 
returned 
incomplete 
Assume 
death for 
HIV related 
causes is 
twice as 
high for 
<200 CD4 
count 
SSK 
dispensed 
by 
reception 
SSK 
dispense
d by GP 
at £50 per 
patient 
SSK        
Total HIV 
positive 
diagnosed 
using SSK 
8 12.4 10 8 8 8 8 
Cost SSK test £49,375 £87,304 £60,041 £46,739 £49,133 £42,875 £246,217 
SSK – total 
number of new 
infections 
35 34 36 34 33 35 36 
SSK – total cost 
inc. HIV 
treatment 
(discounted) 
£21,8240
75 
£20,706,3
92 
£22,082,3
40 
£21,736,36
7 
£19,991,3
97 
£21,313,5
67 
£21,809,2
62 
SSK – QALYs 
discounted 
509,956 509,853 509,899 509,877 509,633 509,956 509,816 
Current Practice        
Current – total 
number of new 
infections 
38 39 39 39 35 39 39 
Current – total 
cost inc. HIV 
treatment 
(discounted) 
£21,360,
691 
£21,336,78
2 
£21,336,78
2 
£21,336,782 
 
£20,562,6
84 
£21,336,7
82 
£21,336,7
82 
Current – 
QALYs 
discounted 
509,645 509,680 509,680 509,680 509,531 509,680 509,680 
ICER £1,489 Dominant £3,407 Dominant Dominant Dominant £3,468 
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10.3 Summary 
This preliminary model of a SSK test dispensed to black Africans in the GP or in community 
settings suggests that SSK are a cost-effective way to identify new cases of HIV with SSK 
dominating current practice, resulting in more QALYs for less cost. Using the Monte Carlo 
error to test uncertainty there does not appear to be significant differences in QALYs or costs. 
The results would benefit from additional runs of the model. This was not possible within the 
limited timelines of the project and computational power to run the model.
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Chapter 11:  Discussion  
The overarching principles in selection of our intervention was that it had to expand on 
current HIV testing opportunities for black Africans, that it had be acceptable to intervention 
users and providers, and that it had to be sustainable in the current economic climate. It also 
had to address the known barriers to HIV testing for these communities. This chapter is 
comprised of a discussion focused on how the aims and objectives of this study were 
addressed.  
11.1 Discussion of Stage 1  
11.1.1  Barriers and facilitators to use of SSK  
The first objective of Stage 1 was to clarify barriers and facilitators to provision, access and 
use of HIV SSK by black Africans, in community settings. The policy review revealed a 
facilitative environment for STK and SSK for HIV, with use of these kits viewed as an 
innovative method of increasing uptake. Guidelines have shown HIV testing in medical and 
community settings as both feasible and acceptable, with SSKs suggested as a route to 
broaden testing options. Evidence on the use and effectiveness of SSKs however, was scant- 
especially for black African groups.  
The data yielded through interviews and FGDs echoed many of these reported barriers and 
facilitators to SSK use. The privacy and convenience afforded by SSKs were viewed as major 
strengths, as they negated the need to attend a sexual health clinic and potential stigma. 
Service providers and non-specialists alike felt that SSKs increased individual autonomy and 
testing opportunities. However, both FGD participants and interviewees voiced concern over 
the amount of blood required to provide a TINY vial sample. Service providers in particular 
voiced doubts over the ability of members of the public to produce a sufficient sample. 
Participants also pointed out that fear of needles and blood, and the complexity of using the 
kit could discourage some from using the SSKs. Another concern was the potential isolation 
that could be experienced by users of the SSKs. 
Many participants mentioned the stigmatising association of HIV with ‘sexual immorality’ 
and promiscuity (an association that many FGD participants and interviewees described as 
being heightened within black African communities) as a barrier to testing among black 
Africans. SSKs however helped mitigate the risk of others discovering one was testing for 
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HIV due to the privacy afforded, however, as described above, what was regarded as the 
‘benefit’ of privacy by some was regarded by others as carrying a risk of increased isolation 
for those receiving news of a reactive result  
The difference between individual and community-level risk perception was also viewed as a 
barrier, with participants stating that those targeted may not appreciate the epidemiological 
data used as justification to target black Africans exclusively for the intervention. Participants 
recognised that due to the low risk perception and stigma an opportunistic provider-led offer 
of a SSK was more likely to increase HIV testing than a user-led model. The participants 
warned that offers of SSKs exclusively to black Africans may be perceived as racist and as 
fuelling anti-immigrant rhetoric.  
11.1.2 Determine appropriate SSK-based intervention models for different settings  
As participants in FGDs and interviewees recognised that black Africans were already 
accessing primary care and CBOs, the addition of SSK into their service menus was viewed 
as a convenient extension that would immediately increase testing opportunities. There was 
almost universal approval of CBOs working with African communities and HIV prevention 
to be involved in distribution, as they were seen as possessing the expertise required to target 
black Africans in a sensitive manner. CBOs however would not be extending their outreach 
activities and HIV testing was already widely integrated into their services, thus there was 
some concern from the research team that this would not significantly increase HIV testing 
opportunities for the wider African community.  
Participants advised that targeted offers needed to be couched in clear terms, using 
epidemiological evidence, and to avoid the perception that offers were being made because of 
racist or xenophobic sentiment. It was deemed of utmost importance that distributors were 
regarded as trustworthy, knowledgeable, and non-judgemental in order to foster a realistic 
degree of reflection about HIV risk among those to whom they encouraged SSK use, all of 
which staff in General Practice settings and outreach teams in CBOs were felt to possess. 
Ultimately, there was a universal view among participants that SSK distributors needed to 
actively resist HIV stigma rather than potentially reinforce it. 
The formative work revealed concerns about the limited amount of time available to 
providers to initiate discussions and gain informed consent, especially in GP surgeries. 
Embedding the intervention into routine practice was considered a critical component by the 
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research team if it were to be sustainable. Therefore, specific appointments for intervention 
delivery should not be part of the model. 
Prior to intervention development it was apparent that ideally a saliva based or more user 
friendly SSK would be preferable to the TINY vial. Unfortunately despite this knowledge as 
described in section 5.4 we were unable to proceed with an alternative option as we could not 
identify an service provider that was willing to assume the liability for using a product off 
license in the context of a research project. Currently the TINY vial is the only CE approved 
HIV SSK available in the UK. An alternative option would have been be to formally test a 
salivary SSK against the TINY vial however  this would have represented a significant shift 
in the original research question and design which was  not considered an appropriate option 
for HAUS. 
The final intervention model for both settings utilised a theoretically informed scripted 
conversation in conjunction with distribution of a SSK during a routine encounter. The script 
was to assist providers in overcoming anxieties in targeting black African communities 
(addressing the issue of capability) while also motivating users and increasing opportunities 
for HIV testing; it also provided consistency of message to enable intervention fidelity. The 
information supplied with the kit (including weblink to video demonstration) and via the 
provider was designed to further increase capability and motivation of service users. The 
study team were not able to deliver the intervention with what they believed would be the 
optimum SSK due to governance and regulation restrictions. A copy of the intervention and 
training manuals are available on request. 
 The model  
11.1.3 Determine robust HIV result management pathways  
The formative work highlighted a disconnect between accepted current practice of delivery of 
results by text message or phone call, and the relatively widespread concern that SSK users 
may be isolated and at risk of self-harm when receiving test results. Use of SSKs was 
perceived to reduce opportunities for HIV prevention messaging, with lack of recognition 
that there is no strong evidence that routine pre or post-test counselling subsequently affects 
behaviour for those testing negative. Participants also warned that a profusion of HIV testing 
interventions could lead to a disjointed and confusing service landscape. 
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The clinical pathways within HAUS were all subject to clinical governance regulations and 
designed to ensure best practice would be delivered. The research team felt it important that 
an organisation with experience and expertise in managing HIV results, and ideally SSKs, 
were involved to ensure appropriate and sensitive delivery of test results, including the 
offering of retest to those with indeterminate results and confirmatory tests to those with 
reactive results; and linking those who test HIV positive to care.  
The process of establishing these clinical pathways highlighted uncertainty and confusion 
over where duty of care and liability should lie for a SSK intervention delivered in 
community settings by non NHS Trust employees.  
Provision of results as quickly as possible to service users, whether positive or negative, is 
emphasised throughout clinical standards and the recommended time-period for receipt of 
results is ideally within 48 hours and no more than 14 working days. The process evaluation 
demonstrated that while this was achieved for everyone testing negative for those with 
insufficient samples there was occasionally delay while information from recruiting sites was 
awaited. The FGDs had highlighted significant concerns regarding confidentiality and 
privacy among potential users, this had led us to request only initials rather than a name with 
the returning sample which in hindsight was an error as it meant we could not make contact 
with participants until the additional information was received from the recruitment site. All 
negative results were delivered by SMS via an automated system and this worked well. No 
reactive results were received so the processes for confirmatory testing and linkage to care 
were not tested. There was also concern that people may not test if their General Practitioner 
was automatically informed of the result. As a consequence we obtained specific consent to 
notify GPs of results; 98.9% of participants recruited through primary care consented to this, 
suggesting this concern was unfounded.  
11.2 Discussion of Stage 2  
In November 2015, PHE launched a national HIV self-sampling service. This initiative 
enabled people at higher-risk of HIV across the country to order an HIV SSK online. Self-
sampling is further promoted by the London HIV Prevention Programme which is aimed at 
black African communities and MSM. Through its ‘Do it London’ website 
(https://doitlondon.org/), users can click on a link to directly order a SSK. Similarly sexual 
health services are increasingly trying to reduce costs by encouraging asymptomatic 
individuals to utilise self-sampling technologies usually through web portals. To comply with 
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BHIVA guidance (use only approved SSKs and that testing should be fourth generation) most 
of these initiatives use the TINY vial SSK (88).  Despite this relatively rapid expansion of 
sexual health and HIV testing through self-sampling, there remains little evidence to support 
its effectiveness or cost-effectiveness for communities beyond MSM. 
The aim of Stage 2 was to conduct an evaluation of selected SSK distribution models to 
assess feasibility of a future Phase III evaluation. The specific objectives are discussed in the 
sections below.  
11.2.1 Establish feasibility and acceptability of interventions for providers and users 
The primary objective of Stage 2 was to determine the feasibility and acceptability of a 
provider-initiated, HIV SSK intervention targeted at black African people in two settings: GP 
surgeries and CBOs. Our findings indicate that although many aspects of the intervention 
were acceptable, scale-up of the intervention to a Phase III evaluation is not feasible. All sites 
reported that the time it took to offer the kit and complete the research-relevant forms 
(consent, baseline questionnaire, and enrolment log) was a major impediment to the 
feasibility and acceptability of the trial. With hindsight a pilot of Stage 2 in a GP surgery and 
a CBO might have identified some of these issues, however project  timelines and resources 
did not enable this. Consent at an individual level was sought to enable collection of baseline 
data, tracking of data and follow up interviews.  Consent at a group (GP or CBO) level and 
limiting data collection to service evaluation may have proved more feasible and better 
reflected how the intervention would be implemented in practice. 
Although interviewed participants reported that the targeting of black Africans was 
acceptable, this is in contrast to the large proportion of respondents who indicated on the 
acceptability questionnaire that it was not acceptable to offer an HIV test based on ethnicity. 
Many distributors, especially at GP surgeries, also continued to express unease at targeting 
black African patients only, despite the provision of training and a script designed to 
specifically overcome these barriers. This unease arose from concerns about exacerbating 
HIV-related stigma and xenophobia.  
Our findings highlighted that community providers as well as many black Africans would 
prefer to use SSKs that involve collection of an oral specimen as opposed to a blood 
specimen. However, currently in the UK there are no CE marked HIV testing assays that can 
be used on saliva. Not being able to proceed with a saliva based option directly impacted on 
the study feasibility. It meant took the SSK took longer to distribute as there was more to 
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explain and motivate; it was no longer possible to demonstrate kit use in the field; and the 
more complicated procedure to collect the sample is likely to have influenced the return rate 
and is likely responsible for the extremely high rate (16.9%) of insufficient samples. This 
figure is remarkably similar to that reported by the national HIV self-sampling service among 
their black African users to date (personal communication). This suggests that an alternative 
to the TINY vial is required if HIV SSK are to be an effective means to increase HIV testing 
in black African communities. 
11.2.2 Evaluate the effectiveness of self-sampling for HIV in increasing the uptake of 
HIV testing by black African people 
Due to the failure of the study to recruit adequate numbers we are unable to evaluate the 
effectiveness of SSKs in increasing HIV testing in black African people.  
The fact that 12 of the 65 participants who returned a kit reported never previously testing 
and that most kit returners tested because of the opportunistic offer of the test suggests that if 
distribution of HIV SSK in these settings were rolled out at scale as part of the range of HIV 
testing options there would be the potential for increasing HIV testing. However, at a 
structural level these services do not have time to ‘bolt-on’ an SSK intervention (or indeed 
anything else) unless there is a strong benefit or incentive to do so.  
11.2.3 Determine the cost effectiveness of distributing the SSKs among black African 
people over other screening methods 
The model of a SSK dispensed to black Africans in GP surgeries or in CBOs presented in 
Chapter 10 suggests that SSKs may be a cost-effective way to identify new cases of HIV as 
SSK resulted in more QALYs for less cost. 
We showed it was feasible to collect data as part of the HAUS trial to update values in the 
model. There were some challenges in collecting data on the time taken to explain SSKs to 
patientsparticipants. This was due to concerns by clinical staff involved in the study regarding 
the amount of paperwork involved. Although there was limited data available on the time 
taken this proved inconsequential to the model given that SSKs could cost as much as £50 per 
test and still be cost-effective.  
The estimation of the uptake rates of SSK taken from HAUS and used in the model may not 
reflect real life. Uptake rate for SSK might be higher as patients may have been put off by the 
research process. It is also possible that use of an alternative SSK that is easier to use may 
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increase return rates and reduce the number of incomplete results. It is likely that these 
improvements would improve the cost-effectiveness of the SSK. 
Further work required includes running the model more times and probabilistic sensitivity 
analysis where values in the model are varied within given confidence intervals and 
distributions to provide an estimate of the probability that SSK is cost-effective compared to 
current practice. Extra value of perfect information (EVPI) would provide a monetary 
estimate of the value of additional research to provide more certainty of the result. The 
computational load required to run this analysis though is significant, potentially taking days 
to run and was not possible as part of this study.  
11.2.4 Monitor ability to trace participants with reactive results, confirmatory testing 
and linkage into specialist care. 
No reactive results were obtained so we were unable to assess the ability to trace participants 
with reactive results through the process of confirmatory testing and linkage to care.  
11.2.5 Determine the cost per person kit distributed and cost per HIV diagnosis per 
setting. 
Data on cost per kit distributed was collected as part of the trial. This is dependent though on 
who distributes the SSK. If a conservative upper estimate was made of a practice nurse taking 
five minutes to explain the kit, the cost of staff time is £4. The economic model did not 
determine cost per setting as originally planned. It is unlikely that Community workers would 
be paid more than a Practice Nurse thus the cost-effectiveness could expect to be greater in 
CBO settings unless time taken to explain the kit differed by setting. A limitation of the 
model is that the time to specifically target the individual and explain the kit could not be 
determined as within the study the research components were so enmeshed with this process.  
The cost of the SSK itself was £3.24 if not used and a returned kit cost £15 (as this included 
the cost of retest for incomplete tests). In a lifetime patient level model of 8,000 black 
Africans in the UK, the cost per case detected of HIV using SSK was £6,000. However, SSK 
resulted in more QALYs for a total lower cost once the cost of treating HIV was included, 
dominating current practice. The Monte Carlo confidence interval of 10 runs of the model 
suggested a significant increase in QALYs, but not cost. 
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11.2.6 Assess the feasibility of collecting data for a lifetime cost-effectiveness model 
alongside the potential Phase III evaluation 
Limited data was able to be collected to inform the cost-effectiveness model due to a need to 
reduce the time taken for patients to complete questionnaires as part of baseline assessment. 
The values that were collected as part of questionnaire that could inform the model 
(percentage of patients sexually active and proportion of people tested in the past 5 years) 
tallied with the best available data in the literature suggesting that data from the literature is 
likely to be adequate and a better source of information. We were able to obtain better 
estimates of the proportion of people that agreed to use SSK and that returned the SSK to 
inform the model, although real life scenarios rather than trials are likely to provide more 
realistic data. 
11.2.7 Assess feasibility, and if appropriate, the optimal trial design for future Phase 3 
evaluation. 
Based on the findings of the HAUS study, in particular the challenges with recruitment in 
both GP and via CBOs, a future Phase III evaluation was not considered feasible by the study 
team.  
11.3 Patient and public involvement 
The HAUS project has been about listening to black African people and community based 
service providers with the aim of adapting HIV testing practice to better meet their needs. We 
found the additional perspectives of community representation to be invaluable in the design 
and implementation of our research. The project has also benefitted from the inclusion of 
participants who were recruited via community contacts as we believe this improved our 
focus group diversity.  
Our findings will be fed back to participating sites over the coming months and a summary of 
the findings will be published on www.haus.org.uk, our study website. 
11.4 Conclusions 
Our findings indicate that although many aspects of the intervention were acceptable, scale 
up of the intervention to a Phase III trial is not feasible. Alternative user-friendly SSKs that 
meet user and provider preferences and UK regulatory requirements are needed. In particular 
blood-based kits not requiring users ‘to milk’ blood and  diagnostic assays that meet CE 
criteria for testing saliva are required. The preliminary economic model suggests that for the 
rates of acceptance and return of the test seen in the trial, SSK is a cost-effective way to 
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identify new cases of HIV but further work is needed to validate this result. Importantly the 
study also found busy services do not have time to ‘bolt-on’ a SSK intervention or research 
generally, unless there is a strong incentive to do so. 
To maximize the individual and public health benefits of HIV testing interventions we must 
consider the technological, psychosocial and socio-cultural contexts of HIV testing. The 
increasing diversification of the tests available demand systematic consideration of the right 
test for particular circumstances and particular sub-populations and recognize that over time 
the same person may well require different testing methods and settings.  
There is a danger that by not grasping the complexity of HIV testing that we only reach the 
low hanging fruit; designing, evaluating and implementing testing interventions that work for 
limited groups of people but do not impact on the actual drivers of HIV transmission such as 
HIV related stigma. This is particularly important when considering how to implement NICE  
HIV testing guidance which recommends expansion of targeted testing in community settings 
for at-risk populations  -  including black African communities.(43, 101) Ethnic targeting 
remained problematic; despite couching the scripted intervention in epidemiological terms 
this was not always perceived as neutral and was the least acceptable aspect of the 
intervention for service users. 
Research studies comparing acceptability and return rates of different types of self-sampling 
methods can help better understand their impact on recruitment.  
Challenges in setting up reliable pathways of care for research participants who accepted a 
SSK was reflected in the lack of willingness of the NHS Trusts to accept duty of care for 
these participants as they were accessing SSK at sites distinct to their own service provision 
sites. Yet to offer the benefit of having results managed by service providers experienced in 
HIV to research participants, or users of SSKs outside research, necessitates this 
arrangement. Given that existing national initiatives in the UK and non-NHS service 
providers are offering SSK for HIV testing, standardised protocols for setting up pathways of 
care should be developed and be made accessible to service providers as well as researchers 
conducting SSK research.  
Changes in commissioning of sexual health services, as well as funding for HIV prevention 
initiatives in the UK, are already affecting research capacity. Our experience also 
demonstrates how the variation in funding models of the CRN and SPCRN has implications 
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for research studies that work across national borders. Researchers doing studies in different 
regions of the UK need to be aware of these differences and budget accordingly. Despite 
efforts to reduce time for obtaining REC and R&D approvals, continually changing systems 
breed confusion and affect study timelines and feasibility of assessing research questions 
substantially.  
While our intervention was not suitable for scale-up to a Phase III evaluation due to process 
related factors this does not mean the intervention is not feasible in practice and we hope that 
our findings will prove useful for future service provision through evidence synthesis.  
Future work 
Sexual and public health services are increasingly utilizing self-sampling technologies 
however alternative user-friendly SSKs that meet user and provider preferences and UK 
regulatory requirements are needed, and additional research is required to understand 
effectiveness and cost-effectiveness for black African communities and the population as a 
whole  
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Appendix A: Topic Guide for Phase 1 Non-Specialist FGD  
Date:                 Facilitators’ Initials:                Location:    
Materials needed: 
- Payment / and payment record sheet 
- Sign in sheet 
- Images 
- Participant info sheets in hard copy 
- Light refreshments 
- Pens 
- 2 digital recorders (and back up batteries) 
- Note paper for observations 
- Stickers for name tags 
- Consent forms printed 
- **NEW – Participant Number Cards* 
Introduction  (10 mins)  
o We are….. [names / institutions and research background BRIEFLY] 
o The information sheets gave you a lot of detail about our study – so we will just give 
you a short background before we start.  
o Many people with HIV in the UK do not know they are infected and are missing the 
chance to benefit from drug treatments that can prevent the development of AIDS, 
allowing people to live healthy lives. 
o A lot of these undiagnosed people are from African backgrounds, preventing them 
from accessing beneficial and effective treatments to keep them, and their partners, 
well. 
o Health services in the UK must increase the numbers of people of African background 
who are regularly taking HIV tests.  
o One of the ideas is for people to take a blood sample themselves, either at home or 
another private place, then send this away to be tested. We think that this might make 
HIV testing more convenient and hope it will increase the numbers people who take a 
test. 
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o Today we would like to hear your views on this, to look at the test kits, to talk about 
whether you think that people might like to use them and to talk about how to give 
them the test kits, the sort of support people might want and how they might like to 
hear about the test results and be helped to access treatment and care.  
o We are most interested in how people talk to each other about things and to find out 
where you all agree and disagree. We are happy to answer any factual questions at the 
end but are really interested in how the group discusses the topics. It is our job to try 
and make sure everyone take parts and sticks to the agenda. Nothing you say will be 
traced back to you, and everything discussed in this room is entirely confidential.  
o We will switch on the digital recorders soon. That is because we can not write down 
everything you say as quickly as you say it. Only those working directly on this study 
will have access to those recordings, and when it is all written down we will 
completely remove any mention of names or other details that might possibly identify 
an individual. 
Any Questions? 
[All consent forms collected before starting…..] 
Ice breakers (5 mins)  
A. Before we talk about these things we’d like to ask you each to introduce yourselves to 
the group (first name only) 
Recording starts  
B. Now that the recorders are on, can you please go around the room and state your 
participant number (using card in front of them), and then just say one place you 
know of where you could get an HIV test if you wanted one, or where would you tell 
a friend to go if they wanted one? 
As group feeds back, focus on the contrasting and similar responses and 
group them (largely) into the following categories (quickly): 
Clinic: 
 Hospital or clinic based test – because you have asked for one 
 Hospital or clinic based test – because you are unwell 
 Routine unanonymised testing (ante-natal) **but not blood donation, 
nor all clinic blood samples 
Community: 
 Community organisation 
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 GP 
o Draw out the different waiting times that people are aware of, as well as 
various sampling methods / requirements 
Introduction to SSK (25 min)  
Introduce the SSK – using two **VIDEOS**  
- Please speak instructions aloud for TINY vial video 
- Give out sample TINY kits, ask participants to explore how they look / feel / operate 
1. What do you think about these kits?  
Prompts: 
 Issues related to self-sampling and collecting a small vial of blood  
 Perceptions of accuracy / efficacy - any different than conventional blood test for 
HIV? 
o What would be the advantages / disadvantages compared to current ways of 
getting an HIV test? 
o Who would struggle with these kits? Why? 
o Who would use them? 
2. What would you like a kit to look like?  
Prompts: 
o Is there anything about the look and packaging that would make people more or 
less likely to take it and use it? 
o branding  
o setting  
Distribution: Acceptability/practicalities of community distribution of testing kits (20 
min) CD 
3. Where do you think these kits should be available? 
**hand out labelled photos/or printed scenarios of different locations to initiate talk 
Ask about best place/worst place 
o advantages/disadvantages 
o Any others places you think might be good?  
o Should people have a choice about where to go?  
Why is this important? 
Prompts:  
What is most private? 
Most Trustworthy? 
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Most professional? 
4. Do you feel that in each of these places, someone needs to be there to actively give out 
the kits and answer questions?  
Prompts: 
GP 
Pharmacist (boots) 
Dentist 
Hairdresser 
University staff 
Faith leader 
Community outreach worker 
5. Would it be better for a person to give out the kit or for people to be able to pick it up 
without talking to anyone?  
6. For the next part of our study, we will actually have to ask people about taking part, and 
agreeing for us to follow up with them to find out what they thought about using the kit. 
For that purpose, what personal details other than a name and contact number do you 
think people would be happy to provide when they collect the kit?  
o identify any firm boundaries / no-go areas? 
Self-sample collection – preferred venue (5 min) CD 
7. Once someone has the kit, where do you think that most people may want to actually 
collect their sample? Will that always be back at home?  
**Use image cards to provoke discussion: 
o Might there be issue with doing the sample at home? 
o in a community venue? 
o somewhere else? 
o Why?  
Return of sample – preferred method CD 
8. What do you think is the best way to get the sample back to the lab?  
Prompts: 
o post the sample personally 
o return it to the venue where they got the kit? 
o Why? – privacy and confidentiality 
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Communicating and confirming HIV test results (15 mins) EM 
Explain what the possible results are: 
- What does it mean to get a negative result 
- What does it mean to get a reactive result 
- The risk and meaning of false positives 
9. What might be the best way to explain all of this to people considering the sampling 
kits, particularly the idea of false positives? 
Currently many sexual health clinics will use HIV test results where the result is given 
instantly, in person. If they have to send the result to a lab, they may need to ask the person to 
return for another appointment to get their result, or they may agree that any negative results 
will be communicated by text, or a phone call, but all HIV positive results are given in 
person. There are home sampling schemes in operation now that give HIV negative results by 
text, and that call those whose test result is reactive. There will be a clinic in charge of each 
patient receiving news of a negative or a reactive result – just in case they need more 
information, a confirmation test, or further support.  
10. What is the best way for people to be told about the result of their test?  
Prompts if needed: 
o Text with actual results 
o Text saying the results are ready 
o Home visit 
o Phone 
o Secure web login 
o Posted letter 
o Other: What?_______________ 
11. What kind of language should be used to communicate test results? 
12. If a person was receiving a negative result, saying they did not have HIV, do you feel 
that is all they should be told? Is there anything else you might expect them to get in 
terms of information /advice? 
13. If a person was receiving a reactive result, indicating that they may have HIV, what sort 
of support should they receive?  
o Should this information be passed on the same way no matter what the result?  
o What kind of follow on information, support, advice should they receive? 
o Is that appropriate to do on the phone? Or is it best in person? 
 187 
14. If someone has a positive test with the home sample kit they would need to have 
another test to confirm that they are HIV positive. How and where should that be done?  
15. Do you feel that people who you know might be interested in using one of these kits? 
Why / Why not? 
Marketing (5 mins) EM 
Mock up packs have already been distributed to the group. 
16. Should there be anything else included with the kit when people collect it? 
Prompts: 
– Condoms? 
– Additional testing kits 
– HIV prevention / information? 
– Support information / contact details? 
Group Closure (5 mins) EM 
17. If you had to say one thing about Home Sampling Kits what would you want to say? 
Just before we close, is there anything you wanted to add that you did not get a chance 
to, or things you feel we should have discussed? 
 Thanks for your time / honesty. 
 Explain process for rest of Phase 1. 
 Website / Twitter for ongoing updates about progress. 
 Sort out payments / receipts etc. 
<END> 
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Appendix B: Topic Guide for Phase 1 Service Provider FGDs and 
interviews 
 
Date:        Facilitators’ Initials:            Location: 
Materials needed: 
- Payment / and payment record sheet 
- Sign in sheet 
- Images 
- Participant info sheets in hard copy 
- Light refreshments 
- Pens 
- 2 digital recorders (and back up batteries) 
- Note paper for observations 
- Stickers for name tags 
- Consent forms printed 
- **Participant Number Cards** NEW 
Introduce Researchers / institutions / HAUS Study  (10 mins ) 
The aim of the HAUS Study, as you will have gathered perhaps already, is to develop the 
best means of distributing HIV home sampling kits in the community in a way that will 
increase the provision and uptake of HIV testing among black Africans using existing 
community and healthcare provision. 
We plan to clarify what may help / hinder distribution of these kits, what might support black 
African people who don’t know their HIV status to access them and use them, and to explore 
what might be the best settings for distribution. After this first consultation phase through 
these focus groups and a few interviews with key stakeholders, we will develop intervention 
manuals for next stage of the larger study (Stage II feasibility trial). 
Any Questions? 
[All consent forms collected before starting…..] 
Names around the room       (5 mins) 
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Please tell others your name / what work you do and where  
Recording begins – recorders will now be switched on 
Please state your participant number and the extent of your experience working with African 
service users in your place of work. 
Background 
Just for those of you who may not be experts in HIV in the UK we wanted to briefly review a 
few points: 
- More than 100,000 people in the UK have HIV 
- About half of this number are people of black African descent who are the single 
ethnic group in this country that are disproportionately affected by HIV 
- About ¼ of ALL those who are infected are unaware of their infection, and late 
diagnosis is most acute among black African people (particularly men) 
- HIV testing has traditionally been undertaken in GUM clinical settings. Increasingly, 
community based HIV prevention organisations have started to offer point of care 
HIV testing in a range of non-clinical settings (sometimes, but not always using GUM 
staff to undertake some element of the test).  
- [TEXT FOR LONDON GROUPS] These community based tests were traditionally 
commissioned within National intervention plans (such as HIV Prevention England), 
or by local PCTs. Since the Health and Social Care Bill and the changes it has meant 
for public health, some of that point of care testing has been commissioned by Local 
Authorities who now have responsibility for HIV prevention in the community, 
however there has been a lot of variability in the way that HIV testing is now 
commissioned from place to place. 
Black African service users and targeted work  (5 mins) 
a. What do you feel are the biggest challenges in terms of encouraging routine and 
regular HIV testing among black African people in the UK? 
Self-testing / sampling technologies (5 mins ) 
b. Newer testing options include both home sampling and home testing kits (need to 
describe the difference) 
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o Have you heard of each of these before?  
o Do you have any thoughts or questions that immediately come to mind before 
we look at the kits in greater detail? 
***30 minute time check*** 
Introduction to SSK     (35 min) 
Brief introduction to SSK using two VIDEOS **Please talk through instructions of TINY 
test** 
and distribution / exploration of sample TINY kits so that participants see how they look / feel 
/ operate 
Acceptability/practicalities of community distribution of testing kits  
[use image cards to support this discussion – can distribute a couple of sets among 
participants – will focus the discussion] 
c. What are your initial thoughts about making these sorts of kits available in: 
 Community outreach in local businesses and locales 
 Pharmacy [focus here on any pharmacists in the group] 
 What sorts of self-testing kits for other conditions are pharmacies distributing? 
 Is this a way of reaching those in greatest need?  
 Are black African using pharmacies to support self-diagnosis and in what ways? 
 GP offer at: 
 initial registration (are new patient checks happening?) 
 cervical testing  
 sexual health check 
 40+ check  
 GP targeting of high-risk group members at their next consultation 
 Colleges/universities 
 Dentists 
o Please vote on your top three from this selection. Any others to add?  
Prompts: 
 Acceptability 
 Barriers / facilitators  
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 How will it be best to reach target audience in each setting without stigmatising? 
d. (for direct contact service providers) Do you think it would be a good idea to 
distribute these kits where you work?  
And could you see a way to ensure that those taking the kits away were 
disproportionately (or exclusively black African?) 
o Why / why not?  
o Are those reasons structural / political / practical / personal? 
What resources would you need to make this possible?  
 Verbally 
 Printed materials 
 Electronic material / QRS scanning code 
e. What are your thoughts on where people should collect their sample and how they 
should return it for testing?  
Prompts: 
o Only for use away from community venue / user returns sample by post 
o Collect kit in community venue / sample in venue / return sample to venue 
o Community venue / sample is undertaken elsewhere / return sample to venue 
 What are the pros and cons of these options? 
 What is most / least practical for those working in such settings? 
**APPROX ONE HOUR TIME CHECK** 
Clinical governance, communicating results and referrals (30 mins) 
f. (for direct service providers only) What information would your service be prepared 
to collect at kit distribution - - eg. Record of numbers, characteristics of users etc. 
o What would be the benefits of anonymity at the time of collection? 
o What has been your experience with self-sampling for other STI testing? 
g. (for direct service providers only) Would your service be prepared to manage reactive 
results? 
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o How would the service deliver result to clients? 
h. (for direct service providers only) Do you have any thoughts about how HIV negative 
/ non-reactive results should be managed? How would your service prefer negative 
results managed 
o Are there comparable models for results delivery from self-testing/sampling 
for other infectious diseases that we could use / adapt / avoid? 
i. [OPTIONAL QUESTION, DEPENDING ON PARTICIPANTS, AS SOME 
COMMUNITY GROUPS MAY NOT FIND IT RELEVANT, WHEREAS THOSE 
WITH TESTING EXPERIENCE WILL…]  
What clinical governance / referral pathways do you see as being necessary for 
distribution of such kits in the community? 
Prompts: 
o What existing models should we be using / adapting / avoiding? 
o How might current procedures need to be modified for SSK? 
o What comparable rapid-referral models might be used / adapted? 
j. What other support/care/services could be provided, in addition to receiving an HIV 
test result? 
o Provision of additional HIV prevention support with a negative test result 
(how, what and when?) 
o Information about other sexual health test kits  
o Information about blood-borne viruses (some African communities also at 
higher risk of hepatitis B and Hep C, thus should referral procedures should be 
flexible enough to identify these as well?) 
k. Reflecting on our conversation, what issues do you see as being the same / different 
with regards to Home Testing Kits?  
Prompts: 
 Attitudes 
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 Use 
 Practical issues at local service provider level 
 Data collection issues 
 Referrals / confirmatory testing provision 
o What would be your preference? Why? 
Just before we close, is there one final thing that you might each like to say about these 
kits – just in one sentence? 
 Thanks for your time / honesty. 
 Explain process for rest of Phase 1. 
 Website / Twitter for ongoing updates about progress. 
 May be in contact with regards to Phase 2. 
 Sort out payments / receipts etc. 
<END> 
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Appendix C. HAUS Study Semi-Structured Interview topic guide  
 
SSK unique code ___________ 
Interviewer initials _________ 
Date_____________________ 
PARTICIPANT CONSENT 
Before we start I need to ensure that you understand the nature of the interview you are 
about to take part in and are happy to proceed.  
This interview will involve me asking you questions about your experience of being 
approached to consider using the HIV self-sampling kit, and your decision about using 
it. We will also ask people who used the kit about their experience of using it. This interview 
should take around 30 minutes. Your participation is voluntary and you may stop the 
interview at any point or refuse to answer any question with which you are not comfortable. 
You will be sent a £10 voucher at the end of the interview. 
I would like to audio-record the interview: this is because I am not able to write down 
everything you say quickly enough.  
The recording will be kept strictly confidential and no one outside of the HAUS study team 
will have access to it. When we are finished taking notes from the interview, the recording 
will be safely destroyed, so there will be no record of your voice or any of your identifying 
details remaining. In any report or presentation that we write about this study, we may use 
some of your exact words, but we will do that in a way that makes sure no one could 
identify you. In the future, other qualified researchers might also be allowed access to the 
written record of your interview, but not your recording. Before sharing the written copy we 
would remove any names or places from the written copy that could identify the person being 
interviewed. 
• Do you have any questions about the interview? 
 195 
 
I would like to start the interview now which means turning on the recording is that ok?  
Yes    No 
I just need to ask you a few confirmation questions again so that we have an audio record of 
you saying that you are happy to go ahead based on what we have just discussed. 
• We have just discussed what the interview is about, and how we will store the 
personal information you give us until it is destroyed. Are you fully aware what your 
participation involves?   
 Yes       No 
• Do you consent to the interview being digitally recorded?  
 Yes   No 
• Are you happy for us to get started? 
  Yes   No 
Section 1 – Kit distribution  
1.1 Is being tested for HIV something that you had done or considered before you were 
asked to consider using this self-sampling kit? 
[prompts: prior access to traditional HIV testing and associated 
benefits/challenges, personal considerations of risk] 
1.2 Before you were approached to consider taking/using an HIV self-sampling kit, did 
you know that such kits were available? 
Note any questions raised:  
 196 
[probes: prior thoughts about SSKs/change in thinking/immediate response 
when learning about them for the first time] 
1.3 Can you think about the time you were offered this kit and let me know what do you 
recall about it? 
[prompts: location, distributor characteristics, what was said] 
1.4 How did you feel about being offered an HIV test because you are African? 
Why/why not? 
1.5 How did you feel about being offered an HIV test in [location]? 
Why/why not? 
1.6 Why did you agree to consider using the kit? 
[prompts: relevance of distributor characteristics/information; personal 
reasons, convenience] 
 
Section 2 – Kit Use and Sample return 
 
2.1 Did you actually open the kit and attempt to use it? 
 No - Why was that? 
 Yes  - Tell me how that went and what you thought of using the kit. 
2.2 In the end, you did [OR] did not return the sample. How did you return it? Did you 
have any issues with that? 
[probes: confidence, privacy, kit characteristics] 
2.2a We did not ask people to put their names on the sample vial. If you had been 
asked to put your name on it, would you have been happy to do so? 
2.3  **only ASK if sample was returned** 
How did you feel about the way that your test results were communicated to you? 
Section 3 – Implications of this approach 
3.1 Would you be willing to use the same kind of HIV self-sampling kit in the future? 
- Why/why not?  
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- Are there particular circumstances that would influence your decision? 
What are they? 
3.2 What was your overall experience of using this kit to test for HIV? Please tell me 
what you liked, and what you think needs to be changed.  
[prompts: consider this in relation to the discussion/the kit/the sample 
return/communicating the results/being targeted] 
3.3 In your view, do you think other black African people like you would like to use a kit 
like this to find out their HIV status? 
- Why do you feel that way? 
- Is that the same for everyone, or are there some for whom this is a better or 
worse option 
3.4 Do you think there are other ways, and maybe even better ways to encourage more 
black African people to test for HIV regularly? 
3.5 Is there anything else you would like to say before we finish the interview? 
That is the end of the interview. 
Thank you very much for your time and your openness. 
[explain how voucher will be sent – confirm email address] 
[give website address: www.HAUS.org.uk in case they want to keep up with study findings] 
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Appendix D: Barriers and facilitators relevant to the intervention 
component ‘the appearance and packaging of the HIV SSK’ 
Thinking about improving the acceptability of your component  
 
Key Barriers to implement 
(Indicate score out of ten to 
indicate relative strength) 
 
Key facilitators to implement 
(Indicate score out of ten to indicate 
relative strength)  
 
Conceptual coherence 
(What is the specific focus 
of barrier/facilitator) 
 
Clear plastic bag containing the 
kit (9) will not be acceptable as 
it will be difficult to carry them 
around. 
Non-transparent material bags for 
packaging the kits (9) 
Confidentiality-packaging 
material 
Avoid using packaging that is 
unique / can be identified as the 
one used only for HIV testing 
kits (9) as it will lead to 
involuntary disclosure of HIV 
test seeking/breach of 
confidentiality 
Use generic / commonly used 
materials for packaging the kits like 
brown paper bags or coloured bags 
(9) 
Confidentiality-packaging 
material/design 
Concerns about the kit being 
tampered with/opened/torn 
prior to being used (7) leading 
to contamination and 
subsequent impact on reliability 
of the test results 
Tight, secure packaging that will not 
break/open/tear prior to use of the 
kits (6) 
Contamination-secure 
packaging 
Concerns about contamination 
of the specimens when posting 
back to the lab (9) 
Good packaging to send the 
specimens back to the lab and 
assurance that it does not get 
contaminated (9) 
Contamination-secure 
packing for specimens 
Not very big or long kit (5) 
 
Small, compact packaging that can 
be easy to carry (4) 
Convenience-size of 
packaging 
No mention on HIV on the 
package (10) due to concerns of 
privacy and confidentiality  
Plain packaging with no reference to 
the kit containing a test for HIV  
Confidentiality-packaging 
design 
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Appendix E. Overview of policies and guidelines relating to HIV testing and self-sampling in the UK between 2008 
and 2016 
Author/Source Year  Title  Policy Content Policy change over time/policy in practice  
BHIVA/BASHH 2008 UK National Guidelines 
for HIV testing 2008 
National Guidelines to address late diagnosis and undiagnosed 
HIV in the UK by expanding HIV testing services beyond 
antenatal and genitourinary medicine (GUM) clinics. The 
guidelines advocate for routine offering of HIV testing in 
general practice where the prevalence rate is higher than 2 per 
1000 among 16-59 year olds; to patients attending specified 
services such as GUM clinics or pregnancy termination 
service; those who report high risk behaviour and those with 
indicator conditions.  
The guidelines discuss two types of tests to use namely 
venepuncture and a screening assay and rapid point of care 
tests (POCT). The guidance does not specifically discuss the 
use of self-sampling kits and how they might address the 
burden of undiagnosed HIV.  
A recent review of national HIV testing by Public 
Health England indicates high national coverage of 
HIV screening and testing in GUM clinics; antenatal 
services, needle exchange and other drug services 
(PHE, 2014). 
However, coverage remains low among patients 
with indicator conditions or attending termination of 
pregnancy services, hospital general medical 
admissions, and primary care settings. Coverage in 
community settings where self-sampling kits are 
used in addition to rapid test kits has been reported 
as both feasible and acceptable. 
Health 
Protection 
Agency (HPA) 
[now Public 
Health England] 
2011 Time to test: 
Expanding HIV testing 
services in community 
and healthcare settings 
in the UK 
This report describes eight pilot projects that were 
commissioned by the Department of Health after publication of 
the BHIVA HIV testing guidelines. The pilot projects assessed 
how the guidelines might be implemented in acute admissions 
unit; emergency departments; primary care settings and in 
community and outreach settings. HIV self-sampling kits were 
successfully used in one of the pilot projects.  
Findings from the pilot projects indicated that HIV 
testing in various medical and community settings 
was feasible and acceptable further supporting the 
implementation of the BHIVA HIV testing 
guidelines.  
NICE  2011 Increasing uptake of 
HIV testing among 
black Africans in 
England 
National guidance providing specific recommendations on 
methods of increasing the uptake of HIV testing among black 
Africans in the UK. Suggested recommendation includes 
engaging the black African community and promoting HIV 
testing; planning services in line with local need; developing a 
strategy and commissioning services in areas of identified 
need; promoting HIV testing among black Africans and 
reducing barriers to HIV testing for black Africans. The 
guidelines also recommend routine offering of HIV testing by 
Guidance has been influential in the expansion of 
HIV testing services for black Africans, however this 
guidance is being updated and new 
recommendations will be published in 2016.  
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Author/Source Year  Title  Policy Content Policy change over time/policy in practice  
health care professionals in all health care setting and 
development of clear referral pathways for patients who test 
positive or negative.  
NATIONAL AIDS 
TRUST (NAT) 
2012  HIV testing in African 
communities: the case 
for an annual test 
recommendation 
Policy briefing suggesting that NICE introduce annual HIV 
testing for black Africans in order to reduce undiagnosed HIV. 
The policy briefing does not discuss self-sampling specifically 
but reiterates the need for wide scale testing in primary, 
secondary and community settings as indicated in the BHIVA 
2008 HIV testing guidelines.  
NICE recommends regular testing for individuals 
with new or casual sexual partners however NICE 
has not specified frequency of testing for black 
Africans.  
 
NAT  2012  HIV Testing Action 
plan to reduce late HIV 
diagnosis in the UK 
This strategy provides rationale and evidence supporting 
increasing HIV testing and screening to address late HIV 
diagnosis in the UK. In line with the 2008 BHIVA guidelines, 
the paper advocates priority actions to reduce undiagnosed 
HIV including offering of opt out HIV testing in areas of high 
HIV prevalence; opt out HIV testing to patients attending 
specific services such as GUM clinics; better prioritisation and 
resourcing of partner notification services for those newly 
diagnosed with HIV; regulating HIV self-testing HIV self-testing 
in the UK; increasing offering of HIV testing in general practice; 
increasing funding for HIV testing initiatives.  
This paper is based on the 2008 guidelines and the 
national response to HIV has changed for example 
the legislation of self-tests in 2014. 
Department of 
Health  
First 
published 
2012 
revised 
2015  
Public Health 
Outcomes Framework 
2013 to 2016 
The Framework details the national public health vision, the 
national public health outcomes to be achieved as well as 
measurable indicators which can be used to evaluate and 
monitor the progress towards achieving the given outcomes. 
The proportion of persons presenting at a late stage of HIV 
infection that is with CD4 count <350/ mm3 has been identified 
as an indicator of essential actions to be taken to protect the 
public’s health. 
Addressing late diagnosis of HIV is a high public 
health priority for addressing the epidemic in the UK 
and this indicator provides measurable progress 
towards addressing late diagnosis.  
NICE  2014  HIV Testing  Guidance and recommendations for local authorities and other 
clinical commissioning groups on delivering HIV testing 
services. NICE recommends that commissioners conduct an 
assessment of local need for HIV testing for black Africans and 
Although this guidance does not discuss 
commissioning of HIV self-sampling initiatives by 
local authorities; under the Health and Social Care 
Act 2013, local authorities are responsible for 
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Author/Source Year  Title  Policy Content Policy change over time/policy in practice  
then develop a local HIV testing strategy with clear referral 
pathways particularly for outreach point of care services. To 
address undiagnosed HIV and late diagnosis of HIV among 
black Africans, NICE recommends that commissioners 
promote HIV testing including the use of modern HIV tests and 
reduce barriers to HIV testing among black Africans. In line 
with the BHIVA 2008 guidelines, NICE recommends that HIV 
testing is offered by health professionals in primary and 
secondary care. 
commissioning comprehensive sexual health 
services including HIV testing. HIV self-sampling 
has been offered in community settings and 
medical settings (NAT, 2012).  
HIV Scotland  2014 HIV Result Instant Self 
testing in Scotland: 
Addressing key 
questions and 
recommending good 
practice 
This document provides guidance on HIV self-testing in 
Scotland. It provides rationale for self-testing; discusses 
legislation of HIV self-testing in the UK and elaborates on how 
self-testing kits may address known barriers to HIV testing and 
possible ways of supporting patients through the process.  
Self-testing kits are now in use in the UK. Their 
impact on late diagnosis has not yet been 
evaluated.  
Westrop et al 
(Public Health 
England -PHE) 
2014   Addressing Late HIV 
Diagnosis through 
Screening and Testing:  
An Evidence Summary 
This report provides rationale and evidence supporting 
increasing HIV testing and screening to address late HIV 
diagnosis in the UK. It provides a brief overview of national 
policies on HIV testing and how this impacts uptake of HIV 
testing. In addition, evidence is reviewed on the effectiveness 
and cost effectiveness of HIV testing in medical and 
community settings. 
The report specifically discusses testing in non-medical 
settings such as community HIV testing and how self-sampling 
and self-testing for HIV broaden the HIV testing options 
available. The acceptability and feasibility of both approaches 
is described.  
Self-testing became legal in 2014 and viewed as 
another innovative testing strategy in addition to 
HIV self-sampling. 
NAT 2015 Instant result HIV test 
kit: information for the 
public in England and 
Wales 
Patient information sheet on the use of self-sampling kits 
including the meaning of results and linkage into care and 
support.  
Although self-testing kits became legal in 2014, 
there are no publications evaluating this type of test 
in the UK.  
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Author/Source Year  Title  Policy Content Policy change over time/policy in practice  
NICE  2015 HIV Testing: 
Encouraging most at 
risk groups in draft 
version due to be 
published in 2016 
Consultation for this guidance is ongoingat the time of writing 
was ongoing, however the and the final guidance will behas 
now been published in 2016[45]. It gives an update to the 2011 
guidance on increasing uptake of HIV testing among black 
Africans and MSM in the UK. Among other this, NICE provide 
guidance on interventions to raise public awareness and 
interventions to increase the type and opportunities for HIV 
testing. The guidance specifically identifies home self sampling 
and home self testing as possible ways to increase HIV testing.  
To be published in 2016  
NICE guidelines were updated in December 
2016, and SSKs were considered a potentially 
innovative way of increasing uptake of HIV 
testing among black Africans given that they 
may address known barriers to HIV testing in 
this risk group.(45)” 
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Appendix F. Systematic review screening criteria and OvidSP MEDLINE 
search strategy  
Systematic review of SSK acceptability  
Inclusion criteria- quantitative studies 
Population – any lay population in any country 
Intervention – SSK for HIV 
Comparison – any other HIV testing method 
Outcomes – Completion of SSK for HIV; participant-reported acceptability; adverse events; first time 
testers; test/strategy; linkage; accuracy; cost-effectiveness 
Study design – any randomised or non-randomised evaluation or observational design 
Publication date: 2000 to present 
Language: English 
Inclusion criteria – qualitative studies 
Studies in any population group in any country describing, summarising or analysing the 
experiences and perceptions of any population group about SSK for HIV. This will include 
studies of experiences of and responses to personal completion of SSK for HIV and also 
perceptions and opinions of potential use. Any text-based qualitative research methodology 
will be included: interviews, focus groups, ethnography. Studies published from 2000 until 
the time of searching will be included.  
Screening 
Titles and abstracts of studies retrieved using the search strategy and those from additional 
sources will be screened by two researchers to identify studies that potentially meet the 
inclusion criteria outlined above. Studies excluded at this stage will be excluded as “not 
relevant to SSK for HIV” and will be counted to allow completion of the PRISMA diagram. 
At this stage, both quantitative and qualitative studies of SSK for HIV will be retained 
together. Where an abstract is not available and the title cannot be used to assess relevance, 
the article will be retained for full text screening 
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The full text of these potentially eligible studies will be retrieved and assessed for eligibility. 
All the pdfs files will be incorporated to the bibliographic database, which will be delivered 
to the rest of the team. A more detailed coding scheme for exclusion reasons will be 
developed and recorded for completion of the PRISMA diagram. Eligible quantitative and 
qualitative studies will be separated at this stage and treated separately in the PRISMA 
diagram.  
At each stage the two researchers (EM & GP) will: 
- Complete a 5% sample of records in parallel to check consistency and 
feasibility of inclusion/exclusion criteria application 
- Split the remaining records and screen individually, with a 10% sample being 
double screened 
 
Any disagreement between the two researchers (EM & GP) over the eligibility of particular 
studies will be resolved through discussion and where needed a third researcher will be 
consulted (FB and/or CD?). For all the excluded references, the exclusion reason will be 
recorded in endnote/Excel spreadsheet. 
The researchers will contact investigators for clarification where eligibility cannot be 
determined from the published study and for any new studies or references that may not be 
published yet and to check that the search has captured important articles in the field. We will 
review backward & forward citation for Web of Knowledge for the publications finally 
identified as relevant after the screening process. 
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Full paper Screening 
1.  
11.4.2 Was the study carried out in any of the 
following countries?  
Australia, Austria, , Belgium, Canada, Czech Republic, 
Denmark, Finland, France, Germany, Greece, Hungary, 
Iceland, Ireland, Italy, Japan, Korea Rep, Luxembourg, 
Netherlands, New Zealand, Norway, Portugal, Slovak 
Republic, Spain, Sweden, Switzerland, United 
Kingdom, United States 
YES/UNCLEAR – 
go to Q2 
NO – exclude 
2.  11.4.3 Was the study published in 2000 or later? 
YES/UNCLEAR – 
go to Q3 
NO – exclude 
3.  11.4.4 Does the paper include information about 
self-sampling for HIV?  
YES/UNCLEAR – 
go to Q4 
NO – exclude 
4.  
11.4.5 Is the paper/study about interventions that 
include any of the following outcomes: 
 Increase / decrease in number of HIV tests 
 Proportion /number of confirmatory tests 
 Proportion /number of participants linked into care 
 Adverse events associated with HIV self-sampling 
 Proportion/number of false positives or failed tests 
 Increase / decrease in the reported history and 
frequency of taking HIV tests  
 Increase / decrease in the number and types of 
venue where HIV testing is offered 
 Barriers or facilitator to self-sampling reported by 
general population 
 Barriers or facilitators to self-sampling reported by 
providers* *qualitative only 
YES/UNCLEAR – 
go to Q5 
NO – exclude 
5.  
Does this paper describe a primary study or is a review 
(of primary studies)? E.g. randomised or non-
randomised controlled trials, prospective observational, 
retrospective observational, cost benefit analysis; cost-
consequence analysis; cost-effective analysis and cost 
utility analysis 
YES/UNCLEAR – 
go to Q6 
NO – go to Q6 
6.  
Is the study exclusively measuring the validity or 
diagnostic effectiveness of different types of HIV test; 
YES - Exclude 
NO/Unclear – 
Include for Full 
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Are the interventions examining testing following 
exposure to HIV in the workplace? 
paper review  
Date range: 1946 to September Week 3 2014  
1. exp HIV Infections/ (238345) 
2. exp HIV/ (86013)  
3. hiv.ti,ab. (225871) 
4. “hiv1".ti,ab. (710)  
5. "hiv2".ti,ab. (149)  
6. "hiv type 1".ti,ab. (3784)  
7. "hiv type 2".ti,ab. (186)  
8. human immunodeficiency virus.ti,ab. (69068)  
9. human immunedeficiency virus.ti,ab. (4)  
10. human immuno-deficiency virus.ti,ab. (186)  
11. human immune-deficiency virus.ti,ab. (245)  
12. (human immun* adj3 deficiency virus).ti,ab. (435)  
13. acquired immunodeficiency syndrome.ti,ab. (14483)  
14. acquired immunedeficiency syndrome.ti,ab. (10) 
15. acquired immuno-deficiency syndrome.ti,ab. (94)  
16. acquired immune-deficiency syndrome.ti,ab. (4904)  
17. (acquired immun* adj3 deficiency syndrome).ti,ab. (5037)  
18. Sexually Transmitted Diseases, Viral/ (1207)  
19. or/1-18 (313426)  
20. (sample adj1 collect*).ti,ab. (5944)  
21. home dried blood spot.ti,ab. (0)  
22. (alternative adj3 test*).ti,ab. (3862)  
23. (option* adj1 test*).ti,ab. (270)  
24. ((Home* or self* or mail*) adj3 (collection* or sampl* or specimen* or test* or 
kit)).ti,ab. (10969)  
25. or/20-24 (20907)  
26. 19 and 25 (1003)  
27. limit 26 to (english language and yr="2000 -Current") (673) 
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Appendix G: Fieldwork Schematic Diagram 
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Appendix H: Baseline Questionnaire 
 
Thank you for taking part in this study. Please complete the following 
information. The questionnaire is confidential and should take less than 5 
minutes to fill in. 
 
First Name  __________________________________ 
 
Surname      __________________________________  
 
Are you:  Male□ Female □ 
What is your date of birth: □□/□□/□□ 
Mobile number: □□□□□□□□□□□  
Alternative contact method (landline): 
 
___________________________________________________________________________ 
 
What is the first half of your postcode: □□□□ 
 
 
 
 
1. In what country were you born? 
Please write it down: 
_____________________________________________ 
 
2. How long have you been living in the UK?  
 Less than one year   
 1 – 2 years  
 2 – 5 years 
 5-10 years 
 More than 10 years  
 All my life  
3. When did you last have an HIV test? (please tick one) 
 
Affix Kit 
number here 
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 Never 
 Less than one year ago   
 1 – 2 years ago 
 2 – 5 years ago 
 More than 5 years ago 
 I am unsure or prefer not to say  
 
4. In the last 12 months, who have you had sex with 
 I have only had sex with men 
 I have only had sex with women 
 I have had sex with men and women 
 I have not had any sex 
 I am unsure or prefer not to say 
 
When you have finished this please return it to the person who you 
have been talking to about the HAUS study 
Thank you. 
 
 
 
Appendix I. Distributor weekly log 
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Appendix J: Acceptability questionnaire 
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Please fill in this survey AFTER you have taken your sample.  
Thank you. 
 
We would like to know your thoughts about this way of testing for HIV. Your answers will 
help us to improve this HIV testing service. 
The questionnaire is confidential and takes only a couple of minutes to fill in.  
1. Is it acceptable to be offered an HIV test in this manner? (circle a face below) 
Acceptable  Unacceptable  
 
2. Is it acceptable to be offered an HIV test because you are African?  
Acceptable  Unacceptable 
  
3. What did you think about the location where you were offered this kit?  
Acceptable  Unacceptable 
4. Did the offer of this kit help you to decide to test? 
Yes □  No □ 
5. Did the person who offered you the kit help you feel more confident about knowing 
your HIV status? 
Yes □  No □    
6. Were the instructions in the kit easy to understand?  
Very easy   Very difficult  
7. How did you feel about taking the sample yourself? 
Comfortable  Uncomfortable 
Why did you feel that way? ______________________________________________ 
8. Did you watch the online video about using this kit? 
Yes □   No □   
If yes - How did watching someone else use the kit make you feel? 
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Confident Unsure  
 
How helpful was the video? 
Helpful Unhelpful  
 
9. How willing would you be to use one of these kits again in the future? 
Very willing  Not at all willing 
10. Can you tell us why you accepted this kit when it was offered to you?  
 
 
 
 
 
11. We are very interested in your views on this service. Please tell us which aspects you 
particularly liked or you think we should change. 
 
 
 
 
 
Please put this completed questionnaire in the free post envelope with your 
sample. 
Thank you again for your time. 
 
 
 
 
 
 
 
Appendix K: Study Close Down Interviews/Group Interviews with 
Distributors 
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Interviewer:     Location: 
Date:      Consent collected for recording: Y/N 
1. How did you feel about offering an HIV test specifically to black Africans? 
2. You were asked to closed follow the intervention wording we provided as you 
targeted black African people. How did you find that worked in reality? 
3. Do you feel your organisation benefitted in any way from distributing these kits? 
What about those who use your services, did they benefit in any way? 
4. How feasible is this approach in the future for you? What would you change? 
   *PROBE about whether it was the script/kit/or the research process and  
 paperwork that needs changing 
5. In your view, do you think black African people would like to use a kit like this to 
find out their HIV status?  
*Probe: why/why not? Was it the same for everyone? How could that be different for 
different people? 
6. Anything else you might like to add before we finish? 
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Appendix L: Further Acknowledgements  
Distribution Sites 
Community Based Organisations 
KwaAfrica: Amanda Amito, Daniel Baliikya, Martha Bisirikirwa, and Esther Namutoosi  
Naz: Parminder Sekhon Priyanka Goel  
Positive East: Amanda Amito,Daniel Baliikya, Martha Bisirikirwa and Esther Namutoosi  
General Practice 
Brigstock Medical Practice: Dr Dipti Gandhi, Nilgun Ahmed, and Pat Southam 
Crawley Road Medical: Dr Rameet Singh Uberoi and Shiraaz Ibrahim  
Eagle House Surgery: Drs Claire Murphy and Margaret Barnes. 
Manor Place Surgery: Ahmed Faheem, Mohammad Halim 
Minet Green Health Practice: Dr Louise Medforth and Sue Chard 
Morden Hall Medical Centre: Drs Fiona White and Ravi Patel; Emma Scerri  
Open Door Surgery: Dr Punam Mittal and Paula Batson 
Paxton Green: Dr Stephen Miller & Alison Peat 
Royal Arsenal Medical Centre: Dr Yann LeFeuvre 
Sir John Kirk Close Surgery: Dr Richard Proctor and Mohammad Halim 
Streatham Common Practice: Dr Ruth Danson and Tracy Hayward-Allingham 
The Corner Surgery: Dr David Wickstead, Filipa Pereira and Michelle Panton 
 
Advisory Group Membership 
Public Health England   Dr Anthony Nardone    
Terrence Higgins Trust    Dr Michael Brady  
& King's College Hospital NHS Foundation Trust 
Pharmacist     Mr Alistair Murray    
Positively UK     Ms Rebecca Mbewe  
Study Steering Committee 
Dr Philippa James (Chair)   GP, Cornbrook Medical Practice, Manchester 
Dr Suzanne Audrey    University of Bristol  
Dr Claudia Estcourt    Queen Mary University of London 
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Foundation Trust 
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